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Abstract
Background: Smoking is a known cause of the outcomes COPD, chronic bronchitis (CB) and emphysema, but no
previous systematic review exists. We summarize evidence for various smoking indices.
Methods: Based on MEDLINE searches and other sources we obtained papers published to 2006 describing
epidemiological studies relating incidence or prevalence of these outcomes to smoking. Studies in children or
adolescents, or in populations at high respiratory disease risk or with co-existing diseases were excluded. Study-
specific data were extracted on design, exposures and outcomes considered, and confounder adjustment. For each
outcome RRs/ORs and 95% CIs were extracted for ever, current and ex smoking and various dose response indices,
and meta-analyses and meta-regressions conducted to determine how relationships were modified by various
study and RR characteristics.
Results: Of 218 studies identified, 133 provide data for COPD, 101 for CB and 28 for emphysema. RR estimates are
markedly heterogeneous. Based on random-effects meta-analyses of most-adjusted RR/ORs, estimates are elevated
for ever smoking (COPD 2.89, CI 2.63-3.17, n = 129 RRs; CB 2.69, 2.50-2.90, n = 114; emphysema 4.51, 3.38-6.02, n =
28), current smoking (COPD 3.51, 3.08-3.99; CB 3.41, 3.13-3.72; emphysema 4.87, 2.83-8.41) and ex smoking (COPD
2.35, 2.11-2.63; CB 1.63, 1.50-1.78; emphysema 3.52, 2.51-4.94). For COPD, RRs are higher for males, for studies
conducted in North America, for cigarette smoking rather than any product smoking, and where the unexposed
base is never smoking any product, and are markedly lower when asthma is included in the COPD definition.
Variations by sex, continent, smoking product and unexposed group are in the same direction for CB, but less
clearly demonstrated. For all outcomes RRs are higher when based on mortality, and for COPD are markedly lower
when based on lung function. For all outcomes, risk increases with amount smoked and pack-years. Limited data
show risk decreases with increasing starting age for COPD and CB and with increasing quitting duration for COPD.
No clear relationship is seen with duration of smoking.
Conclusions: The results confirm and quantify the causal relationships with smoking.
Background
It has been known for many years that smoking causes
chronic obstructive pulmonary disease (COPD). In 1984,
the US Surgeon General [1] concluded that, in the United
States, 80 to 90% of morbidity from COPD is attributable
to cigarette smoking. However, we know of no previous
systematic review quantifying this relationship by meta-
analysis, and we attempt to rectify this omission. It is
recognized [1] that COPD comprises three separate,
often interconnected disease processes: (1) airway thick-
ening and narrowing with expiratory airflow obstruction;
(2) chronic mucus hypersecretion, resulting in chronic
cough and phlegm production; and (3) emphysema, an
abnormal dilation of distal airspaces combined with
destruction of alveolar walls. The present review consid-
ers all three processes by summarizing the epidemiologi-
cal evidence relating smoking separately to the incidence
or prevalence of COPD, chronic bronchitis (CB) and
emphysema. Elsewhere [2], we systematically review * Correspondence: BarbaraForey@pnlee.co.uk
1P N Lee Statistics and Computing Ltd, Sutton, Surrey, UK
Full list of author information is available at the end of the article
Forey et al. BMC Pulmonary Medicine 2011, 11:36
http://www.biomedcentral.com/1471-2466/11/36
© 2011 Forey et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.evidence on the relationship between smoking and
decline in forced expiratory volume in one second
(FEV1).
B e c a u s eC O P Di sr a r e l ys e e ni nc h i l d r e no ra d o l e s -
cents, we restrict attention to adults. We also limit
attention to studies of the general population, so do not,
for example, consider studies in subjects suffering from
alpha-1 antitrypsin deficiency or exposed to particular
respiratory hazards. To provide a broad description of
the relationship, we do not concentrate on one primary
analysis, but quantify the relationship of each of the
three outcomes studied (COPD, CB, emphysema) to
each of a range of indices of smoking, investigating how
these relationships vary according to characteristics such
as sex, age, location, study design, period considered,
definition of outcome, definition of exposure and extent
of confounder adjustment.
Methods
Full details of the methods used are described in Addi-
tional file 1, and are summarized below.
Inclusion and exclusion criteria
Attention was restricted to epidemiological studies pub-
lished before 2007 on COPD, CB or emphysema, pro-
viding relative risk (RR) estimates for one or more
defined “major indices” (ever, current or ex smoking
compared with never smoking) or “dose-related indices”
(amount smoked, age of starting to smoke, pack-years
smoked, duration of smoking or duration of quitting).
Throughout this paper, we use the term RR to include
its various estimators, including the odds ratio and the
hazard ratio.
Studies were excluded if in children or adolescents, or
in subjects at especially high risk of respiratory disease
(e.g. workers in risky occupations), selected as having
co-existing diseases or conditions, or from atypical
populations likely to have a highly unusual prevalence of
smoking or disease. Also excluded were uncontrolled
case studies, and studies of disease exacerbation or
undiagnosed disease, of symptom-free subjects, or where
the only results were adjusted for symptoms or precur-
sors of disease.
Definition of the outcomes
COPD
The term COPD is quite recent, so studies with out-
comes described otherwise were also included. These
could be based on International Classification of Dis-
eases (ICD) codes, on lung function criteria, on a com-
bination of lung function criteria and symptoms, or on
combinations of diagnosed conditions (such as CB or
emphysema, or CB, emphysema or asthma), where diag-
noses were extracted from medical records or reported
in questionnaires. Unacceptable outcomes included CB
or emphysema separately, acute or unspecified bronchi-
tis, non-specific respiratory disease, or outcomes based
only on symptoms and not on lung function. The range
of ICD codes had to cover both CB and emphysema,
and could also cover asthma, acute and unqualified
bronchitis, bronchiectasis and some other defined lung
conditions. Broader-ranging definitions (e.g. respiratory
disease) were not accepted. Acceptable lung function
criteria included those of the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) [3,4], the
British Thoracic Society (BTS) [5], the European
Respiratory Society (ERS) [6] and the American Thor-
acic Society (ATS) [7-9]. Use of a bronchodilator was
not a requirement.
CB
W h e r eb a s e do nt h eI C D ,t h er a n g eh a dt oi n c l u d et h e
code(s) for CB and could also include codes for acute or
unspecified bronchitis. Acceptable outcomes could also
be based on medical records, in-study diagnosis, self-
report of physician diagnosis or of history of the disease,
or on symptoms. The British Medical Research Council
(MRC) criterion of daily productive cough for at least
three consecutive months for more than two successive
years [10,11] was recognized as a set of symptoms defin-
ing CB. Diagnoses or symptoms called “bronchitis” were
accepted where the context clearly indicated it was
chronic. Diagnoses based on symptoms not referred to
as CB were also accepted, provided the definition
included both chronic cough and phlegm.
Emphysema
The outcome could be based on the ICD code for
emphysema, on medical records, in-study diagnosis, or
on self-report of physician diagnosis or history of the
disease.
Choice of outcome
Where a study provided data for multiple acceptable
definitions of an outcome, results were entered only for
one. Additional file 1 gives the rules specifying choice of
outcome, and, for studies providing a choice, lists defini-
tions selected and rejected. It also gives, for all studies,
the description of the disease and the source of the
diagnosis for all outcomes where data were entered.
Literature searching
Searching was carried out in phases. Initially, 1407
potentially relevant papers, published up to 2002, were
derived by AJT from an unpublished project which used
the MeSH terms chronic bronchitis and symptoms,
emphysema, lung function, genetic determinants, mor-
tality, adults and smoking. Subsequently, additional
Medline searches were conducted in 2006 by AJT and
in 2008 by BAF, using the MeSH term “Pulmonary dis-
ease, chronic obstructive”. Papers were also sought from
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cited in papers obtained. Publications before 2007 were
considered, with no restriction on language or on peer-
reviewed journals. Reasons for rejection were recorded.
Identification of studies
Relevant papers were allocated to studies, noting multi-
ple papers on the same study, and papers reporting on
multiple studies. Each study was given a unique refer-
ence code (REF) of up to 6 characters (e.g. DICKIN or
CHEN3), based on the principal author’s name, and dis-
tinguishing multiple studies by the same author. Occa-
sionally, an original study was split into separate studies
(e.g. where follow-up periods differed by sex).
Some studies were noted as having overlaps or links
with other studies. To minimize problems in meta-ana-
lysis arising from double-counting of cases, these links
were divided into three types, as shown in Additional
file 2. The first involved no such double-counting, while
the second included studies with minor overlap, which
could not be disentangled, and which it was decided to
ignore. The third type contains sets of studies which
probably or definitely overlap. Here the set member
containing the most valuable data (e.g. largest study size
or longest follow-up) was called the ‘principal study’,
other members being ‘subsidiary studies’ only consid-
ered in meta-analyses where the required RR was una-
vailable from the principal study.
Data recorded
For each study, relevant information was entered onto a
study database and a linked RR database. The study
database contains a record for each study, describing
relevant publications, sexes considered, age range, loca-
tion, timing, length of follow-up, whether principal or
subsidiary, overlaps or links with other studies, study
design, populations studied, major study weaknesses,
outcome definitions, numbers of cases and subjects,
types of controls and matching factors used in case-con-
trol studies, confounding variables, and availability of
results for each smoking index. The RR database holds
the detailed results, typically containing multiple records
for each study. Each record is linked to the relevant
study and refers to a specific RR, recording the compari-
son made and the results. This record includes the out-
come, the sex and the analysis type (prevalence or
incidence). Smoking exposure is defined by status (ever,
current or ex), product (any, cigarettes, cigarettes only)
and similar information about the unexposed base. For
dose-related indices, the level of exposure is recorded.
The source of the RR is also recorded, as are details on
adjustment variables. Results recorded include numbers
of exposed and unexposed cases, and, for unadjusted
results, numbers of exposed and unexposed members of
the comparison group. The RR itself and its lower and
upper 95% confidence limits (LCL and UCL) are always
recorded, with the odds ratio chosen if available for a
prevalence analysis and the relative risk (or hazard ratio
if provided) for an incidence analysis. These may be as
reported, or derived by various means (see below), with
the method of derivation noted.
Identifying which RRs to enter
For each outcome RRs were entered relating to defined
combinations of smoking index (major or dose-related),
confounders adjusted for, and sex, as described below.
The major smoking indices
The intention was to enter RRs comparing current smo-
kers, ever smokers or ex smokers with never smokers.
Near-equivalent definitions were accepted when stricter
definitions were unavailable, so that never smokers
could include occasional smokers (or exceptionally, light
smokers), while current smokers could include, and ex-
smokers exclude, those who quit smoking up to two
years ago. If available, results were entered for five com-
parisons: any product vs. never any product, cigarettes
vs. never any product, cigarettes only vs. never any pro-
duct, cigarettes vs. never cigarettes, and cigarettes only
vs. never cigarettes. Here “cigarettes” ignores whether
other products (i.e. pipes and cigars) are smoked, while
“cigarettes only” excludes mixed smokers.
Dose-related smoking indices
RRs were entered for five measures: amount smoked,
age of starting, pack-years (cigarettes smoked per day
times years of smoking, divided by 20), duration of
smoking and duration of quitting. RRs were expressed
relative to never smokers (or near equivalent), if avail-
able, or relative to non smokers otherwise. For duration
of quitting, RRs were also expressed relative to current
smokers. Further RRs were entered, restricted to smo-
kers, and expressed relative to the level expected to
have the lowest risk (e.g. lowest amount smoked, or
longest time quit).
Confounders adjusted for
For prospective studies, results were entered adjusted
for age and the greatest number of potential confound-
ing variables for which results were available, and also
adjusted for age only or age and the smallest number of
confounders. Unadjusted results were only entered if no
age-adjusted results were available. For other study
types, results were entered adjusted for the greatest
number of confounders, and also unadjusted (or
adjusted for the smallest number of confounders). These
alternative RRs are subsequently referred to as “most-
adjusted” and “least-adjusted”. For dose-related RRs
restricted to smokers, results with “most adjustment”
but without adjustment for other aspects of smoking
were also entered if available.
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Results were entered for males and females separately
when available, with combined sex results only entered
where sex-specific results were not available.
Derivation of RRs
Adjusted RRs and their 95% CIs were entered as pro-
vided, when available. Unadjusted RRs and CIs were cal-
culated from their 2 × 2 table, using standard methods
(e.g. [12]), noting any discrepancies between calculated
values and those provided by the author. Sometimes the
2 × 2 table was constructed by summing over groups (e.
g. adding current and ex smokers to obtain ever smo-
kers) or from a percentage distribution. Various other
methods were used as required to provide estimates of
the RR and CI. The more commonly used methods are
summarized below, fuller details being given in Addi-
tional file 1.
Correction for zero cell.I ft h e2×2t a b l eh a saz e r o
cell, 0.5 was added to each cell, and the standard formu-
lae applied. Combining independent RRs. RRs were com-
bined over ℓ s t r a t a( e . g .f r o ma2×2×ℓ table) using
fixed-effect meta-analysis [13], giving an estimate
adjusted for the stratifying variable. Combining non-
independent RRs. The Hamling et al method [14] was
used (e.g. to derive an adjusted RR for ever smokers
from available adjusted RRs for current and ex smokers,
each relative to never smokers, or to combine adjusted
RRs for several diseases, each relative to a single control
or disease-free group). Estimating CI from crude num-
bers. If an adjusted RR lacked a CI or p-value but the
corresponding 2 × 2 table was available, the CI was esti-
mated assuming that the ratio UCL/LCL was the same
as for the equivalent unadjusted RR.
Data entry and checking
Master copies of all the papers in the study file were
read closely, with relevant information highlighted to
facilitate checking. Where multiple papers are available
for a study, a principal publication was identified,
although details described only in other publications
were also recorded. Preliminary calculations and data
entry were carried out by one author and checked by
another, and automated checks of completeness and
consistency were also conducted. RR/CIs underwent
validation checks ([15]).
Selecting RRs for the meta-analyses
All meta-analyses are restricted to records with available
RR and CI values. The process of selecting RRs for
inclusion in a meta-analysis must try to include all rele-
vant data and to avoid double-counting. For a given
analysis (e.g. of current cigarette smoking), several
definitions of RR may be acceptable (e.g. cigarette
smoking, or cigarette only smoking), so, for studies with
multiple RRs, the one to be used is determined by an
order of preference defined for the meta-analysis.
Orders of preference may be required for smoking sta-
tus, smoking product, the unexposed base, and extent of
confounder adjustment. As the definitions of RR avail-
able may differ by sex (e.g. a study may provide RRs for
any product smoking for males, but for cigarette smok-
ing for females), the most appropriate RR is chosen
within each sex. Sexes combined results are only consid-
ered where sex-specific results are not available. Simi-
l a r l yR R sf r o mas u b s i d i a r ys t u d ya r eo n l yu s e dw h e r e
eligible RRs are unavailable from the principal study.
When multiple orders of preference are involved, the
sequence of implementation may affect the selection, so
preferences for the most important aspects, usually con-
cerning smoking, are implemented first.
Carrying out the meta-analyses
Fixed-effect and random-effects meta-analyses were
conducted using the methods of Fleiss and Gross [13],
with heterogeneity quantified by H, the ratio of the het-
erogeneity chisquared to its degrees of freedom. For all
meta-analyses, Egger’s test of publication bias [16] was
also conducted.
A series of meta-analyses was conducted for each of
the three main outcomes. For each meta-analysis con-
ducted, combined estimates were made first for all the
RRs selected, then for RRs subdivided by level of various
characteristics, testing for heterogeneity between levels.
These characteristics may include sex, continent,
national cigarette type (blended, Virginia), start year of
study, publication year, study type, lowest age included,
highest age included, presence of study weakness, out-
come subtype, how asthma was taken into account, use
of a bronchodilator, study size (number of cases), analy-
sis type (prevalence, onset), smoking product (any, cigar-
ettes, cigarettes only), unexposed base (never any
product, never cigarettes), smoking results available
(ever smoking, current smoking, both), number of
adjustment variables, whether the RR was adjusted for
sex, age or for other factors, and how the RR and CI
were derived. In this univariate approach, differences in
fixed-effect estimates by level of a characteristic were
tested for significance using an F-test which compared
variation between and within levels of the characteristic
considered. Additional file 1 fully defines the levels of
each characteristic considered, and which characteristics
are considered in each meta-analysis. It also details all
the meta-analyses conducted, and describes the layout
and notation used in the meta-analyses and associated
forest and funnel plots.
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meta-analyses were conducted based on most-adjusted
and least-adjusted RRs.
For the major smoking indices, four broad types of
meta-analysis were conducted: A ever smoking, B cur-
rent smoking, C ever smoking (but using current smok-
ing RRs if ever smoking RRs are not available) and D ex
smoking. In each type, RRs for the “main analysis” were
selected in the following order of preference: firstly for
smoking of any product vs. never smoked any product,
then for smoking of cigarettes (or of cigarettes only) vs.
never smoked any product, and then for smoking of
cigarettes vs. never smoked cigarettes, accepting RRs vs.
near-equivalents to never smokers only when RRs vs.
never smokers were unavailable. A variant analysis used
a different order of preference, so that RRs for cigarette
smoking were preferred. In type C meta-analyses, a
further variant analysis preferred RRs for current
smoking to those for ever smoking. Other variant ana-
lyses restricted attention to specific subtypes of outcome
(e.g. for COPD, whether the definition was based on
mortality, on lung function criteria only, or on other
definitions).
For the dose-related indices, meta-analyses were con-
ducted for: E amount smoked, F age of starting to
smoke, G pack-years, H duration of smoking, I duration
of quitting compared to never smokers (or long-term ex
smokers), and J duration of quitting compared to cur-
rent smokers (or short-term quitters). For any measure,
a study typically provides a set of non-independent RRs
for each dose-category, expressed relative to a common
base. To avoid double-counting only one was included
in any one meta-analysis. Two approaches were adopted.
The first involves specifying a scheme with a number of
levels of exposure ("key values”), then carrying out
meta-analyses for each level in turn. For an RR to be
allocated to a key value, its dose-category has to include
that key value and no other. Schemes with a few, widely
spaced, key values tend to involve RRs from more stu-
dies, whereas schemes with more key values, closely
spaced, involve RRs from fewer studies, but ones with
dose categories more closely clustered around the key
value. The key value schemes used were: 5, 20 & 45 and
1, 10, 20, 30, 40 & 999 for amount smoked; 26, 18 & 14
for age of starting to smoke; 5, 20 & 45 and 1, 10, 20, 30
& 999 for pack-years; 12, 7 & 3 and 20, 12 & 3 for dura-
tion of quitting vs. never; and 3, 7 & 12 and 3, 12 & 20
for duration of quitting vs. current (with 999 indicating
an open-ended category). The second approach involves
meta-analysing RRs comparing the highest vs. lowest
categories of exposure. Though this approach generally
includes RRs from all studies, whereas the key-value
approach does not, the highest and lowest categories
compared may vary markedly by study.
Meta-regression analyses of the major smoking indices
For COPD and CB meta-regression analyses were also
carried out using the sets of RRs selected for the main
meta-analyses for ever smoking and for current smok-
ing. Following preliminary meta-regressions (not
shown), a “basic model” was fitted which included
eight categorical variables (sex, continent, outcome
subtype, how asthma was taken into account, smoking
product, unexposed base group, adjustment for age,
and adjustment for factors other than age or sex) and
also midpoint age, a continuous variable estimated
from the age range of the population. The significance
of each of these variables was estimated by an F-test
based on the increase in deviance resulting from its
exclusion from the basic model. A list of secondary
variables was also defined (national cigarette type, pub-
lication year, study type, presence of a study weakness,
use of a bronchodilator, study size, smoking results
available for the study, method of derivation of the RR
and CI and analysis type), with the significance of add-
ing each characteristic to the basic model estimated by
an F-test based on the increase in deviance. Alternative
formulations of some basic variables were also tested;
see also Additional file 1.
Additional analyses
For each outcome, and for ever smoking and current
smoking, pairs of corresponding RR and CI estimates
within the same study for males and for females were
used to carry out meta-analyses of the sex ratio. Pairs of
corresponding least-adjusted or most-adjusted RRs were
also identified. Unlike the sex-specific pairs, these pairs
were non-independent and the variance of their ratio
c a n n o tr e a d i l yb ec a l c u l a t e d .H e r et h en u m b e r so fp a i r s
where the most-adjusted/least-adjusted ratio exceeded
or did not exceed 1 were compared by the sign test,
with separate meta-analyses also conducted for the
least-adjusted and most-adjusted members. Similar
methods were also used to compare non-independent
p a i r so fR R sf o rc u r r e n ts m o k e r so fc i g a r e t t e so n l ya n d
for current smokers of cigarettes ignoring other
products.
Software
All data entry and most statistical analysis were carried
out using ROELEE version 3.1 (available from P.N.Lee
Statistics and Computing Ltd, 17 Cedar Road, Sutton,
Surrey SM2 5DA, UK). Some analyses were conducted
using Excel 2003.
Results
Studies identified
Some 218 relevant studies were identified, based on
information from 298 papers.
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in Table 1, with further details of the searching, includ-
ing a flow diagram, shown in Additional file 1. Many
papers had multiple reasons for rejection, the counts in
Table 1 relating only to the first listed reason which
applied. A Reference Manager file is available on request
which, for each rejected publication, gives its reference
and the reasons for rejection.
Table 2 presents selected details of the 218 studies
while Table 3 gives the distribution of their major char-
acteristics. Additional file 2 gives fuller descriptions of
the studies, including overlapping and linked studies,
medical and other exclusions, detailed definitions of dis-
ease outcomes, and fuller distributions.
Of the 218 studies, 193 are classified as principal, 20
(10.4%) of these being case-control studies, 39 (22.7%)
prospective, and 134 (69.4%) cross-sectional. The other
25 studies are classified as subsidiary. Ninety-three prin-
cipal studies are of COPD only, 63 of CB only, nine of
emphysema only, with 28 providing results for multiple
outcomes. In total, information is available on COPD
for 133 studies (116 principal), CB for 101 (87 principal)
and emphysema for 28 (26 principal). Of the principal
studies, only 9 (10.3%) are prospective for CB, compared
with 35 (30.2%) for COPD and 7 (26.9%) for emphy-
sema. There are no case-control studies for emphysema.
Of the 193 principal studies, 145 (75.1%) provide
results for both sexes, 42 (21.8%) for males only, and six
(3.1%) for females only. Ninety-six (49.7%) of the studies
include subjects under 30 (at baseline for prospective
studies), while only 24 (12.4%) are restricted to subjects
aged 50 or more. Subjects aged 80 or more are included
by 103 (53.6%), while only 20 (10.3%) are restricted to
subjects aged 60 or less. Fifty-six (29.0%) principal stu-
dies were conducted in USA or Canada, with 32 (16.6%)
in Scandinavia, 32 (16.6%) in Asia, 23 (11.9%) in the
UK, 17 (8.8%) in Western Europe, 14 (7.3%) in other
parts of Europe, eight (4.1%) in South or Central Amer-
ica and seven (3.6%) elsewhere. Four (2.1%) were carried
o u ti nm o r et h a no n eo ft h e s ea r e a s .O ft h e1 5 9p r i n c i -
pal studies where the start year is given, 76 (47.7%)
started before 1980. For 26 (13.5%) of the 193 studies a
major study weakness is noted. Most commonly this is a
failure to clarify, or to state at all, how study subjects
were selected (studies ALESSA, ANDER3, COCCI, ITA-
BAS, MOLLER, SHIMUR, ZIETKO). Other more com-
monly occurring weaknesses include use of
unrepresentative samples which oversampled smokers
(DEJONG, DETORR, JENSEN), those with respiratory
disease (VOLLM1, VOLLM2) or those with occupa-
tional exposure (PETO, PRATT), and the use of con-
trols that systematically differ from cases and controls in
v a r i o u sw a y s( B R O G G E ,D E A N 1 ,L U N D B 2 ,S T E R L I ) .
These weaknesses are described more fully in the foot-
notes to Table 2.
Most principal studies provide some results compared
to never smokers, 146 (75.6%) for current smokers, 134
(69.4%) for ex smokers and 158 (81.8%) for ever smo-
kers. Dose-response data a r ec o m m o n l ya v a i l a b l eb y
amount smoked (77 studies, 39.9%) and by pack-years
Table 1 Reasons for rejection of publications identified
Reason
a Number of
publications
IMMEDIATE REJECTS 63
Title of publication indicates it is irrelevant (abstract/
paper unavailable)
60
Publication could not be obtained 3
PUBLICATION DOES NOT PROVIDE ORIGINAL DATA 430
Results the same as or superseded by another
publication
16
Review (including guideline, handout, lecture,
bibliography, meta-analysis)
329
Editorial 31
Comment, letter, interview or news article 47
Publication is a theoretical modelling exercise 7
STUDY POPULATION INAPPOPRIATE 343
Study of children or adolescents 30
Animal study 5
Study in population at high risk of respiratory disease,
such as risky occupations
71
Study of alpha-1antitrypsin deficient subjects 39
Study of subjects with other coexisting diseases or
conditions
105
Study of atypical populations 7
Subjects selected on smoking habits 61
Study of symptom-free or symptom-restricted
populations
25
STUDY DESIGN INAPPROPRIATE 323
Not a case-control, prospective or cross-sectional study 84
Study of cases only 216
Control group not appropriate 9
Selection of subjects not clear 14
OUTCOME INAPPROPRIATE 566
Outcome not relevant 557
Study of undiagnosed disease 4
Study of disease exacerbation 5
USEFUL RESULTS BY SMOKING UNAVAILABLE 425
Never smokers not considered 36
No relevant results by smoking 304
Comparisons with never smokers and ex-smokers
combined
17
Study of smokers of unusual cigarettes (e.g. chuttas) 2
Relative risks not calculable 61
Relative risks adjusted for symptoms or precursors of
disease
5
Total rejected 2150
aWhere publications had more than one reason for rejection, the publication
is counted under the first relevant reason listed
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Study REF
[refs]
Study
type
a
Country Years
b Population
c Outcome
(s)
d
Study group (if
Subsid)
e
Weakness
f
ALDERS [26,27] CCh UK/England 1977-82 CB No
ALESSA [28] CCp Italy 1992-93 COPD Yes
AMIGO [29] CCh Chile 2001-03 COPD No
ANDER1 [30] CS Canada 1963 COPD, CB No
ANDER2 [31] CS USA (ca 1964?) EM No
ANDER3 [32,33] CCp Poland (ca 1997?) COPD Yes
AUERBA [34,35] CS USA 1963-70 EM No
BANG [36] CS USA 1982-84 hispanic CB No
BECK1 [37] CS USA 1972-73 CB No
BECK2 [37] P USA 1972-73/1978 CB No
BEDNAR [38] CS Poland 2000-02 COPD No
BEST [39,40] P Canada 1955-56/1962 military veterans COPD, CB,
EM
No
BJORNS [41] CS Sweden 1990 CB No
BROGGE [42] CCm Norway 2003 COPD JOHANN Yes
BROWN [43] CS UK/England 1956 CB No
CERVER [44] CS Italy 1998-00 CB No
CHAPMA [45] CS USA 1976 parents CB HOUSE No
CHEN1 [46] P China 1972-78/1993 workers at 11 factories COPD No
CHEN2 [47] CS Canada 1994-95 household members COPD No
CHEN3 [48] CS Canada 2000-01 household members COPD Yes
CHENG [49] CS China 1992 COPD No
CLEMEN [50] P Belgium 1960-*/1975 Air Force personnel COPD No
COATES [51] CS USA 1962 Post Office employees CB No
COCCI [52] CCp Italy (ca 2000?) COPD Yes
COLLEG [53,54] CS UK/GB (ca 1960?) CB No
DEAN1 [55,56] CCp UK/England 1969-73 COPD Yes
DEAN2 [57] CS UK/GB 1972 CB No
DEANE [58] CS USA 1963 telephone company employees CB No
DEJONG [59] CS USA (ca 2003?) COPD Yes
DEMARC [60-62] CS Multi-Europe 1991-93 COPD, CB No
DETORR [63] CS Spain 2001-03 patients COPD Yes
DICKIN [64] CS UK/England (ca 1997?) COPD No
DOLL1 [65-67] P UK 1951/1991 doctors COPD, CB No
DOLL2 [66,68] P UK 1951/1973 doctors COPD, CB No
DONTA1 [69] CS Greece 1960 COPD JACOBS Yes
DONTA2 [69] P Greece 1960/1970 CB, EM JACOBS Yes
DOPICO [70] CS USA (ca 1982?) employed
g CB No
EHRLIC [71] CS South Africa 1998 household members CB No
EKBERG [72] CS Sweden 1974-92 COPD No
ENRIGH [73] CS USA 1989-90 health insurance members CB, EM No
ENSTRO [74] P USA 1960/1998 household members COPD HAMMO2 No
FERRI1 [54,75-77] CS USA 1961 household members COPD, CB FERRI2 No
FERRI2 [75,78] CS USA 1967 household members, long term
residents
COPD No
FERRI3 [79] CS USA 1973 household members, long term
residents
COPD FERRI2 No
FIDAN [80] CS Turkey 2000-01 coffeehouse or shop workers COPD No
FINKLE [81] CS USA 1969-70 military recruits CB No
FLETCH [82] CS UK 1956-57 employed
g CB No
FORAST [83] CS USA 1993-94 COPD Yes
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Page 7 of 61Table 2 Selected details of the 218 studies of COPD, CB and/or emphysema (Continued)
FOXMAN [84] CS USA (ca 1981?) CB No
FUKUCH [85] CS Japan 2000 household members COPD No
GEIJER [86] P Netherlands 1998/2003 COPD No
GODTFR [18,87] P Denmark 1964-93/1997 COPD No
GOLDBE [88] CS USA 1970 parents CB No
GULSVI [89-91] CS Norway 1972-74 COPD, EM No
HAENSZ [92] CS Norway 1964 mixed
h CB No
HAMMO2
[93-97]
P USA 1959-60/1965 household members COPD, EM No
HARDIE [98] CS Norway 1998-99 COPD, CB,
EM
No
HARIKK [99] P USA 1962-*/(ca
2000?)
COPD No
HARRIS [100] CS Nigeria (ca 1992?) soldiers CB No
HAWTHO [101] P UK/Scotland 1965-75/1977 mixed
h COPD, CB TANG Yes
HAYES [102] CS USA 1970 parents CB No
HEDMAN [103] CS Finland 1996 COPD No
HIGGI2 [104] CS UK/Wales 1956 CB PETO No
HIGGI3 [105] CS UK/Scotland 1956 CB No
HIGGI4 [106,107] P USA 1962-79/1987 COPD Yes
HIGGI6 [108,109] CS USA 1962-65 CB HIGGI4 No
HIRAYA
[110,111]
P Japan 1965/1982 CB, EM No
HO [112,113] CS Hong Kong 1991 long term residents COPD, CB,
EM
No
HOLLA2 [114] CS USA 1962 telephone company employees CB No
HOLLNA
[115,116]
CS Denmark 1976-77 CB No
HOUSE [117] CS USA 1970 parents CB No
HOZAWA
[118-120]
CS USA 1987-89 COPD, EM No
HRUBEC [121] CS USA (ca 1972?) veterans and twins CB No
HUCHON [122] CS France (ca 2001?) household members CB No
HUHTI1 [123] CS Finland 1961 COPD, CB,
EM
No
HUHTI2 [124] CS Finland 1971 long term residents COPD, CB HUHTI1 No
HUHTI3 [125] CS Finland 1968-70 COPD, CB No
ITABAS [126] CCp Japan (ca 1989?) COPD Yes
JACOBS [127] P Multi-Europe 1957-64/(ca
1989?)
COPD No
JAENDI [128] CS Spain 2001-02 patients COPD Yes
JENSEN [129] CS Denmark (ca 1996?) patients CB Yes
JINDA2 [130] CS India (ca 2004?) household members CB No
JOHANN
[131-134]
CS Norway 1996-97 long term residents COPD No
JOSHI [135] CS India (ca 1974?) employed
g CB No
JOUSI1 [136] CS Finland 1972-77 CB No
KACHEL [137] CS Poland (ca 2002?) workers at five factories COPD No
KAHN [138-144] P USA 1954-57/1980 military veterans COPD, CB,
EM
No
KAHN2 [138] P USA 1954-57/1962 military veterans COPD, CB,
EM
KAHN No
KARAKA [145] NCCp Greece */1996 COPD VINEIS No
KATANC [146] CS USA 1997-98 mixed
h COPD No
KATO [147] CS Japan 1985 CB No
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Page 8 of 61Table 2 Selected details of the 218 studies of COPD, CB and/or emphysema (Continued)
KHOURY [148] CS USA (1970s) mixed
h COPD Yes
KIM [149] CS Korea 2001-02 household members COPD No
KIRAZ [150] CS Turkey 1999 mixed
h COPD, CB No
KLAYTO [151] CS USA (ca 1974?) employed
g COPD Yes
KOJIMA [152] CS Japan 2001-02 COPD No
KOTAN1 [153] CS Finland 1995-96 CB No
KOTAN2 [154] CS Finland 1996-97 COPD KOTAN1 No
KRZYZA [155] P Poland 1968/1981 COPD No
KUBIK [156] CS Czechoslovakia 1972 CB Yes
KULLER [157] P USA 1972-74/1980 volunteers COPD No
LAI [158] CS China 2001-03 COPD No
LAM1 [159] P China 1976/1996 employed
g COPD No
LAM2 [160,161] CS China 1987 military veterans COPD No
LAM3 [160-162] P China 1987/2005 military veterans COPD No
LAMBER
[163,164]
CS UK 1965 household members CB TODD No
LANGE [165-169] P Denmark 1976-78/1989 COPD GODTFR No
LANGE2 [170] CS Denmark 1991-94 CB VESTBO No
LANGHA [19] CS Norway 1995-97 CB No
LAVECC [171] CS Italy 1983 household members CB, EM No
LEBOWI
[172-177]
CS USA 1972-73 household members COPD, CB,
EM
No
LEE [164,178] P UK 1964-65/1977 siblings of migrants COPD No
LIAW [179] P Taiwan 1982-86/1993 volunteers COPD WEN No
LINDBE [180] P Sweden 1996/2003 long term residents COPD No
LINDST [181] CS Europe (ca 1998?) COPD, CB No
LIU1 [182] CCd China 1986-91 COPD No
LIU2 [183,184] CS China 2002-03 COPD No
LUNDB1
[185,186]
CS Sweden 1996-97 long term residents COPD No
LUNDB2
[187-189]
CCp Sweden 1986 CB LUNDB1 Yes
MADOR [190] CCh USA (ca 2002?) military veterans COPD No
MAGNUS [191] CS Iceland 1993 CB No
MANFRE [192] CS Canada 1978-79 CB No
MANNI1
[193-198]
CS USA 1988-94 COPD No
MANNI2
[199,200]
CS USA 1971-75 household members COPD No
MANNI3 [199] P USA 1971-75/1992 household members COPD No
MARAN1 [201] CS Thailand 1998 COPD Yes
MARAN2 [201] P Thailand 1998/1999 COPD Yes
MARCUS [202] P USA 1965-68/1984 Japanese ancestry COPD No
MATHES [203] CCp Australia (ca 2005?) COPD No
MELLST [204] CS Sweden 1971-77 CB No
MENEZ1 [205] CS Brazil 1990 household members CB No
MENEZ2
[206,207]
CS Brazil 2003 household members COPD No
MENEZ3 [206] CS Chile 2003 household members COPD No
MENEZ4 [206] CS Mexico 2003 household members COPD No
MENEZ5 [206] CS Uruguay 2003 household members COPD No
MENEZ6 [206] CS Venezuela 2003 household members COPD No
MEREN [208] CS Estonia 1995-96 CB No
MILLER [209] CS USA 1978 household members CB, EM No
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Page 9 of 61Table 2 Selected details of the 218 studies of COPD, CB and/or emphysema (Continued)
MILNE [210,211] CS UK/Scotland 1968-70 CB No
MOLLER [212] CCp Germany (ca 1999?) CB Yes
MONTNE
[213-215]
CS Sweden 1992 COPD No
MUELLE [216] CS USA 1967 household members COPD, CB No
NAWA [217] CS Japan 1998-00 mixed
h EM No
NEJJAR [218] CS France 1991 household members CB No
NIEPSU [219] CS Poland 2001 COPD Yes
NIHLEN
[220,221]
P Sweden 1992/2000 long term residents COPD No
NILSSO
[222-224]
P Sweden 1963/1996 COPD No
OGILVI [225] CCp UK/England 1955-56 household members CB No
OMORI [226] CS Japan (ca 2004?) EM Yes
OSWAL1 [227] CCh UK/England 1951-53 mixed
h CB No
OSWAL2 [228] CS UK/England 1954-55 civil servants CB Yes
PANDEY
[229,230]
CS Nepal 1979-80 CB No
PEAT [231,232] P Australia 1966-75/1984 COPD No
PELKON [233] P Finland 1959/2000 COPD, CB JACOBS No
PEREZP [234] CCm Mexico 1992-94 COPD, CB No
PETO [235] P UK/England and
Wales
1954-61/1981 mixed
h COPD Yes
PRATT [236] CS USA (ca 1978?) military veterans EM Yes
PRICE [237,238] CS UK (ca 2004?) COPD No
REID [239] CS USA 1962-63 mixed
h CB No
RENWIC [240] CS UK/England 1992-94 COPD No
RICCIO [241] CS Italy 2002 patients COPD Yes
RIMING
[242,243]
CS UK/England 1970 volunteers CB No
RYDER [244] CS UK/Wales (ca 1969?) EM No
SARGEA
[245,246]
CS UK/England 1993-96 COPD VINEIS No
SAWICK
[247,248]
CS Poland 1968 COPD, CB No
SCHWAR
[249,250]
CS USA 1976-80 household members CB No
SHAHAB [251] CS England 2001 COPD No
SHARP [252,253] CS USA 1960-61 employed
g CB No
SHIMUR [254] CCh Japan (ca 1994?) CB Yes
SHIN [255] CS Korea 1999-00 household members COPD No
SICHLE [256] CS Greece 2000-01 COPD No
SILVA [257-260] P USA 1972-*/(ca
1992?)
household members COPD, CB,
EM
No
SOBRAD
[261-264]
CS Spain 1996-97 CB No
SPEIZE [265] P USA 1974-77/1986 household members COPD No
STERLI [266,267] CCp USA 1986-87 COPD Yes
STJERN [268] CS Sweden 1981 CB No
STROM [269] CS Sweden 1982-83 long term residents COPD No
SUADIC [270] CS Denmark 1985-86 employed
g CB No
SUTINE [271] CS Finland 1971-72 EM No
TAGER [272] CS USA 1973-74 COPD No
TAGER2 [273] CS USA 1973-74 household members CB Yes
TANG [274] P UK 1967-82/* mixed
h COPD No
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THUN
[96,97,275,276]
P USA 1982/1988 household members COPD No
TODD [164,178] P UK 1965-66/1977 household members COPD No
TROISI [277] P USA 1980/1990 nurses CB No
TRUPIN
[278,279]
CS USA 2001 telephone subscribers COPD No
TSUSHI [280] CS Japan 2003-04 volunteers COPD No
TVERDA [281] P Norway 1972-78/1988 COPD Yes
URRUTI [282] CS Spain (ca 2004?) CB DEMARC No
VESTBO
[168,283]
CS Denmark 1976-78 COPD No
VIEGI1 [284] CS Italy 1980-82 household members CB No
VIEGI2 [285] CS Italy 1988-91 COPD No
VIKGRE [286-288] P Sweden 1994-95/2001 long term residents EM No
VINEIS [289] P Europe 1993-98/(ca
2003?)
volunteers COPD No
VOLLM1 [290] CS USA 1971-72 volunteers COPD VOLLM2 Yes
VOLLM2 [290] P USA 1971-72/1982 volunteers COPD Yes
VONHER [291] CS Finland 1978-80 COPD No
WAGEN2
[292-294]
CCp Netherlands 2001 employed
g CB No
WALD [295] P UK/England 1975-82/1993 professional/business men COPD TANG Yes
WANG2 [296] CS Japan 1996-98 volunteers EM No
WATSON [297] CCp UK (ca 2000?) COPD No
WEISS [298] CS USA 1961 volunteers COPD, EM No
WEN [299] P Taiwan 1982-92/2000 mixed
h COPD, CB,
EM
No
WIG [300] CS India (ca 1963?) household members CB Yes
WILHEL [301] CS Sweden 1967 CB No
WILSO1 [302] CS Australia 2000 household members COPD No
WILSO2 [303] CS Australia 1998 household members CB, EM No
WOJTYN
[304,305]
CS Poland 1968-73 COPD, CB SAWICK No
WOODS [306] CS Australia (ca 1998?) CB No
WOOLF [307] CS Canada (ca 1970-73?) employed
g CB No
XIAO [308] CCp China (ca 2003?) COPD No
XU [309] CS China 2000-01 long term residents COPD No
YAMAGU
[20,310]
CS China 1986 long term residents COPD, CB No
YUAN [311] P China 1986-89/1993 COPD No
ZIELI1 [312-314] CS Poland 1999 volunteers COPD No
ZIELI2 [315-317] CS Poland 2000-03 volunteers COPD No
ZIETKO [318] CCp Poland (ca 2003?) COPD Yes
ZOIA [319] CS Italy (ca 1993?) CB No
aCS = cross-sectional, P = prospective, CC = case control, NCC = nested case-control, h = hospital or clinic controls, p = population controls, d = decedent
controls, m = mixed controls.
b* = unknown. Values in brackets are approximate, based on one year before first publication. For prospective studies, baseline year(s)/final follow-up year.
Results refer to the full follow-up period except:
DOLL1, DOLL2 CB, to 1961
HIRAYA Emphysema (except by amount smoked), to 1978
KAHN Current smoking by amount smoked, to 1970
NILSSO Smoking of any product, to 1979
THUN Ex and ever smoking, to 1986
c Unless shown otherwise in this column, the study specified no major inclusion criteria.
d COPD = chronic obstructive lung disease, CB = chronic bronchitis, EM = emphysema
e For subsidiary studies, this column shows the relevant principal study.
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Page 11 of 61f Weakness identified, including studies where the base for comparison of the major smoking indices was not strictly never smokers:
ALESSA Small clinical study, not stated how subjects selected
ANDER3 Small clinical study, not clear how controls were selected
BROGGE More cases than controls were drawn from hospital sample (with hospitalisation for COPD in last 5 years) and their average age was 3.5 years older
CHEN3 Analysis combines current smokers with those who gave up in last 5 years, and omits those who started smoking before age 13 or after age 22
COCCI Small clinical study, not stated how cases and controls were selected
DEAN1 Cases occurred in 1969-72 while information on controls was collected in 1973. Cases were population sample but controls were household members
only
DEJONG Non-representative convenience sample particularly aimed at smokers
DETORR Subjects were volunteers, invited from all smokers attending wards or clinics, so likely to have concomitant disease
DONTA1 Inclusion of various lung diseases other than COPD in study endpoint, exclusion of subjects who died, emigrated or made dramatic changes to their
smoking habits during follow-up
DONTA2 Exclusion of subjects who died, emigrated or made dramatic changes to their smoking habits during follow-up
FORAST Cases without symptoms in the last year were excluded
HAWTHO Base for comparison includes smokers of up to 5 cigarettes per day
HIGGI4 Because of inadequate detail in the report and use of differing age groups in different tables, estimates are rather speculative
ITABAS Small clinical study, not stated how cases and controls were selected
JAENDI Study population were those who visited their primary care physician, so may have been less healthy than the general population. Some attempts were
made to contact patients who did not visit their physician during the study period, but it is unclear if they were then included in the study. It is not clear why
only 7% of subjects were age 65+
JENSEN All subjects were participants in smoking cessation programme
KHOURY 13% of sample were 1st degree relatives of COPD cases, and a further 3% were 1st degree relatives of lung cancer cases
KLAYTO Base for comparison includes smokers of up to 5 pack-years
KUBIK Base for comparison includes smokers of up to 3 cigarettes per day
LUNDB2 A few subjects were analysed as controls (as determined at the start of the study) even if diagnosed with CB or asthma at the second phase of the
study when the diagnosis category of the cases was determined
MARAN1 Base for comparison includes smokers of up to 0.5 pack-years
MARAN2 Base for comparison includes smokers of up to 0.5 pack-years
MOLLER Small clinical study, not clear how subjects were selected
NIEPSU Numbers of smokers not given for subset of participants undergoing spirometry (74%), therefore estimated using same proportions as whole study
sample
OMORI Different diagnostic techniques used for smokers
OSWAL2 Base for comparison includes smokers of up to 5 cigarettes per day or who had smoked for less than 5 years
PETO Three of the samples were drawn from mining areas with over 60% miners or other dusty jobs, implying about 40% of the overall sample were
occupationally exposed.
PRATT Study contained small number of subjects who were cotton or tobacco farmers or who worked in tobacco factory
RICCIO Subjects were recruited through a respiratory clinic but it is not stated whether they all had respiratory conditions. The definition of a smoker seems
implausible
SHIMUR Small autopsy study, not clear how subjects were selected
STERLI All decedents proxy vs. none of living sample. Living sample 1 year later than decedents
TAGER2 Age distribution for both men and women in study sample was significantly different from general population from which sample was drawn. Subjects
who smoked but did not inhale were excluded
TVERDA Includes acute bronchitis
VOLLM1 Study population consists of volunteers who responded to extensive media advertising and cohort is biased towards those with respiratory disease, and
analysis restricted to those with follow-up data. Subjects with abnormal baseline FEV were not invited to some phases so may have different follow-up rate
VOLLM2 Study population consists of volunteers who responded to extensive media advertising and cohort is biased towards those with respiratory disease, and
analysis restricted to those with follow-up data. Subjects with abnormal baseline FEV were not invited to some phases so may have different follow-up rate
WALD Includes ICD9: 416 (chronic pulmonary heart disease) and 519 (other diseases of respiratory system)
WIG Urban area is not a typical sample, as socio-economic status is above average
ZIETKO Small clinical study, not clear how controls were selected
Note that weakness is in respect of the current review, and is not a criticism of the original study which may have been designed with different objectives.
g Study conducted in employed or occupational group:
DOPICO outdoor workers for city and power company
FLETCH men-postmen, women-clerical workers
JOSHI employees at machine tool factory and woollen hosiery mill
KLAYTO employees at two research facilities
LAM1 employees in a machine factory
SHARP clerical and light assembly workers at power company
SUADIC armed forces, customs service, railway, telephone, post, banking and construction companies
WAGEN2 heterogeneous population of employees from different companies and organisations
WOOLF employees of large commercial firms
h Study conducted in mixed groups:
HAENSZ nationwide sample plus siblings of migrants to USA still resident in Norway
HAWTHO occupational groups (from industry, not otherwise specified) and census-identified sample
KATANC whites from Medicare, blacks from general population
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Page 12 of 61(58, 30.1%), but less so by age of starting to smoke (17,
8.8%), duration of smoking (12, 6.2%) or duration of
quitting (18, 9.3%).
Of the 116 principal studies of COPD, outcome is
b a s e do nI C Dc o d e si n2 9( 2 5 . 0 % ) ,a n dl u n gf u n c t i o n
only in 59 (50.9%). The GOLD criteria are used in 27
( 2 3 . 2 % )s t u d i e s ,w i t hM R C ,A T S ,E R So rB T Sc r i t e r i a
used in 12 (10.3%). In 69 (59.5%) studies the subjects’
asthma status is ignored, in 18 (15.5%) all asthmatics
subjects are excluded, and in 14 (12.1%) the disease defi-
nition includes asthma. Only 19 (16.4%) of the 116 prin-
cipal studies mention conducting spirometry after use of
a bronchodilator. The outcome is based on prevalence
in 79 (68.1%) principal studies, mortality in 28 (24.1%)
and incidence in 10 (8.6%). In the principal studies, the
median number of subjects is 2,033, and of cases 131
(range 13 to 32,822).
Of the 87 principal studies of CB, the outcome is
based on symptoms (not lung function) in 59 (67.8%),
and on ICD in only six (6.9%). Other studies use self-
report, a doctor diagnosis, or other definitions. The
MRC questionnaire is used in 21 (24.1%). Asthmatics
are excluded totally from six (6.9%) studies, with asth-
matics excluded only from the controls in three (3.4%).
The outcome is based on prevalence in 78 (89.7%) of
the principal studies, mortality in six (6.9%) and inci-
dence in three (3.4%). The median number of subjects is
2,826, and of cases 193.5 (range 2 to 4,769).
Of the 26 principal studies of emphysema, the out-
c o m ei sb a s e do nv i s u a lc o m p a r i s o ni n1 0( 3 8 . 5 % ) ,o n
diagnosis in seven (26.9%), on ICD codes in five (19.2%)
and on other sources including self-report in four
(15.4%). Asthmatics are excluded in two (7.7%) studies.
The outcome is based on prevalence in 19 (73.1%) of
the studies, on mortality in five (19.2%) and on inci-
dence in two (7.7%). The median number of subjects is
2,433, and of cases 96.5 (range 2 to 1384).
Relative risks
A total of 3,538 RRs are entered, 1,578 for COPD, 1,689
for CB and 271 for emphysema, the number recorded
per study varying from 1 to 211. Some 675 relate to
subsidiary studies. Table 4 summarizes the distribution
of various characteristics of the RRs by outcome, by
study type for the principal studies, and overall. For
fuller distributions of the RRs, referred to as necessary
below, see Additional file 3.
Of the 2,863 RRs in principal studies, 67.8% relate to
cross-sectional, 19.8% to prospective, and 12.4% to case-
control studies. 81.2% of RRs are sex-specific. About
half the RRs (52.0%) are adjusted for one or more vari-
ables. Of 1,488 adjusted RRs, age is adjusted for in 1,382
(92.9%) but only 490 (32.9%) are adjusted for variables
other than age, sex or other smoking aspects. 34.0% of
the RRs are given directly or calculated from a 2 × 2 or
2×2×ℓ table, the rest being derived.
Of the 3,538 RRs, 1,439 are for major smoking indices,
and 2,099 for dose-related indices (including 236 and
439 respectively in subsidiary studies). Of the 1,203 RRs
in principal studies for major indices, 34.6% are for ever
smoking, 37.8% current smoking and 27.6% ex smoking.
53.6% are for cigarette smoking ignoring other products,
33.8% any product smoking, and 12.6% cigarettes only.
The unexposed group is typically never any product
(55.8%) or never cigarettes (43.1%).
The distribution of smoking status for the 1,660 RRs
in principal studies for dose-related indices differs con-
siderably, with 22.8% for ever smoking, 59.6% current
smoking and 17.6% ex smoking. Again, most (59.8%)
RRs relate to cigarette smoking ignoring other products.
The unexposed group is never smoking (any product or
cigarettes) for 50.4% of these RRs, low smoking for
39.2%, and current smoking for 3.9%. 52.7% of RRs are
for amount smoked, 8.1% age of starting, 19.8% pack-
years, 4.4% years duration, and 15.1% years quit (about
half compared to never smokers or long-term quitters,
t h er e s tc o m p a r e dt oc u r r e n ts m o k e r so rs h o r t - t e r m
quitters). Based on RRs with an unexposed base of
never smoking, there are 174 sets of categorical data for
amount smoked, 18 for age of starting, 52 for pack-
years, 11 for duration of smoking, and 26 for duration
of quitting. For emphysema, there are few dose-related
data other than for amount smoked
None of the RRs included in the meta-analyses and
meta-regressions show more than minor failures of the
validation tests used, attributable to rounding errors or
small imprecisions or uncertainties in estimating the
RRs and CIs. Additional File 3 provides further detail.
KHOURY subjects were relatives of COPD cases (cases having been identified through Johns Hopkins Hospital respiratory laboratory), relatives of lung cancer and
non-pulmonary patients, or community-based samples (neighbours and teachers)
KIRAZ rural group using biomass cookers and urban group using fuel oil
NAWA healthy workers/retired persons
OSWAL1 cases were general clinic patients, and civil servants referred after repeated sickness due to bronchitis
PETO occupational groups (transport and clerical workers) and census-identified sample
REID general and migrants from UK and Norway
TANG businessmen/professionals, civil servants, general population from socially deprived area, industrial workers
WEN community cohort were volunteers invited for screening and comprised 25% of population in study areas; other cohort were civil servants and teachers in
government employee insurance scheme
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Disease studied (principal studies) Study type (principal studies)
a Subsidiary All
Characteristic Level COPD CB EMP CC Prosp Cross-sec studies studies
Study status Principal 116 87 26 20 39 134 - 193
Subsidiary (17) (14) (2) - - - 25 25
Study type Case/control 14 7 0 20 - - 2 22
Prospective 35 9 7 - 39 - 8 47
Cross-sectional 67 71 19 - - 134 14 148
Nested case/control 0 0 0 - - - 1 1
Study sex Both 89 62 18 17 20 108 20 165
Male 23 20 8 2 17 23 5 47
Female 4 5 0 1 2 3 0 6
Lowest age
b <2 0 2 6 2 2 1 0 5 4 4 2 3 5 4
20-29 28 25 2 3 10 32 9 54
30-39 23 12 4 6 15 11 6 38
40-49 26 17 4 5 7 29 5 46
50+ 13 11 6 1 3 20 2 26
Highest age
b <5 0 3 6 0 0 2 6 1 9
50-59 4 8 0 0 4 8 1 13
60-69 20 21 6 2 9 29 5 45
70-79 19 12 1 4 6 19 8 37
80+ 70 39 19 14 18 71 10 113
Unknown 0 1 0 0 0 1 0 1
Region USA/Canada 31 28 12 2 14 40 7 63
S/C America 7 2 0 2 0 6 0 8
UK 11 13 1 5 6 12 5 28
Western Europe 8 9 1 4 2 11 1 18
Scandinavia 18 16 5 0 6 26 7 39
Other Europe 12 4 0 2 1 11 4 18
Asia 22 10 6 4 7 21 1 33
Other 3 4 1 1 1 5 0 7
Multicountry 4 1 0 0 2 2 0 4
Start year of study < 1960 7 10 3 2 7 4 3 16
1960-1969 19 15 4 1 12 17 8 38
1970-79 15 19 5 1 9 23 6 39
1980-89 12 10 4 2 5 13 2 22
1990-99 23 16 6 2 6 29 3 40
> 1999 25 1 0 2 0 24 1 27
Unknown 15 16 4 10 0 24 2 36
Major study weakness Present 19 5 2 9 4 13 6 32
Smoking results available Current v never 89 70 15 14 34 98 23 169
Ex v never 82 65 12 12 29 93 19 153
Ever v never 95 71 20 16 29 113 18 176
Amount smoked 39 42 10 7 23 47 14 91
Age started 13 3 1 5 7 5 3 20
Pack years 42 13 3 10 5 43 5 63
Duration of smoking 6 4 3 2 4 6 2 14
Duration of quitting 8 7 2 3 8 7 4 22
Outcomes COPD only 93 - - 13 28 52 11 104
CB only - 63 - 6 2 55 7 70
Emp only - - 9 0 1 8 0 9
More than one 23 24 17 1 8 19 7 35
COPD 116 - - 14 35 67 17 133
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Page 14 of 61Table 3 Distribution of the main characteristics of the 218 studies of COPD, CB and/or emphysema (Continued)
CB - 87 - 7 9 71 14 101
Emp - - 26 0 7 19 2 28
All studies 116 87 26 20 39 134 25 218
a CC = case control, Prosp = prospective, Cross-sec = cross-sectional
b At start of study.
Table 4 Distribution of the main characteristics of the relative risks (principal studies only
a)
RRs Characteristic Level Outcome
COPD CB Emphysema Total
All RRs Total Total 1,342 1,311 210 2,863
Study type Case/control 194 162 0 356
Prospective 414 86 66 566
Cross-sectional 734 1,063 144 1,941
Sex Both 289 215 35 539
Male 660 552 114 1,326
Female 393 544 61 998
Adjusted for any variable No 605 677 93 1,375
Yes 737 634 117 1,488
Adjusted for age No 624 758 99 1,481
Yes 718 553 111 1,382
Adjusted for other confounders
b No 1,051 1,135 187 2,373
Yes 291 176 23 490
Derivation Original or 2 × 2
c 409 478 86 973
Other derived 933 833 124 1890
RRs for major smoking indices Total Total 551 547 105 1,203
Exposed group: smoking status Ever 185 186 45 416
Current 214 205 36 455
Ex 152 156 24 332
Exposed group: smoking product Any product 166 211 29 406
Cigarettes (+/- other) 314 269 62 645
Cigarettes only 71 67 14 152
Unexposed Never any product 283 335 53 671
Never cigarettes 261 206 52 519
Other
d 76 0 1 3
RRs for all dose-response indices Total Total 791 764 105 1,660
Exposed group: smoking status Ever 221 138 19 378
Current 415 492 83 990
Ex 155 134 3 292
Exposed group: smoking product Any product 64 176 8 248
Cigarettes (+/- other) 525 399 69 993
Cigarettes only 202 189 28 419
Unexposed Never (any or cigs) 389 387 60 836
Low
e (any or cigs) 318 295 38 651
Current (any or cigs) 33 32 0 65
Other
f/not applicable
g 51 50 7 108
RRs for amount smoked Total Total 335 474 65 874
Exposed group: smoking status Ever 3 51 9 63
Current 323 413 55 791
Ex 9 10 1 20
Sets for amount smoked vs. never (any or cigs) 66 94 14 174
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Page 15 of 61The meta-analyses and meta-regressions
The main findings are summarized in the following sec-
tions, with tables and forest plots. Fuller results of the
meta-analyses for the major smoking variables are given in
Additional file 4 for COPD, Additional file 5 for CB and
Additional file 6 for emphysema. Similar results for the
dose-related smoking variables are given in Additional file
7 for COPD, Additional file 8 for CB and Additional file 9
for emphysema. An Excel file, available as Additional file
10, allows the user readily to view selected results from all
these meta-analyses. Detailed meta-regression outputs are
given in Additional file 11. For dose-related indices,
Additional file 12 presents within-study plots of the dose-
response relationships, while Additional file 13 gives
results that were originally presented in a form unsuitable
for meta-analysis. The interested reader should first refer
to Additional file 1, which describes the content and struc-
ture of all these Additional files.
A. Risk from ever smoking
Figures 1 and 2 (COPD), 3 and 4 (CB) and 5 (emphy-
sema) present the results of the main meta-analyses for
ever smoking any product (or cigarette smoking from
studies without RRs for any product), based on most-
adjusted RRs. Additional results subdivided by level of
Table 4 Distribution of the main characteristics of the relative risks (principal studies only
a) (Continued)
vs. low amount 65 97 16 178
vs. non
h 29 0 1 1
Non categorical 9 11 3 23
RRs for age started Total Total 78 50 6 134
Exposed group: smoking status Ever 6 38 0 44
Current 65 12 6 83
Ex 7 0 0 7
Sets for age started vs. never (any or cigs) 12 4 2 18
vs. later start 21 9 2 32
vs. non
h 10 01
Non categorical 6 0 0 6
RRs for pack-years Total Total 225 88 15 328
Exposed group: smoking status Ever 208 48 5 261
Current 14 30 10 54
Ex 3 10 0 13
Sets for pack-years vs. never (any or cigs) 34 15 3 52
vs. low pack-years 41 15 3 59
Non categorical 25 9 2 36
RRs for duration of smoking Total Total 17 39 17 73
Exposed group: smoking status Ever 4 1 5 10
Current 13 37 12 62
Ex 0 1 0 1
Sets for duration of smoking vs. never (any or cigs) 2 6 3 11
vs. low duration 2 6 2 10
Non categorical 5 5 0 10
RRs for duration of quitting Total Total 136 113 2 251
Sets for duration of quitting vs. never (any or cigs) 13 13 0 26
vs. current 12 11 0 23
vs. long term ex 14 11 0 25
vs. recent ex 14 11 0 25
Non categorical 2 3 2 7
a The number of additional RRs recorded for subsidiary studies was 236 for COPD, 378 for CB and 61 for emphysema.
b Variables other than sex, age and aspects of smoking
c Calculated directly from 2 × 2 or 2 × 2 × ℓ table
d Never or low amount (any or cigs)
e Low in terms of the measure of exposure (e.g. low amount for amount smoked, later starting for age started)
f Never or low amount (any or cigs); or never and ex smokers combined
g Dose-response RR not for categorical data
h Never and ex smokers combined
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0.2  0.4  1 25  50 
REF SEX  Weight  Relative Risk  Relative Risk
(%)  95% CI  95% CI
  ALESSA b 0.07  2.07 (0.76, 5.65) 
  AMIGO m  0.03  4.65 (0.98, 22.09) 
  AMIGO f 0.06  7.88 (2.55, 24.36) 
  ANDER1 m 0.03  5.13 (1.14, 23.05) 
  ANDER1 f  0.12  1.18 (0.53, 2.64) 
  ANDER3 m 0.01  31.00 (1.59, 605.65)
  ANDER3 f  0.01  2.00 (0.11, 35.81) 
  BEDNAR b  0.26  1.58 (0.92, 2.71) 
  BEST m  0.11  10.02 (4.42, 22.72) 
  CHEN2 m  0.13  3.43 (1.60, 7.38) 
  CHEN2 f 0.35  2.57 (1.62, 4.07) 
  CLEMEN m  0.18  2.26 (1.18, 4.33) 
  COCCI b 0.01  19.74 (1.03, 379.94)
  DEAN1 m  0.56  2.54 (1.76, 3.66) 
  DEAN1 f 0.66  1.92 (1.37, 2.69) 
  DEJONG b  0.01  24.79 (1.49, 411.13)
  DEMARC b 1.87  1.76 (1.44, 2.15) 
  DICKIN b 0.02  25.45 (3.44, 188.43)
  DOLL1 m  0.23  6.54 (3.71, 11.53) 
  DOLL2 f  0.02  11.02 (1.43, 84.78) 
  EKBERG m  5.65  2.10 (1.87, 2.36) 
  EKBERG f  2.29  2.57 (2.15, 3.08) 
  FERRI2 m  0.17  3.88 (2.01, 7.49) 
  FERRI2 f  0.54  2.28 (1.57, 3.31) 
  FIDAN m  0.03  6.96 (1.45, 33.26) 
  FORAST f 0.34  2.36 (1.48, 3.77) 
  FUKUCH b 0.86  2.97 (2.21, 4.00) 
  GODTFR b 1.09  5.46 (4.20, 7.10) 
  GULSVI m  0.02  18.60 (2.52, 137.03)
  GULSVI f 0.19  3.52 (1.88, 6.58) 
  HAMMO2 m 0.76  9.27 (6.76, 12.70) 
  HAMMO2 f 0.64  5.87 (4.17, 8.26) 
  HARDIE m 0.13  5.43 (2.55, 11.58) 
  HARDIE f  0.34  2.75 (1.72, 4.39) 
  HARIKK m  0.12  2.05 (0.93, 4.53) 
  HARIKK f  0.01  16.64 (0.96, 287.29)
  HIGGI4 m  0.22  3.08 (1.72, 5.52) 
  HO m 0.29  2.05 (1.24, 3.41) 
  HO f 0.26  2.71 (1.58, 4.66) 
  HOZAWA b 10.19 2.77 (2.54, 3.02) 
  HUHTI1 m  0.12  8.18 (3.68, 18.18) 
  HUHTI1 f  0.23  2.88 (1.62, 5.13) 
  HUHTI3 m  0.06  7.74 (2.62, 22.87) 
  ITABAS b 0.13  1.96 (0.91, 4.24) 
  JACOBS m 0.44  3.08 (2.03, 4.65) 
  JOHANN b  0.36  4.15 (2.62, 6.56) 
  KACHEL b 0.11  4.28 (1.91, 9.62) 
  KAHN2 m 0.56  6.69 (4.63, 9.66) 
  KARAKA b  0.24  2.20 (1.26, 3.84) 
  KATANC b 0.27  2.44 (1.44, 4.11) 
  KIM m 0.33  2.31 (1.44, 3.72) 
  KIM f 0.15  1.74 (0.85, 3.57) 
  KIRAZ f 0.07  6.86 (2.47, 19.06) 
  KLAYTO b 0.11  5.75 (2.50, 13.24) 
  KOJIMA m  0.33  3.02 (1.87, 4.86) 
  KOJIMA f  0.08  2.80 (1.05, 7.52) 
  KRZYZA m  0.10  2.63 (1.09, 6.38) 
  KRZYZA f 0.26  1.41 (0.82, 2.41) 
  LAI m  0.31  5.62 (3.43, 9.22) 
  LAI f  0.10  1.77 (0.75, 4.18) 
  LAM1 m  0.06  4.05 (1.31, 12.50) 
  LAM1 f 0.01  26.61 (2.08, 339.00)
  LAM2 m  0.67  2.68 (1.92, 3.75) 
  LAM3 m  0.12  1.81 (0.83, 3.98) 
  LEBOWI m  0.07  5.02 (1.76, 14.35) 
  LEBOWI f  0.38  1.66 (1.07, 2.59) 
5  10  2 
Figure 1 Forest plot of ever smoking of any product and COPD-part 1. Table 5 presents the results of a main meta-analysis for COPD
based on 129 relative risk (RR) and 95% confidence interval (CI) estimates for ever smoking of any product (or cigarettes if any product not
available). The individual study estimates are shown numerically and graphically on a logarithmic scale in Figures 1 and 2. The weights (inverse-
variance) are also shown numerically, expressed as a percentage of the overall weight. The studies are sorted in order of sex within study
reference (REF). In the graphical representation individual RRs are indicated by a solid square, with the area of the square proportional to the
weight. Arrows indicate where the CI extends outside the range allocated. Where the RR value falls outside the range, the size of the plotting
symbol indicates the weight but the position is not true to the scale.
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  0.2  0.4  1  25  50 
REF SEX  Weight  Relative Risk  Relative Risk
(%)  95% CI  95% CI 
  LEE m  0.02  4.73 (0.65, 34.28) 
  LEE f  0.07  1.74 (0.60, 5.09) 
  LINDBE b 0.27  2.28 (1.34, 3.88) 
  LINDST b  1.83  1.84 (1.50, 2.25) 
  LUNDB1 b  0.37  3.16 (2.01, 4.97) 
  MADOR m  0.01  18.20 (0.84, 396.21) 
  MANNI1 m  1.58  2.69 (2.16, 3.34) 
  MANNI1 f  1.91  3.18 (2.61, 3.88) 
  MANNI2 b  2.74  2.64 (2.24, 3.12) 
  MANNI3 b  0.49  1.47 (0.99, 2.17) 
  MARAN1 b  0.75  6.05 (4.41, 8.30) 
  MARAN2 b  0.29  5.47 (3.29, 9.11) 
  MARCUS m  0.22  2.17 (1.20, 3.90) 
  MATHES b  0.24  3.14 (1.78, 5.51) 
  MENEZ2 b  0.62  1.54 (1.08, 2.17) 
  MENEZ3 b  0.70  1.11 (0.80, 1.54) 
  MENEZ4 b  0.35  1.65 (1.04, 2.63) 
  MENEZ5 b  0.62  1.64 (1.16, 2.33) 
  MENEZ6 b  0.50  2.73 (1.85, 4.03) 
  MONTNE b  1.32  2.39 (1.88, 3.04) 
  MUELLE m  0.03  4.41 (1.01, 19.20) 
  MUELLE f  0.02  1.60 (0.26, 9.92) 
  NIEPSU b  0.12  3.94 (1.78, 8.74) 
  NIHLEN b 0.34  3.19 (1.99, 5.11) 
  NILSSO m  0.20  2.78 (1.50, 5.14) 
  NILSSO f  0.50  5.93 (4.02, 8.75) 
  PEREZP f  0.19  1.30 (0.69, 2.44) 
  PETO m  0.01  25.48 (1.59, 409.05) 
  RENWIC b  0.13  3.31 (1.54, 7.12) 
  RICCIO b  1.54  2.03 (1.62, 2.53) 
  SARGEA b  5.47  1.40 (1.25, 1.58) 
  SHAHAB b  3.94  2.14 (1.87, 2.46) 
  SHIN b  0.30  1.87 (1.14, 3.09) 
  SICHLE b  0.89  2.17 (1.63, 2.91) 
  SILVA b  0.30  1.59 (0.96, 2.63) 
  SPEIZE m  0.01  11.40 (0.69, 187.05) 
  SPEIZE f  0.07  4.20 (1.51, 11.66) 
  STROM m  0.23  2.81 (1.60, 4.96) 
  TANG m  0.23  4.12 (2.33, 7.28) 
  THUN m  0.85  8.96 (6.66, 12.06) 
  THUN f  1.06  8.05 (6.17, 10.50) 
  TODD m  0.02  6.88 (0.96, 49.58) 
  TODD f  0.04  0.89 (0.22, 3.57) 
  TRUPIN b 0.92  3.45 (2.59, 4.59) 
  TSUSHI b  0.12  5.42 (2.42, 12.12) 
  TVERDA m  0.12  2.88 (1.31, 6.33) 
  VESTBO b  3.61  1.91 (1.65, 2.20) 
  VIEGI2 m  0.28  1.39 (0.83, 2.32) 
  VIEGI2 f  0.46  1.20 (0.80, 1.80) 
  VONHER m  1.02  5.61 (4.28, 7.36) 
  VONHER f  1.18  3.79 (2.95, 4.88) 
  WEISS m  0.04  3.42 (0.79, 14.77) 
  WILSO1 b  0.37  3.93 (2.50, 6.16) 
  XIAO b  0.19  4.79 (2.57, 8.92) 
  XU m  2.85  1.26 (1.07, 1.48) 
  XU f  0.63  2.61 (1.85, 3.68) 
  YAMAGU b 1.72  1.97 (1.60, 2.43) 
  YUAN m  0.24  1.40 (0.80, 2.45) 
  ZIELI1 b  4.41  2.06 (1.81, 2.35) 
  ZIELI2 m  5.70  2.45 (2.18, 2.74) 
  ZIELI2 f  10.22  1.40 (1.29, 1.53) 
  ZIETKO m 
0.01 
77.17 (4.23, 1408.01) 
  ZIETKO f
0.01 
44.23 (2.23, 875.91) 
Total (95% CI)  100.00  2.89 (2.63, 3.17) 
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Figure 2 Forest plot of ever smoking of any product and COPD-part 2. This is a continuation of Figure 1, presenting the remaining
individual study data included in the main meta-analysis for COPD shown in Table 5. Also shown are the combined random-effects estimates.
These are represented by a diamond of standard height, with the width indicating the 95% CI.
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Page 18 of 610.20  0.40  1  25  50 
REF SEX  Weight  Relative Risk Relative Risk 
(%)  95% CI 95% CI 
  ALDERS m  0.27  2.81 (1.74, 4.54)
  ALDERS f  0.75  2.79 (2.09, 3.72)
  ANDER1 m  0.05  4.51 (1.53, 13.29)
  ANDER1 f  0.12  2.20 (1.08, 4.51)
  BECK1 m  0.04  4.41 (1.27, 15.26)
  BECK1 f  0.06  2.68 (0.96, 7.48)
  BECK2 m  0.02  1.94 (0.38, 9.91)
  BECK2 f  0.03  2.13 (0.48, 9.42)
  BEST m  0.05  11.44 (3.61, 36.25)
  BJORNS b  3.32  2.18 (1.90, 2.50)
  BROWN m  0.19  1.66 (0.94, 2.95)
  CERVER b  7.17  2.52 (2.29, 2.76)
  COATES b  0.28  3.63 (2.26, 5.82)
  COLLEG m  0.05  2.88 (0.98, 8.47)
  COLLEG f  0.22  2.64 (1.54, 4.52)
  DEANE m  0.04  6.15 (1.83, 20.63)
  DEMARC b 1.10  2.96 (2.33, 3.75)
  DOLL1 m  0.04  7.40 (2.22, 24.69)
  DONTA2 m  0.13  3.00 (1.48, 6.09)
  DOPICO m  0.07  2.53 (1.01, 6.32)
  EHRLIC m  0.25  1.27 (0.77, 2.10)
  EHRLIC f 0.50  1.64 (1.15, 2.34)
  ENRIGH m  0.22  2.04 (1.19, 3.49)
  ENRIGH f  0.71  1.62 (1.20, 2.18)
  FERRI1 m  0.13  3.22 (1.62, 6.42)
  FERRI1 f  0.27  2.17 (1.35, 3.51)
  FINKLE m  7.70  3.44 (3.14, 3.76)
  FOXMAN m  0.49  2.48 (1.73, 3.54)
  FOXMAN f  0.63  2.58 (1.88, 3.53)
  GOLDBE m  1.40  1.48 (1.20, 1.83)
  GOLDBE f  0.75  2.87 (2.15, 3.83)
  HAENSZ m  0.37  2.27 (1.51, 3.42)
  HAENSZ f  0.64  3.32 (2.43, 4.53)
  HARDIE m  0.02  10.90 (2.06, 57.56)
  HARDIE f  0.11  3.33 (1.59, 6.98)
  HARRIS m  0.06  3.87 (1.43, 10.41)
  HAWTHO m 0.72  3.25 (2.42, 4.36)
  HAWTHO f  1.21  2.95 (2.35, 3.70)
  HAYES b  0.56  5.70 (4.08, 7.97)
  HIGGI2 m  0.02  2.72 (0.35, 20.89)
  HIGGI2 f  0.05  2.46 (0.77, 7.83)
  HIGGI3 m  0.01  1.02 (0.05, 20.27)
  HIGGI3 f  0.01  12.17 (0.57, 262.12)
  HIGGI6 m  0.25  4.59 (2.78, 7.59)
  HIGGI6 f  0.42  2.99 (2.03, 4.40)
  HO b  0.39  2.32 (1.55, 3.46)
  HOLLA2 m  0.07  6.05 (2.41, 15.23)
  HOLLNA m 0.13  5.53 (2.79, 10.93)
  HOLLNA f  0.17  4.56 (2.50, 8.31)
  HOUSE m  0.64  4.21 (3.08, 5.75)
  HOUSE f  0.99  4.47 (3.48, 5.75)
  HUCHON b 1.79  2.21 (1.83, 2.66)
  HUHTI1 m  0.10  7.05 (3.17, 15.67)
  HUHTI1 f  0.12  3.63 (1.78, 7.40)
  HUHTI3 m  0.32  2.91 (1.87, 4.51)
  JINDA2 b  3.82  2.45 (2.16, 2.79)
  JOSHI m  0.12  6.30 (3.02, 13.14)
  JOUSI1 m  4.09  2.42 (2.14, 2.74)
  JOUSI1 f  2.94  1.66 (1.43, 1.92)
  KAHN2 m  0.18  2.75 (1.54, 4.93)
  KATO m  1.54  1.33 (1.09, 1.63)
  KATO f  2.76  1.92 (1.65, 2.23)
  KIRAZ f 0.09  4.00 (1.76, 9.08)
  KOTAN1 b  0.64  1.75 (1.28, 2.39)
  KUBIK m  5.67  3.77 (3.39, 4.19)
  KUBIK f  3.35  2.02 (1.76, 2.32)
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Figure 3 Forest plot of ever smoking of any product and CB-part 1. Table 5 presents the results of a main meta-analysis for CB based on
114 relative risk (RR) and 95% confidence interval (CI) estimates for ever smoking of any product (or cigarettes if any product not available). The
individual study estimates are shown numerically and graphically on a logarithmic scale in Figures 3 and 4. The weights (inverse-variance) are
also shown numerically, expressed as a percentage of the overall weight. The studies are sorted in order of sex within study reference (REF). In
the graphical representation individual RRs are indicated by a solid square, with the area of the square proportional to the weight. Arrows
indicate where the CI extends outside the range allocated.
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Page 19 of 61certain characteristics are shown in Table 5. From these
findings, various observations can be made.
First, the RRs for all three outcomes are markedly het-
erogeneous, with H at least 5 for all three diseases (p <
0.001). Individual RRs vary up to 77.17 for COPD (study
ZIETKO for males), 20.27 for CB (MILLER/females) and
16.58 for emphysema (HUHTI/males). Based on random-
effects estimates, a positive association is seen, strongest
for emphysema (RR 4.51, 95% CI 3.38-6.02, based on 28
RRs), but also clearly evident for COPD (2.89, 2.63-3.17, n
= 129) and CB (2.69, 2.50-2.90, n = 114). Although the
strength of association varies markedly by study, the
0.2  0.4  1  25  50 
REF SEX  Weight  Relative Risk Relative Risk
(%)  95% CI 95% CI
  LAMBER m  0.25  2.60 (1.58, 4.30)
  LAMBER f  0.53  2.88 (2.04, 4.06)
  LANGHA m  2.54  2.66 (2.28, 3.12)
  LANGHA f  3.29  1.95 (1.70, 2.24)
  LAVECC b 9.99  2.27 (2.10, 2.46)
  LEBOWI b  0.24  1.13 (0.68, 1.87)
  LINDST b  4.01  1.52 (1.34, 1.72)
  LUNDB2 m  0.15  7.84 (4.14, 14.83)
  LUNDB2 f 0.18  4.14 (2.30, 7.44)
  MAGNUS m 0.19  4.18 (2.36, 7.38)
  MANFRE m  0.04  5.40 (1.56, 18.72)
  MANFRE f  0.20  3.01 (1.72, 5.28)
  MELLST m  0.20  2.92 (1.67, 5.11)
  MENEZ1 b 0.26  2.93 (1.79, 4.80)
  MEREN b  1.14  1.75 (1.39, 2.22)
  MILLER m  0.14  5.24 (2.70, 10.17)
  MILLER f 0.03  20.27 (4.89, 84.04)
  MILNE m 0.04  8.25 (2.45, 27.77)
  MILNE f 0.09  3.54 (1.53, 8.18)
  MOLLER b 0.02  7.94 (1.41, 44.80)
  MUELLE m 0.03  7.08 (1.66, 30.19)
  MUELLE f 0.03  10.49 (2.74, 40.22)
  NEJJAR b  0.68  1.56 (1.15, 2.11)
  OGILVI m  0.12  3.28 (1.60, 6.71)
  OGILVI f 0.42  2.29 (1.56, 3.38)
  OSWAL2 m  1.09  1.41 (1.11, 1.79)
  OSWAL2 f  0.90  1.69 (1.30, 2.20)
  PANDEY m 0.11  5.37 (2.52, 11.45)
  PANDEY f  0.68  1.76 (1.30, 2.38)
  PELKON m 0.74  1.76 (1.32, 2.36)
  PEREZP f 0.21  1.08 (0.63, 1.87)
  REID m  0.24  4.61 (2.77, 7.70)
  REID f 0.35  3.32 (2.17, 5.07)
  SAWICK m  0.21  5.67 (3.27, 9.82)
  SAWICK f 0.44  4.17 (2.86, 6.09)
  SHIMUR b  0.01  1.00 (0.08, 12.56)
  SILVA b  0.19  1.76 (0.99, 3.16)
  SOBRAD b  0.20  6.68 (3.83, 11.63)
  STJERN b  0.07  3.93 (1.52, 10.20)
  TROISI f 2.78  1.93 (1.66, 2.24)
  VIEGI1 m  0.06  3.88 (1.36, 11.02)
  VIEGI1 f  0.01  0.27 (0.03, 2.24)
  WAGEN2 b 1.15  1.72 (1.36, 2.17)
  WILHEL m 0.02  7.57 (0.99, 57.56)
  WOODS b 2.72  2.46 (2.12, 2.87)
  WOOLF f 0.13  7.07 (3.58, 13.99)
  YAMAGU b 1.33  2.26 (1.82, 2.81)
  ZOIA b  0.10  1.45 (0.66, 3.16)
Total (95% CI)  100.00  2.69 (2.50, 2.90)
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Figure 4 Forest plot of ever smoking of any product and CB-part 2. This is a continuation of Figure 3, presenting the remaining individual
study data included in the main meta-analysis for CB shown in Table 5. Also shown are the combined random-effects estimates. These are
represented by a diamond of standard height, with the width indicating the 95% CI.
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Page 20 of 61consistency of direction is clear, with only one of the 129
COPD RRs, one of the 114 CB RRs, and none of the 28
emphysema RRs below 1.0.
These estimates are little affected by preferring RRs
for ever smoking cigarettes to those for ever smoking
any product, the random-effects estimates changing to
2.92 (2.65-3.20) for COPD, 2.70 (2.50-2.91) for CB and
4.57 (3.40-6.15) for emphysema. This is partly due to
many studies providing only one type of RR, so that for
COPD, for example, 117 of the 129 RRs are common to
both meta-analyses. Nor are they affected by preferring
least-adjusted, rather than most-adjusted RRs, with the
estimates now 2.85 (2.59-3.15, n = 133) for COPD, 2.73
(2.52-2.95, n = 119) for CB and 4.16 (3.03-5.71, n = 30)
for emphysema, slightly more RRs being included as
some studies have sex-specific unadjusted RRs but only
sexes combined adjusted RRs.
Returning to the main meta-analysis (most-adjusted
and preferring ever smoking any product), there is also
large variation between RRs in the weight they contri-
bute to the analysis. For COPD, of a total weight of
5,116 for the 129 RRs (mean 39.7), the largest weight is
523 for study ZIELI2 for females, with six other RRs
having weights of over 200. For CB, of the total of 6,146
for the 114 RRs (mean 53.9), the largest weight is 614
for study LAVECC for sexes combined, with eight other
RRs having weights over 200. For emphysema, where
the total weight is much lower, 489 (mean 17.5 for the
28 RRs), the weight of 241 for LAVECC for the sexes
combined RR contributes almost a half.
In investigating sources of heterogeneity, variation was
studied firstly using a univariate approach, the results
for the characteristics considered in Table 5 being sum-
marized below.
 
0.2  0.4  1  25    50   
REF SEX  Weight  Relative Risk Relative Risk
(%)  95% CI 95% CI 
  ANDER2 b  1.18  5.95 (2.63, 13.48)
  BEST m  0.58  8.47 (2.65, 27.11)
  DONTA2 m  0.62  1.05 (0.34, 3.23)
  ENRIGH m  3.62  2.56 (1.61, 4.09)
  ENRIGH f  3.84  3.95 (2.51, 6.20)
  GULSVI m  0.73  2.37 (0.84, 6.66)
  GULSVI f  2.05  1.82 (0.98, 3.38)
  HAMMO2 m  3.88  8.64 (5.51, 13.55)
  HAMMO2 f  2.25  6.44 (3.57, 11.63)
  HARDIE m  0.37  13.38 (3.14, 56.98)
  HARDIE f  1.33  2.55 (1.18, 5.48)
  HO b  1.58  2.87 (1.42, 5.81)
  HOZAWA b  2.48  10.59 (6.03, 18.61)
  HUHTI1 m  0.20  16.58 (2.28, 120.74)
  HUHTI1 f  0.47  1.97 (0.54, 7.17)
  KAHN2 m  3.52  9.11 (5.68, 14.61)
  LAVECC b  49.31  2.05 (1.81, 2.33)
  LEBOWI b  0.85  4.86 (1.86, 12.74)
  MILLER m  0.10  6.56 (0.37, 116.09)
  MILLER f 0.05  6.03 (0.12, 308.75)
  NAWA m 6.06  6.86 (4.79, 9.84)
  OMORI m  0.63  9.73 (3.18, 29.82)
  PRATT m  2.31  3.96 (2.21, 7.09)
  RYDER b  1.17  11.69 (5.16, 26.51)
  SILVA b  1.82  2.10 (1.09, 4.06)
  SUTINE b  1.87  3.62 (1.89, 6.92)
  WANG2 b 6.90  5.53 (3.94, 7.75)
  WEISS m  0.19  4.39 (0.58, 33.34)
Total (95% CI)  100.00  4.51 (3.38, 6.02)
  2 5  10 
Figure 5 Forest plot of ever smoking of any product and emphysema. Table 5 presents the results of a main meta-analysis for emphysema
based on 28 relative risk (RR) and 95% confidence interval (CI) estimates for ever smoking of any product (or cigarettes if any product not
available). The individual study estimates are shown numerically and graphically on a logarithmic scale. The weights (inverse-variance) are also
shown numerically, expressed as a percentage of the overall weight. The studies are sorted in order of sex within study reference (REF). In the
graphical representation individual RRs are indicated by a solid square, with the area of the square proportional to the weight. Arrows indicate
where the CI extends outside the range allocated. Also shown are the combined random-effects estimates. These are represented by a diamond
of standard height, with the width indicating the 95% CI.
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Page 21 of 61Table 5 Main meta-analyses for ever smoking of any product (or cigarettes if any product not available)
a
Characteristic Level Statistic
b COPD CB Emphysema
All All n 129 114 28
F 2.34 (2.27-2.40) 2.42 (2.36-2.48) 3.22 (2.95-3.52)
R 2.89 (2.63-3.17) 2.69 (2.50-2.90) 4.51 (3.38-6.02)
H, PH 8.11, < 0.001 5.81, < 0.001 6.42, < 0.001
Sex Male n 49 51 13
F 2.69 (2.55-2.84) 2.87 (2.74-3.00) 5.71 (4.74-6.87)
R 3.60 (2.98-4.34) 3.18 (2.77-3.65) 5.42 (3.69-7.96)
Female n 35 39 6
F 2.16 (2.04-2.28) 2.22 (2.11-2.32) 3.44 (2.60-4.55)
R 2.73 (2.17-3.43) 2.57 (2.28-2.89) 3.25 (2.07-5.10)
Combined n 45 24 9
F 2.26 (2.17-2.35) 2.24 (2.15-2.33) 2.62 (2.36-2.92)
R 2.51 (2.23-2.82) 2.29 (2.05-2.57) 4.47 (2.72-7.34)
Between levels PB NS < 0.001 < 0.05
Continent N America n 35 38 14
F 3.21 (3.04-3.39) 2.91 (2.75-3.07) 5.33 (4.49-6.33)
R 3.48 (2.88-4.20) 3.17 (2.70-3.71) 5.32 (3.86-7.32)
Europe n 59 60 10
F 2.09 (2.01-2.17) 2.34 (2.27-2.41) 2.19 (1.95-2.46)
R 2.79 (2.46-3.16) 2.62 (2.39-2.89) 3.13 (2.01-4.87)
Asia n 23 9 4
F 2.26 (2.08-2.45) 2.08 (1.92-2.24) 5.76 (4.59-7.23)
R 2.73 (2.15-3.46) 2.21 (1.78-2.75) 5.59 (3.93-7.95)
Other or multicountry n 12 7 0
F 1.91 (1.71-2.14) 2.34 (2.09-2.61)
R 2.13 (1.66-2.73) 2.09 (1.59-2.74)
Between levels PB < 0.001 < 0.05 < 0.001
Publication year Before 1980 n 25 49 13
F 3.82 (3.40-4.29) 3.02 (2.86-3.18) 5.81 (4.74-7.12)
R 3.79 (2.82-5.10) 3.22 (2.82-3.68) 5.37 (3.72-7.75)
1980-89 n 10 28 5
F 2.13 (1.80-2.50) 2.44 (2.33-2.56) 2.10 (1.86-2.37)
R 2.34 (1.79-3.05) 2.72 (2.33-3.17) 2.39 (1.49-3.82)
1990-99 n 19 17 3
F 3.75 (3.36-4.18) 2.09 (1.96-2.22) 3.14 (2.34-4.22)
R 3.31 (2.39-4.58) 2.24 (1.91-2.63) 3.14 (2.34-4.22)
2000 or later n 75 20 7
F 2.19 (2.13-2.26) 2.19 (2.09-2.29) 5.76 (4.72-7.04)
R 2.62 (2.36-2.90) 2.19 (1.93-2.48) 5.58 (3.63-5.58)
Between levels PB < 0.001 < 0.001 < 0.001
Study type Case-control n 16 10 0
F 2.51 (2.10-2.99) 2.35 (2.04-2.69)
R 2.95 (2.14-4.06) 2.72 (1.85-3.77)
Prospective n 37 11 6
F 4.49 (4.12-4.89) 2.30 (2.08-2.55) 6.12 (4.77-7.85)
R 3.71 (2.94-4.69) 2.60 (2.04-3.30) 4.95 (2.72-8.99)
Cross-sectional n 76 93 22
F 2.16 (2.10-2.22) 2.43 (2.36-2.49) 2.93 (2.67-3.22)
R 2.54 (2.32-2.80) 2.70 (2.49-2.93) 4.36 (3.19-5.96)
Between levels PB < 0.001 NS < 0.05
Outcome subtype Mortality n 29 3 4
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Page 22 of 61Table 5 Main meta-analyses for ever smoking of any product (or cigarettes if any product not available)
a (Continued)
F 4.50 (4.09-4.94) 4.10 (2.54-6.60) 8.24 (6.24-10.87)
R 3.95 (3.00-5.21) 5.49 (2.14-14.11) 8.24 (6.24-10.87)
Lung function (COPD) or
symptoms (CB)
n 6 08 30
F 2.16 (2.09-2.23) 2.51 (2.44-2.58)
R 2.35 (2.13-2.59) 2.78 (2.55-3.03)
Other n 40 28 24
F 2.31 (2.19-2.45) 2.11 (2.00-2.22) 2.89 (2.63-3.18)
R 3.10 (2.56-3.76) 2.31 (2.01-2.65) 4.00 (2.97-5.37)
Between levels PB < 0.001 < 0.05 < 0.01
How asthma taken into account Ignored n 76 103 26
F 2.60 (2.52-2.70) 2.44 (2.38-2.50) 3.22 (2.94-3.52)
R 2.95 (2.62-3.32) 2.69 (2.50-2.91) 4.61 (3.43-6.19)
Excluded n 21 7 2
F 1.83 (1.73-1.94) 1.91 (1.71-2.13) 3.22 (1.45-7.11)
R 2.35 (1.92-2.87) 2.13 (1.61-2.80) 3.20 (0.36-28.37)
Included in outcome definition n 19 - -
F 1.76 (1.61-1.92)
R 2.55 (2.00-3.26)
Other n 13 4 0
F 3.68 (3.20-4.24) 5.41 (3.58-8.18)
R 3.62 (2.80-4.69) 5.37 (3.13-9.21)
Between levels PB < 0.001 < 0.1 NS
Number of cases 1-50 n 23 17 6
F 4.06 (3.12-5.29) 2.70 (1.98-3.69) 2.89 (1.78-4.67)
R 4.45 (3.19-6.21) 2.70 (1.98-3.69) 2.89 (1.78-4.67)
51-100 n 29 13 9
F 2.42 (2.12-2.75) 3.71 (2.91-4.72) 2.87 (2.15-3.83)
R 2.55 (2.09-3.12) 4.15 (2.97-5.80) 3.19 (2.10-4.85)
101-200 n 30 19 5
F 2.39 (2.18-2.63) 3.07 (2.66-3.53) 7.30 (5.31-10.03)
R 2.69 (2.24-3.24) 3.48 (2.64-4.58) 7.48 (4.73-11.85)
201+ n 47 65 8
F 2.31 (2.24-2.38) 2.38 (2.32-2.44) 3.03 (2.74-3.24)
R 2.91 (2.54-3.32) 2.51 (2.31-2.72) 4.96 (2.99-8.22)
Between levels PB NS NS NS
Analysis type Prevalence n 93 105 22
F 2.17 (2.11-2.23) 2.43 (2.37-2.50) 2.93 (2.67-3.22)
R 2.57 (2.35-2.81) 2.71 (2.51-2.93) 4.36 (3.19-5.96)
Onset n 36 9 6
F 4.55 (4.17-4.96) 2.02 (1.78-2.28) 6.12 (4.77-7.85)
R 3.77 (2.98-4.78) 2.37 (1.80-3.13) 4.95 (2.72-8.99)
Between levels PB < 0.001 NS < 0.05
Smoking product Any n 48 61 11
F 2.60 (2.47-2.74) 2.59 (2.51-2.68) 2.51 (2.24-2.80)
R 2.99 (2.61-3.44) 2.89 (2.63-3.19) 4.16 (2.55-6.78)
Cigarettes (ignoring other
products)
n 7 35 11 5
F 2.08 (2.01-2.15) 2.18 (2.10-2.26) 4.96 (4.26-5.78)
R 2.48 (2.23-2.76) 2.44 (2.17-2.73) 4.58 (3.33-6.30)
Cigarettes only n 8 2 2
F 6.38 (5.61-7.24) 3.03 (2.29-4.01) 6.69 (3.43-13.05)
R 6.42 (4.22-9.78) 5.04 (1.29-19.70) 6.69 (3.43-13.05)
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Page 23 of 61Sex R R sf o rm a l e sa r eh i g h e s tf o ra l lt h r e eo u t c o m e s ,
with the variation by sex significant for CB (p < 0.001)
and emphysema (p < 0.05).
Continent There is significant variation by continent for
COPD (p < 0.001), CB (p < 0.05) and emphysema (p <
0.001). For COPD and CB, RRs are higher for North
A m e r i c at h a nf o rE u r o p e ,A s i ao ro t h e rc o u n t r i e s
(including multicentre results). For emphysema, RRs are
again relatively low for Europe, though RRs for North
America and Asia are similar.
Publication year For all three outcomes, there is sig-
nificant (p < 0.001) variation by publication year.
Though there is some indication that RRs are relatively
high for studies published before 1980, the pattern is
erratic for both COPD (high for pre-1980 and 1990-99,
low for 1980-89 and 2000 or later) and emphysema
(high for pre-1980 and 2000 or later, low for 1980-89
and 1990-99).
Study type For COPD, there is marked variation (p <
0.001), with RRs higher for prospective studies than for
other study designs. For CB, no variation is evident,
most RRs coming from cross-sectional studies. For
emphysema, where no results come from case-control
studies, RRs are again higher in prospective studies,
particularly for the fixed-effect estimates (p < 0.05).
Outcome subtype For all three outcomes, the estimates
are substantially higher when based on mortality,
although for CB and emphysema few RRs are so based.
For COPD, the random-effects estimates of 3.95 (3.00-
5.21, n = 29) based on mortality, and 2.35 (2.13-2.59, n
= 60) based on lung function, differ substantially.
How asthma was taken into account For COPD,
the random-effect estimates tend to be lower when
asthmatics are excluded (2.35, 1.92-2.87, n = 21) or
when asthma is included as part of the definition (2.55,
2.00-3.26, n = 19), than when it is ignored (2.95, 2.62-
3.32, n = 76) or is taken into account in other ways or
it is unclear whether the definition of the outcome
includes asthma or not (3.62, 2.80-4.69, n = 13). For CB
and emphysema, the great majority of RRs come from
studies where the comparison is made irrespective of
asthma.
Table 5 Main meta-analyses for ever smoking of any product (or cigarettes if any product not available)
a (Continued)
Between levels PB < 0.001 < 0.05 < 0.01
Unexposed base
c Never any product n 57 70 14
F 2.95 (2.82-3.09) 2.61 (2.52-2.69) 2.75 (2.47-3.06)
R 3.44 (2.95-4.01) 2.90 (2.65-3.18) 4.76 (3.02-7.50)
Never cigarettes n 72 44 14
F 2.05 (1.98-2.12) 2.16 (2.07-2.24) 4.62 (3.93-5.43)
R 2.47 (2.22-2.74) 2.42 (2.15-2.73) 4.28 (3.08-5.96)
Between levels PB < 0.001 < 0.01 < 0.05
RR adjusted for age Yes n 69 63 15
F 2.46 (2.35-2.56) 2.17 (2.10-2.24) 2.70 (2.43-3.00)
R 2.97 (2.56-3.45) 2.46 (2.26-2.69) 4.44 (2.90-6.82)
N o n 6 05 11 3
F 2.26 (2.18-2.34) 2.78 (2.67-2.88) 4.91 (4.17-5.79)
R 2.77 (2.46-3.12) 3.03 (2.69-3.41) 4.67 (3.45-6.33)
Between levels PB NS < 0.001 < 0.05
RR adjusted for factors other than age
or sex
Y e s n 3 43 06
F 2.09 (1.98-2.21) 2.28 (2.20-2.37) 2.11 (1.87-2.38)
R 2.64 (2.23-3.13) 2.41 (2.14-2.71) 2.11 (1.87-2.38)
N o n 9 58 42 2
F 2.43 (2.35-2.51) 2.53 (2.45-2.61) 5.26 (4.62-6.00)
R 3.00 (2.68-3.36) 2.86 (2.60-3.15) 5.02 (3.88-6.50)
Between levels PB < 0.1 < 0.1 < 0.001
a Within each study, results are selected in the following order or preference, within each sex, for: unexposed group-never any product, never cigarettes, other;
smoking product-any, cigarettes (ignoring other products), cigarettes only; overlapping studies-principal, subsidiary; and then for single sex results in preference
to combined sex results. Results adjusted for the most potential confounders are selected.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p ≥ 0.1), PB = probability value for between levels
(see methods) similarly expressed.
c Includes acceptable near-equivalent estimate (see methods) if estimate for strictly defined never smoker base not available (COPD: 3 for never cigarettes, CB: 2
for never any product and 4 for never cigarettes).
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Page 24 of 61Study size There is no convincing evidence that RRs
vary according to the number of cases of the outcome
that are studied.
Analysis type For COPD, RRs based on onset are
clearly higher than those based on prevalence (p <
0.001). A similar tendency is seen for emphysema (p <
0.05), though only six RRs are based on onset. For CB,
where again nearly all RRs are based on prevalence, no
difference is seen by analysis type.
Smoking product For COPD, a clear difference is seen
by definition of smoking product (p < 0.001), with ran-
dom-effects estimates of 6.42 (4.22-9.78, n = 8) for
cigarette only smoking, 2.48 (2.23-2.76, n = 73) for
cigarettes ignoring other products, and 2.99 (2.61-3.44,
n = 48) for any product. For CB and emphysema, RRs
based on cigarette only smoking are few, and the pattern
less clear.
Unexposed base group For COPD, RRs are lower when
the comparison group is never cigarettes (so that smo-
kers of other products only may be included in the
denominator) than when it is never any product (p <
0.001). For CB, there is a smaller difference in the same
direction (p < 0.01). For emphysema, however, fixed-
effect estimates are lower when the comparison group is
never any product (p < 0.05), but this difference is
reversed when random-effects estimates are used.
Age-adjustment For COPD, there is no difference in
RRs based on age-adjusted or age-unadjusted RRs. For
CB (p < 0.001) and emphysema (p < 0.05), however,
adjusted RRs are lower.
A d j u s t m e n tf o rf a c t o r so t h e rt h a na g eo rs e xFor all
three outcomes, there is a tendency for RRs adjusted for
other factors to be lower than those that are not so
adjusted (p < 0.1 for COPD and CB, p < 0.001 for
emphysema).
Variation by other characteristics (see Additional file
10) was also studied. For no outcome is there any clear
evidence that RRs varied by the type of tobacco
(blended or Virginia) typically used in the country
where the study was conducted, by the lowest, or high-
est, age of subjects included in the study, by presence of
the study weaknesses defined in Table 2, by whether the
outcome was assessed using a bronchodilator (only rele-
vant to COPD), or by whether the RR was directly avail-
able, derived from 2 × 2 tables provided, or using more
complex methods. Differences are seen by start year of
the study, but, like publication year, they do not follow
any clear pattern over time. For emphysema, estimates
are higher (p < 0.001) for studies providing RRs only for
ever smoking than studies providing RRs for both ever
smoking and current smoking, with random-effects esti-
mates, respectively, 5.51 (4.08-7.43, n = 11) and 3.77
(2.63-5.42, n = 17). Sexes combined RRs tend to be
lower if adjusted for sex for COPD (p < 0.05) and
emphysema (p < 0.001), but not for CB. RRs adjusted
for more factors tend to be lower for COPD (p < 0.01),
CB (p < 0.01) and emphysema (p < 0.001). This is
unsurprising given the results already noted for adjust-
ment for age and for factors other than age or sex.
For COPD, the relationship to the characteristics was
also studied separately for three subtypes of outcome-
based on mortality (31 RRs), on lung function (62 RRs)
and on other definitions (42 RRs). The tendency for RRs
to be higher for North American studies is clearest
when outcome is based on mortality, also evident when
based on lung function only, but not evident when
based on other definitions. The relationship of risk to
study type cannot usefully be studied as nearly all rele-
vant mortality studies are prospective, and nearly all
other studies are cross-sectional. Similarly most data
from mortality studies are of onset, whereas most data
from other studies are of prevalence. The higher RRs
noted in the overall results for smoking of cigarettes
only are also evident solely in the mortality studies, as
no RRs for this exposure are included for the other
COPD subtypes. There is, however, a consistent ten-
dency for all subtypes for RRs to be higher when the
comparison group is never smoking of any product than
when it is never smoking of cigarettes.
As only three CB RRs based on mortality are included,
the relationship to the characteristics for CB is only stu-
died separately for two subtypes-outcomes based on
symptoms (83 RRs), and other than on mortality or
symptoms (28 RRs). Tendencies noted in Table 5 for
RRs to be higher in males than females, lower if
adjusted for age than if unadjusted, and lower if the
unexposed base group is never cigarettes than if it is
never any product, are apparent for both subtypes.
For emphysema, the relationship to the characteristics
separated by subtype of outcome cannot usefully be stu-
died due to limited numbers, with four of the 28 RRs
being based on mortality, and 24 based on other
definitions.
In an attempt to evaluate the independent role of the
characteristics, meta-regression analyses were conducted
f o rC O P Da n dC B ,t h er e s u l t sf r o mt h eb a s i cm o d e l
being summarized in Table 6. There are too few data
points for emphysema for useful meta-regression analy-
sis, especially since almost half the total weight comes
from one study (LAVECC).
For COPD the deviance reduces from 1,038.1 on 128
degrees of freedom to 421.8 on 112 degrees of freedom
on fitting the basic model, substantially reducing, but
not eliminating, the heterogeneity. The results in Table
6 demonstrate an independent role of six characteristics
noted in the univariate analyses: sex (lower RRs for
females), continent (higher for North America), smoking
product (higher for cigarette smokers than smokers of
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product than never cigarettes), and particularly the out-
come subtype (lower when based on lung function), and
the way asthma is taken into account (lowest when
asthma is included in the COPD definition). Effects of
adjustment and of age are not clearly seen, however. For
none of the secondary characteristics do their inclusion
into the model significantly improve the fit (at p < 0.05).
This includes study type and analysis type, which are
highly significant (p < 0.001) in the univariate analyses
shown in Table 5. Both these are highly correlated with
outcome subtype-thus where mortality is the outcome,
the study type will nearly always be prospective, and the
analysis type will nearly always be onset.
Inspection of standardized residuals from the basic
model for COPD reveals two estimates where the
observed RR differ markedly from the RR fitted by the
model. The largest residual of -3.49 is for males in study
XU, where an observed RR of 1.26 compares with a
fitted RR of 2.20. The corresponding RRs for females
are 2.61 observed and 1.78 fitted, with a residual of
+1.12. For study GODTFR, sexes combined, the
observed RR of 5.46 compares with a fitted value of
2.79, with a residual of +2.58. Other residuals are all less
than +/- 2.20.
For CB the deviance reduces from 657.1 on 113
degrees of freedom to 433.3 on 103 degrees of freedom
on fitting the basic model, again substantially reducing,
but not eliminating, the heterogeneity. Though the
direction of differences by level of the various charac-
teristics is quite similar to that for COPD, the effects
of individual characteristics are less clear, with signifi-
cant differences (at p < 0.05) only for continent, how
asthma was taken into account, and age-adjustment.
No secondary characteristics help to improve the
model fit (at p < 0.05), except for publication year,
where a tendency is seen for earlier published studies
to provide higher RRs.
Table 6 Meta-regression results for ever smoking of any product (or cigarettes if any product not available)
a
COPD CB
Characteristic Level Estimate
b (SE
c)p
d Estimate
b (SE
c)p
d
Constant +1.149 (0.141) +1.316 (0.266)
Sex Male Base < 0.05 Base < 0.1
Female -0.212 (0.044) -0.171 (0.036)
Combined -0.006 (0.039) -0.121 (0.077)
Continent N America Base < 0.05 Base < 0.01
Europe -0.200 (0.040) -0.278 (0.039)
Asia -0.295 (0.067) -0.281 (0.060)
Other -0.355 (0.072) -0.177 (0.074)
Outcome subtype Mortality Base < 0.01 Base NS
Lung function (COPD) or symptoms (CB) -0.404 (0.092) -0.212 (0.249)
Other -0.114 (0.085) -0.302 (0.248)
How asthma taken into account Ignored Base < 0.001 Base < 0.05
Excluded -0.143 (0.043) -0.109 (0.066)
Included in outcome definition -0.461 (0.060) No data
Other +0.283 (0.093) +0.996 (0.214)
Smoking product Any Base < 0.01 Base NS
Cigarettes (ignoring other products) +0.428 (0.128) -0.060 (0.128)
Cigarettes only +0.589 (0.107) +0.449 (0.149)
Unexposed group Never any product Base < 0.05 Base NS
Never cigarettes -0.603 (0.123) -0.111 (0.126)
RR adjusted for age Yes Base NS Base < 0.01
No +0.046 (0.045) +0.214 (0.032)
RR adjusted for factor other than age or sex Yes Base < 0.1 Base NS
No +0.195 (0.052) -0.113 (0.070)
Midpoint age Per 10 years +0.003 (0.002) NS +0.003 (0.001) NS
a Based on the same data as for Table 5. See that table for further definition of RRs selected for analysis, and numbers of estimates of each characteristic level.
b Estimates are of log RR. For a particular entry, the predicted RR for a given estimate is calculated by adding the constant to the values for each level applicable
to the estimate (taking the value for the base level as zero) and taking the exponential of the result.
c SE = standard error.
d The p value is estimated from the drop in deviance from removing the characteristic from the model using an F-test. It is expressed as p < 0.001, p < 0.01, p <
0.05, p < 0.1 or NS (p ≥ 0.1).
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Page 26 of 61The largest standardized residual from the basic
model for CB, -2.74, is for males in study GOLDBE,
where the observed RR of 1.48 compares to a fitted RR
of 2.69, corresponding RRs for females being 2.87
observed and 2.27 fitted, with a residual of +0.79.
Another large residual, -2.53, is for females in study
JOUSI1, where the observed RR of 1.66 compares to a
fitted value of 2.43, with the corresponding RRs for
males being 2.42 observed and 2.88 fitted, with a resi-
dual of -1.36. Other residuals are all less than +/- 2.20.
B. Risk from current smoking
Figures 6 and 7 (COPD), 8 and 9 (CB) and 10 (emphy-
sema) present the results of the main meta-analyses for
current smoking of any product. As before, RRs for
smoking of cigarettes are used if RRs for any product
smoking are not available, and RRs are most-adjusted.
Some results by levels of characteristics studied are
shown in Table 7.
A sf o re v e rs m o k i n g ,t h eR R sf o rC O P D ,C Ba n d
emphysema are heterogeneous (p < 0.001), with the lar-
gest seen being 43.92 for COPD (DICKIN/sexes com-
bined), 27.02 for CB (MILLER/females), and a
remarkable 489.54, with lower 95% CL 211.74, for
emphysema (AUERBA/males). The random-effects esti-
mates (COPD 3.51, 95% CI 3.08-3.99, n = 120; CB, 3.41,
3.13-3.72, n = 113; emphysema 4.87, 2.83-8.41, n = 22)
are all clearly positive, and somewhat larger than the
corresponding estimates for ever smoking. Similarly to
ever smoking, the individual RRs are virtually all above
1.0, though varying substantially. The estimates are also
little affected by preferring RRs for current smoking of
cigarettes to those for current smoking of any product,
the random-effects estimates changing to 3.59 (3.15-
4.09) for COPD, 3.45 (3.17-3.77) for CB and 5.00 (2.87-
8.72) for emphysema. The estimates are again little
affected by preferring least, rather than most, adjusted
RRs, with the estimates now 3.41 (3.00-3.87) for COPD,
3.43 (3.12-3.77) for CB and 4.32 (2.40-7.78) for
emphysema.
For the main meta-analysis, the studies contributing
the most to the total weight are the same as for the cor-
responding meta-analysis for ever smoking: ZIELI2/
females for COPD (11.7% of the total of 4,226), and
LAVECC/sexes combined for CB (11.4% of 4,326) and
emphysema (61.9% of 287).
For the characteristics considered in Table 7 the
pattern of variation seems quite similar to that for
ever smoking in Table 5. Thus, as for ever smoking,
R R st e n dt ob eh i g h e rf o rm a l e sa n df o rN o r t hA m e r i -
can studies for all three outcomes, higher for prospec-
tive studies for COPD, and higher when based on
mortality for COPD and CB, with no obvious variation
by study size, and an erratic pattern for publication
year. RRs also show a similar pattern by how asthma
i st a k e ni n t oa c c o u n tf o rC O P Dt ot h a ts e e nf o re v e r
smoking, and are again higher when based on onset
for COPD, higher for cigarette only smoking for
COPD, higher when the unexposed group is never
smoked any product for COPD, and lower for RRs
unadjusted for age for CB. As for ever smoking, varia-
tion in RRs by other characteristics (not shown in
Table 7) was also studied. For most of these there
seems little evidence of any difference. For COPD,
there is a tendency (p < 0.001) for estimates to be
higher for studies providing RRs only for current
smoking than for studies providing RRs for both ever
smoking and current smoking, with random-effects
estimates, respectively, 4.52 (2.69-7.59, n = 10) and
3.40 (3.00-3.87, n = 110), but no such differences are
seen for CB and emphysema. Compared to the results
for ever smoking, there seems less clear evidence of
an effect of adjustment, except as already noted for
adjustment for age for CB (Table 7).
For COPD, the relationship to the characteristics was
also studied separately for outcomes based on mortality
(33 RRs), based only on lung function (58 RRs) and
based on other definitions (36 RRs). As for ever smok-
ing, risk is higher in North American studies when the
outcome is based on mortality or lung function, but not
when based on other definitions. Also as for ever smok-
ing, and for reasons stated in the previous section, varia-
tion cannot usefully be studied by study type, or by
analysis type (onset or prevalence), or in relation to
smoking of cigarettes only. Again RRs are consistently
higher for all the outcome subtypes when the compari-
son group is never smoking of any product than when it
is never smoking of cigarettes.
As only four CB RRs based on mortality are included,
the relationship to the characteristics for CB is only stu-
died separately for outcomes based on symptoms (81
RRs) and based other than on mortality or symptoms
( 2 8R R s ) .T h et e n d e n c yn o t e di nT a b l e7f o rR R st ob e
higher for North American studies is only evident when
outcome is based on symptoms, but the tendency for
RRs to be lower if adjusted for confounders seems evi-
dent in both groups.
As is the case for ever smoking, the relationship to the
characteristics by outcome subtype cannot usefully be
studied for emphysema due to limited numbers, with
only four of 28 RRs based on mortality.
Also as for ever smoking, meta-regression analyses are
conducted for COPD and CB, the results from the basic
model being summarized in Table 8.
For COPD the deviance reduces from 1,643.4 on 119
degrees of freedom to 433.3 on 103 degrees of freedom
on fitting the basic model. The results in Table 8 con-
firm the independent role of the six characteristics
noted for ever smoking: sex, continent, smoking
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0.2  0.4  1  25  50 
REF SEX  Weight  Relative Risk Relative Risk 
(%)  95% CI 95% CI 
  ALESSA b  0.05  1.48 (0.39, 5.71)
  ANDER1 m  0.04  6.33 (1.38, 28.99)
  ANDER1 f  0.11  1.08 (0.44, 2.65)
  ANDER3 m  0.01  13.91 (0.62, 312.60)
  ANDER3 f  0.01  0.33 (0.01, 11.34)
  BEDNAR b  0.26  2.05 (1.13, 3.73)
  BEST m  0.13  9.57 (4.20, 21.78)
  CHEN2 m  0.13  3.72 (1.61, 8.56)
  CHEN2 f  0.37  4.21 (2.57, 6.89)
  CHEN3 m  0.31  3.22 (1.87, 5.53)
  CHEN3 f  1.19  3.11 (2.36, 4.10)
  CLEMEN m  0.21  2.34 (1.22, 4.52)
  COCCI b  0.01  6.26 (0.30, 128.88)
  DEAN1 m  0.66  2.57 (1.77, 3.72)
  DEAN1 f  0.69  1.89 (1.31, 2.71)
  DEJONG b  0.01  22.49 (1.34, 378.31)
  DEMARC b 1.99  2.02 (1.63, 2.50)
  DICKIN b 0.02  43.92 (5.56, 346.92)
  DOLL1 m  0.28  8.11 (4.58, 14.35)
  DOLL2 f  0.02  18.42 (2.33, 145.41)
  EKBERG m  6.37  2.52 (2.24, 2.84)
  EKBERG f  2.63  3.15 (2.62, 3.80)
  FERRI2 m  0.21  4.73 (2.44, 9.18)
  FERRI2 f  0.60  2.71 (1.84, 4.00)
  FORAST f  0.21  4.66 (2.41, 9.02)
  FUKUCH b  0.86  2.96 (2.14, 4.09)
  GODTFR b  1.31  6.35 (4.88, 8.26)
  HAMMO2 m  0.89  8.81 (6.40, 12.13)
  HAMMO2 f  0.58  5.89 (3.97, 8.76)
  HARDIE m  0.14  7.77 (3.43, 17.61)
  HARDIE f  0.24  3.41 (1.85, 6.31)
  HARIKK m  0.12  4.48 (1.90, 10.56)
  HARIKK f  0.01  42.49 (2.37, 760.27)
  HIGGI4 m  0.24  2.93 (1.59, 5.38)
  HO m  0.27  2.16 (1.21, 3.88)
  HO f  0.17  3.63 (1.75, 7.54)
  HOZAWA b  9.49  4.21 (3.82, 4.64)
  HUHTI1 m  0.14  10.96 (4.90, 24.50)
  HUHTI1 f  0.20  2.45 (1.25, 4.81)
  HUHTI3 m  0.08  8.96 (3.02, 26.65)
  JACOBS m  0.53  3.39 (2.24, 5.14)
  JOHANN b  0.37  3.56 (2.17, 5.84)
  KACHEL b  0.14  5.32 (2.35, 12.08)
  KAHN m  4.25  10.07 (8.70, 11.65)
  KARAKA b  0.24  3.02 (1.64, 5.59)
  KATANC b  0.18  5.29 (2.60, 10.75)
  KIM m  0.38  2.34 (1.44, 3.82)
  KIM f  0.15  1.74 (0.79, 3.81)
  KOJIMA m  0.38  3.37 (2.07, 5.49)
  KOJIMA f  0.09  4.48 (1.66, 12.05)
  KRZYZA m  0.11  2.84 (1.15, 7.01)
  KRZYZA f 0.27  1.56 (0.87, 2.80)
  LAM2 m  0.66  2.34 (1.62, 3.40)
  LAM3 m  0.11  1.46 (0.58, 3.68)
  LEBOWI m  0.07  4.87 (1.60, 14.86)
  LEBOWI f  0.40  1.94 (1.20, 3.13)
  LEE m  0.02  4.83 (0.66, 35.29)
  LEE f  0.07  1.93 (0.61, 6.08)
  LINDBE b 0.25  4.55 (2.50, 8.27)
  LINDST b  1.74  2.00 (1.59, 2.51)
  LUNDB1 b  0.33  6.53 (3.87, 11.01)
  MADOR m  0.01  26.60 (1.01, 702.94)
  MANNI1 m  1.70  3.48 (2.76, 4.38)
  MANNI1 f  2.01  4.05 (3.28, 5.02)
  MANNI2 b  3.02  3.07 (2.58, 3.65)
  MANNI3 b  0.50  1.39 (0.91, 2.13)
2  5  10 
Figure 6 Forest plot of current smoking of any product and COPD-part 1. Table 7 presents the results of a main meta-analysis for COPD
based on 120 relative risk (RR) and 95% confidence interval (CI) estimates for current smoking of any product (or cigarettes if any product not
available). The individual study estimates are shown numerically and graphically on a logarithmic scale in Figures 6 and 7. The weights (inverse-
variance) are also shown numerically, expressed as a percentage of the overall weight. The studies are sorted in order of sex within study
reference (REF). In the graphical representation individual RRs are indicated by a solid square, with the area of the square proportional to the
weight. Arrows indicate where the CI extends outside the range allocated.
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0.2  0.4  1  25  50 
REF SEX  Weight  Relative Risk Relative Risk 
(%)  95% CI 95% CI 
  MARAN1 b  0.77  6.17 (4.38, 8.69)
  MARAN2 b  0.31  6.22 (3.62, 10.67)
  MARCUS m  0.25  2.11 (1.15, 3.86)
  MATHES b  0.13  7.45 (3.19, 17.38)
  MENEZ2 b  0.51  2.40 (1.55, 3.62)
  MENEZ3 b  0.71  1.22 (0.85, 1.74)
  MENEZ4 b  0.28  1.32 (0.74, 2.33)
  MENEZ5 b  0.55  1.61 (1.07, 2.42)
  MENEZ6 b  0.47  2.58 (1.66, 4.00)
  MONTNE b  1.38  2.56 (1.98, 3.31)
  MUELLE m  0.04  5.21 (1.18, 23.03)
  MUELLE f  0.03  1.86 (0.30, 11.59)
  NIEPSU b  0.13  4.51 (1.93, 10.55)
  NIHLEN b  0.36  3.08 (1.86, 5.10)
  NILSSO m  0.23  3.25 (1.73, 6.07)
  NILSSO f  0.59  7.16 (4.83, 10.60)
  PEAT b  0.34  4.85 (2.89, 8.11)
  PETO m  0.01  26.84 (1.67, 431.23)
  RENWIC b  0.13  4.40 (1.92, 10.06)
  RICCIO b  1.10  1.86 (1.39, 2.47)
  SARGEA b  2.70  1.60 (1.33, 1.92)
  SAWICK m  0.09  5.52 (1.99, 15.29)
  SAWICK f  0.25  1.17 (0.64, 2.14)
  SHAHAB b  4.10  2.31 (1.99, 2.68)
  SHIN m  0.22  2.07 (1.10, 3.92)
  SILVA b  0.32  2.90 (1.70, 4.94)
  SPEIZE m  0.01  12.18 (0.72, 204.91)
  SPEIZE f  0.08  4.46 (1.50, 13.31)
  STERLI m  0.28  7.32 (4.13, 12.97)
  STERLI f  0.36  12.63 (7.64, 20.88)
  STROM m  0.24  3.93 (2.14, 7.24)
  TANG m  0.28  5.42 (3.05, 9.63)
  THUN m  1.46  11.70 (9.10, 15.00)
  THUN f  2.02  12.80 (10.40, 15.90)
  TODD m  0.02  6.69 (0.92, 48.54)
  TODD f  0.02  0.74 (0.08, 6.59)
  TRUPIN b  0.87  4.40 (3.20, 6.10)
  TSUSHI b  0.13  5.79 (2.51, 13.38)
  TVERDA m  0.14  3.65 (1.65, 8.08)
  VESTBO b  4.26  2.05 (1.77, 2.38)
  VIEGI2 m  0.31  1.38 (0.80, 2.37)
  VIEGI2 f  0.37  1.58 (0.96, 2.58)
  VOLLM2 b  0.02  6.13 (0.81, 46.33)
  VONHER m  1.16  10.92 (8.26, 14.45)
  VONHER f  1.27  6.71 (5.13, 8.77)
  WEISS m  0.04  3.60 (0.82, 15.77)
  WEN m  0.51  2.29 (1.50, 3.50)
  XIAO b  0.20  4.27 (2.17, 8.40)
  YAMAGU b  1.94  1.98 (1.59, 2.45)
  YUAN m  0.27  1.39 (0.78, 2.47)
  ZIELI2 m  6.78  2.23 (1.99, 2.50)
  ZIELI2 f  11.70  1.32 (1.21, 1.44)
  ZIETKO m  0.01  46.74 (2.53, 863.13)
  ZIETKO f  0.01  26.54 (1.30, 543.78)
Total (95% CI)  100.00  3.51 (3.08, 3.99)
  2  5  10 
Figure 7 Forest plot of current smoking of any product and COPD-part 2. This is a continuation of Figure 6, presenting the remaining
individual study data included in the main meta-analysis for COPD shown in Table 7. Also shown are the combined random-effects estimates.
These are represented by a diamond of standard height, with the width indicating the 95% CI.
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0.2  0.4  1  50 
REF SEX  Weight  Relative Risk Relative Risk 
(%)  95% CI 95% CI
  ALDERS m 0.31  3.03 (1.78, 5.17)
  ALDERS f  0.78  3.45 (2.46, 4.84)
  ANDER1 m 0.07  5.86 (1.95, 17.63)
  ANDER1 f  0.16  2.56 (1.21, 5.41)
  BANG b  0.71  1.80 (1.26, 2.55)
  BECK1 m  0.06  8.20 (2.34, 28.71)
  BECK1 f 0.08  3.34 (1.14, 9.81)
  BECK2 m  0.03  2.30 (0.39, 13.60)
  BECK2 f 0.04  3.31 (0.75, 14.59)
  BEST m  0.07  11.25 (3.54, 35.80)
  BJORNS b  4.29  3.10 (2.70, 3.60)
  BROWN m 0.26  2.24 (1.25, 4.01)
  CERVER b  9.30  3.07 (2.78, 3.38)
  COATES b  0.39  4.34 (2.70, 6.98)
  COLLEG m 0.08  3.05 (1.03, 8.99)
  COLLEG f 0.28  2.59 (1.47, 4.55)
  DEAN2 m  0.76  2.28 (1.62, 3.21)
  DEAN2 f 1.23  3.04 (2.32, 3.97)
  DEANE m 0.06  7.92 (2.34, 26.74)
  DEMARC b 1.53  4.07 (3.20, 5.18)
  DOLL1 m  0.06  9.41 (2.81, 31.49)
  DONTA2 m 0.18  3.29 (1.62, 6.69)
  DOPICO m  0.10  4.11 (1.61, 10.49)
  EHRLIC m  0.30  1.58 (0.92, 2.72)
  EHRLIC f 0.47  2.00 (1.29, 3.09)
  ENRIGH m  0.18  2.86 (1.40, 5.81)
  ENRIGH f  0.48  1.56 (1.01, 2.41)
  FERRI1 m  0.19  3.86 (1.93, 7.70)
  FERRI1 f  0.36  2.38 (1.45, 3.90)
  FOXMAN m  0.67  3.29 (2.28, 4.73)
  FOXMAN f  0.85  3.14 (2.27, 4.34)
  GOLDBE m  1.78  1.58 (1.26, 1.97)
  GOLDBE f  1.04  3.68 (2.75, 4.93)
  HAENSZ m 0.51  2.50 (1.65, 3.80)
  HAENSZ f  0.85  3.57 (2.59, 4.94)
  HARDIE m 0.03  18.13 (3.52, 93.37)
  HARDIE f  0.11  4.60 (1.88, 11.24)
  HARRIS m 0.08  6.53 (2.28, 18.70)
  HAWTHO m 1.00  3.98 (2.95, 5.35)
  HAWTHO f 1.67  3.15 (2.50, 3.96)
  HAYES b 0.78  7.90 (5.64, 11.08)
  HIGGI2 m  0.02  2.97 (0.38, 22.93)
  HIGGI2 f 0.07  2.83 (0.89, 9.05)
  HIGGI3 m  0.01  1.01 (0.05, 20.46)
  HIGGI3 f 0.01  9.92 (0.39, 253.48)
  HIGGI6 m  0.35  5.61 (3.39, 9.29)
  HIGGI6 f 0.57  3.34 (2.25, 4.94)
  HO b 0.35  2.62 (1.59, 4.33)
  HOLLA2 m  0.10  7.27 (2.88, 18.32)
  HOLLNA m 0.19  6.86 (3.45, 13.66)
  HOLLNA f 0.24  5.61 (3.07, 10.28)
  HOUSE m  0.88  6.81 (4.96, 9.37)
  HOUSE f  1.30  5.69 (4.38, 7.38)
  HUCHON b 2.04  3.86 (3.13, 4.75)
  HUHTI1 m  0.14  9.43 (4.22, 21.09)
  HUHTI1 f  0.15  3.49 (1.61, 7.59)
  HUHTI3 m  0.44  3.73 (2.37, 5.85)
  JOSHI m  0.16  6.30 (3.02, 13.14)
  JOUSI1 m  5.50  2.99 (2.63, 3.39)
  JOUSI1 f  3.69  1.95 (1.67, 2.28)
  KAHN2 m 0.25  2.86 (1.58, 5.19)
  KATO m 2.09  1.20 (0.98, 1.48)
  KATO f 3.12  1.80 (1.52, 2.13)
  KOTAN1 b 0.70  1.84 (1.29, 2.63)
  LAMBER m  0.34  2.82 (1.70, 4.69)
  LAMBER f  0.72  3.18 (2.24, 4.53)
2  5  10  25 
Figure 8 Forest plot of current smoking of any product and CB-part 1. Table 7 presents the results of a main meta-analysis for CB based
on 113 relative risk (RR) and 95% confidence interval (CI) estimates for current smoking of any product (or cigarettes if any product not
available). The individual study estimates are shown numerically and graphically on a logarithmic scale in Figures 8 and 9. The weights (inverse-
variance) are also shown numerically, expressed as a percentage of the overall weight. The studies are sorted in order of sex within study
reference (REF). In the graphical representation individual RRs are indicated by a solid square, with the area of the square proportional to the
weight. Arrows indicate where the CI extends outside the range allocated.
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Page 30 of 61product, the unexposed group, outcome subtype, and
the way asthma is taken into account. A significant
effect (p < 0.05) of age is also seen. No secondary vari-
able significantly improves the fit (at p < 0.05). The lar-
gest standardized residual from the basic model, +2.30,
is for males in study VONHER where the observed RR
of 10.92 compares to a fitted RR of 5.58, corresponding
RRs for females being 6.71 observed and 4.49 fitted,
with a residual of +1.44.
For CB the deviance reduces from 649.2 on 112
degrees of freedom to 407.7 on 97 degrees of freedom
on fitting the basic model. The characteristics which sig-
nificantly (at p < 0.05) contribute to the model are con-
tinent, outcome subtype, whether the RR is adjusted for
0.2  0.4  1  25  50 
REF SEX  Weight  Relative Risk Relative Risk
(%)  95% CI 95% CI 
  LANGE2 b  1.01  2.80 (2.10, 3.80)
  LANGHA m  3.34  3.91 (3.32, 4.60)
  LANGHA f  4.12  2.48 (2.14, 2.87)
  LAVECC b  11.38  2.26 (2.07, 2.47)
  LEBOWI b  0.27  1.24 (0.70, 2.19)
  LINDST b  4.58  1.89 (1.65, 2.18)
  LUNDB2 m  0.20  9.04 (4.62, 17.70)
  LUNDB2 f 0.20  6.94 (3.58, 13.45)
  MAGNUS m  0.19  6.83 (3.47, 13.43)
  MANFRE m  0.05  9.12 (2.55, 32.64)
  MANFRE f  0.26  4.10 (2.28, 7.37)
  MELLST m  0.27  4.13 (2.32, 7.34)
  MENEZ1 b  0.33  4.31 (2.56, 7.27)
  MEREN b  1.52  2.02 (1.59, 2.58)
  MILLER m  0.19  7.12 (3.61, 14.03)
  MILLER f 0.04  27.02 (6.50, 112.31)
  MILNE m  0.06  10.05 (2.94, 34.40)
  MILNE f  0.10  3.40 (1.35, 8.61)
  MOLLER b  0.02  1.83 (0.25, 13.47)
  MUELLE m  0.04  8.36 (1.94, 35.98)
  MUELLE f  0.05  13.35 (3.44, 51.76)
  NEJJAR b  0.45  1.60 (1.03, 2.50)
  OGILVI m  0.17  3.60 (1.75, 7.41)
  OGILVI f  0.54  2.62 (1.74, 3.92)
  PANDEY m  0.15  5.33 (2.49, 11.38)
  PANDEY f  0.94  1.65 (1.21, 2.24)
  PELKON m  1.02  1.91 (1.42, 2.56)
  REID m  0.33  6.25 (3.72, 10.52)
  REID f  0.45  3.69 (2.37, 5.74)
  SAWICK m  0.29  6.48 (3.73, 11.24)
  SAWICK f 0.59  4.70 (3.19, 6.93)
  SHIMUR b  0.01  0.24 (0.01, 8.62)
  SILVA b  0.24  3.20 (1.70, 5.80)
  SOBRAD b  0.38  12.95 (8.01, 20.94)
  STJERN b  0.09  5.33 (2.01, 14.13)
  TAGER2 m  0.11  5.19 (2.12, 12.70)
  TAGER2 f  0.06  11.65 (3.43, 39.64)
  TROISI f  3.42  2.85 (2.42, 3.34)
  VIEGI1 m  0.08  3.50 (1.19, 10.24)
  VIEGI1 f  0.01  0.16 (0.01, 2.84)
  WAGEN2 b  1.38  3.03 (2.35, 3.90)
  WEN m  0.07  3.13 (1.05, 9.29)
  WILHEL m 0.02  10.20 (1.32, 78.60)
  WOODS b  3.27  3.33 (2.79, 3.88)
  WOOLF f 0.19  9.60 (4.83, 19.08)
  YAMAGU b 1.81  2.42 (1.94, 3.02)
  ZOIA b  0.10  4.40 (1.70, 11.70)
Total (95% CI)  100.00  3.41 (3.13, 3.72)
 
  
2  5  10 
Figure 9 Forest plot of current smoking of any product and CB-part 2. This is a continuation of Figure 8, presenting the remaining
individual study data included in the main meta-analysis for CB shown in Table 7. Also shown are the combined random-effects estimates.
These are represented by a diamond of standard height, with the width indicating the 95% CI.
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Page 31 of 61age, and how asthma is taken into account. As for ever
smoking, the largest standardized residuals are for males
in study GOLDBE (-3.44) and females in study JOUSI1
(-2.88).
C. Risk from ever or current smoking
In an attempt to incorporate data from all the studies
(except those with only dose-related data), additional
analyses were carried out. The first set of analyses uses
results for ever smoking if available from a study, but if
not results for current smoking. Conversely, the second
set prefers results for current smoking to results for
ever smoking where both are available. The meta-analy-
sis RRs are shown in Table 9. The RRs are intermediate
between those for ever smoking (Table 5) and those for
current smoking (Table 7). For example for COPD, ran-
dom-effects estimates are 2.89 (95%CI 2.63-3.17) specifi-
cally for ever smoking, 3.00 (2.71-3.32) preferring ever
smoking, 3.46 (3.07-3.90) preferring current smoking,
and 3.51 (3.08-3.99) specifically for current smoking. As
so many of the RRs are common between the specific
ever smoking analyses in Table 5 and the analyses pre-
ferring ever smoking in Table 9 the pattern of RRs by
level of the characteristics studied tends to be quite
similar. The same is true for the specific current smok-
ing analyses and the analyses preferring current smoking
i nT a b l e9 .R e s u l t sf o re v e ro rc u r r e n ts m o k i n gb yl e v e l
of selected characteristics are therefore only presented
in the Additional files.
D. Risk from ex smoking
Figures 11 and 12 (COPD), 13 and 14 (CB) and 15
(emphysema) present the results of the main meta-ana-
lyses for ex smoking of any product (or cigarettes if any
product was not available), based on most-adjusted RRs.
S o m er e s u l t sb yl e v e l so fc h a racteristics are shown in
Table 10.
Again the RRs are markedly heterogeneous (p < 0.001
for all three outcomes), ranging up to 55.86 for COPD
(ANDER3/males), 96.60 for CB (MOLLER/combined
sexes) and 12.50 for emphysema (BEST/males). The ran-
dom-effects estimates (COPD 2.35, 95% CI 2.11-2.63, n
0.2  0.4  1  25  50 
REF SEX  Weight  Relative Risk  Relative Risk
(%)  95% CI  95% CI 
  AUERBA m  1.91  489.54 (211.74, 1131.81) 
  BEST m  0.97  7.72 (2.39, 24.95) 
  DONTA2 m  1.03  1.15 (0.37, 3.61) 
  ENRIGH m  4.19  5.07 (2.88, 8.93) 
  ENRIGH f  3.58  3.08 (1.67, 5.67) 
  HARDIE m  0.61  15.04 (3.40, 66.58) 
  HARDIE f  1.47  3.59 (1.38, 9.29) 
  HIRAYA m  5.28  2.22 (1.34, 3.67) 
  HIRAYA f  3.61  2.72 (1.48, 5.00) 
  HO b  1.67  2.30 (0.94, 5.62) 
  HUHTI1 m  0.34  19.03 (2.60, 139.11) 
  HUHTI1 f  0.32  0.52 (0.07, 3.99) 
  KAHN2 m  5.91  9.09 (5.65, 14.64) 
  LAVECC b  61.86  1.76 (1.52, 2.04) 
  LEBOWI b  1.22  3.82 (1.34, 10.88) 
  MILLER m  0.16  7.21 (0.39, 133.19) 
  MILLER f 0.09  9.07 (0.18, 446.54) 
  OMORI m  1.03  14.50 (4.63, 45.40) 
  SILVA b  2.76  4.10 (2.03, 8.18) 
  VIKGRE m  0.15  3.27 (0.16, 65.49) 
  WEISS m  0.32  5.03 (0.66, 38.51) 
  WEN m  1.52  1.12 (0.44, 2.88) 
Total (95% CI)  100.00  4.87 (2.83, 8.41) 
  2  5  10 
Figure 10 Forest plot of current smoking of any product and emphysema. Table 7 presents the results of a main meta-analysis for
emphysema based on 22 relative risk (RR) and 95% confidence interval (CI) estimates for current smoking of any product (or cigarettes if any
product not available). The individual study estimates are shown numerically and graphically on a logarithmic scale. The weights (inverse-
variance) are also shown numerically, expressed as a percentage of the overall weight. The studies are sorted in order of sex within study
reference (REF). In the graphical representation individual RRs are indicated by a solid square, with the area of the square proportional to the
weight. Arrows indicate where the CI extends outside the range allocated. Where the RR value falls outside the range, the size of the plotting
symbol indicates the weight but the position is not true to the scale. Also shown are the combined random-effects estimates. These are
represented by a diamond of standard height, with the width indicating the 95% CI.
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Page 32 of 61Table 7 Main meta-analyses for current smoking of any product (or cigarettes, if any product not available)
a
Characteristic Level Statistic
b COPD CB Emphysema
All All N 120 113 22
F 3.00 (2.91-3.09) 2.82 (2.74-2.90) 2.61 (2.33-2.93)
R 3.51 (3.08-3.99) 3.41 (3.13-3.72) 4.87 (2.83-8.41)
H, PH 13.81, < 0.001 5.80, < 0.001 11.54, < 0.001
Sex Male N 48 51 13
F 3.80 (3.60-4.02) 3.08 (2.90-3.28) 6.71 (5.29-8.53)
R 4.11 (3.28-5.15) 4.07 (3.44-4.83) 7.66 (3.00-19.61)
Female n 31 37 5
F 2.53 (2.39-2.68) 2.75 (2.60-2.90) 2.85 (1.94-4.18)
R 3.28 (2.35-4.58) 3.23 (2.80-3.72) 2.85 (1.94-4.18)
Combined n 41 25 4
F 2.81 (2.69-2.95) 2.74 (2.62-2.86) 1.86 (1.62-2.14)
R 3.04 (2.60-3.55) 2.98 (2.57-3.47) 2.54 (1.54-4.20)
Between levels PB < 0.05 NS < 0.05
Continent N America n 39 40 10
F 5.02 (4.76-5.29) 3.44 (3.20-3.69) 8.13 (6.32-10.45)
R 4.56 (3.69-5.62) 4.11 (3.41-4.97) 8.99 (3.34-24.26)
Europe n 55 58 7
F 2.31 (2.22-2.41) 2.79 (2.69-2.89) 1.83 (1.58-2.11)
R 3.31 (2.80-3.92) 3.28 (2.96-3.62) 2.88 (1.36-6.09)
Asia n 17 9 5
F 2.73 (2.45-3.05) 1.83 (1.65-2.02) 2.52 (1.83-3.47)
R 2.86 (2.27-3.60) 2.26 (1.67-3.05) 2.74 (1.50-4.99)
Other or
multicountry
n 960
F 2.15 (1.89-2.44) 3.32 (2.94-3.75)
R 2.37 (1.75-3.21) 3.11 (2.33-4.16)
Between levels PB < 0.001 < 0.001 < 0.01
Publication year Before 1980 n 24 50 7
F 5.64 (5.12-6.21) 3.59 (3.36-3.84) 15.01 (10.59-21.28)
R 3.81 (2.64-5.50) 3.96 (3.41-4.59) 10.21 (2.09-49.96)
1980-89 n 11 26 6
F 2.18 (1.84-2.59) 2.29 (2.16-2.44) 1.83 (1.59-2.10)
R 2.47 (1.87-3.27) 3.25 (2.67-3.96) 1.83 (1.59-2.10)
1990-99 n 18 17 3
F 6.20 (5.59-6.88) 2.74 (2.56-2.93) 3.65 (2.50-5.31)
R 4.91 (3.37-7.16) 3.04 (2.51-3.68) 3.57 (2.30-5.55)
2000 or later n 67 20 6
F 2.60 (2.52-2.69) 2.86 (2.72-3.01) 4.04 (2.65-6.16)
R 3.13 (2.73-3.60) 2.94 (2.50-3.47) 4.57 (2.05-10.20)
Between levels PB < 0.001 < 0.001 < 0.01
Study type Case-control n 14 9 0
F 3.72 (3.09-4.48) 3.39 (2.90-3.96)
R 4.69 (2.83-7.77) 3.66 (2.77-4.83)
Prospective n 38 12 8
F 6.46 (6.01-6.95) 2.96 (2.67-3.29) 3.61 (2.81-4.64)
R 4.34 (3.38-5.56) 3.12 (2.56-3.78) 3.12 (1.74-5.60)
Cross-sectional n 68 92 14
F 2.53 (2.45-2.62) 2.78 (2.70-2.87) 2.39 (2.10-2.73)
R 3.00 (2.63-3.41) 3.42 (3.10-3.77) 6.60 (2.74-15.92)
Between levels PB < 0.001 NS NS
Outcome subtype Mortality n 31 4 5
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Page 33 of 61Table 7 Main meta-analyses for current smoking of any product (or cigarettes, if any product not available)
a
(Continued)
F 6.57 (6.09-7.10) 4.16 (2.67-6.48) 3.79 (2.87-5.00)
R 4.57 (3.39-6.15) 4.96 (2.43-10.12) 3.42 (1.60-7.35)
Lung function
(COPD) or symptoms
(CB)
n 5 68 10
F 2.41 (2.32-2.50) 3.06 (2.95-3.17)
R 2.79 (2.42-3.20) 3.63 (3.29-3.99)
Other n 33 28 17
F 3.45 (3.21-3.70) 2.24 (2.12-2.37) 2.42 (2.13-2.74)
R 3.77 (3.01-4.72) 2.69 (2.26-3.21) 5.56 (2.65-11.68)
Between levels PB < 0.001 < 0.001 NS
How asthma taken
into account
Ignored n 72 103 19
F 3.78 (3.64-3.92) 2.80 (2.72-2.89) 2.59 (2.30-2.91)
R 3.60 (3.08-4.20) 3.38 (3.08-3.70) 5.02 (2.80-9.00)
Excluded n 17 6 3
F 1.79 (1.69-1.90) 2.85 (2.53-3.21) 4.03 (1.85-8.77)
R 3.05 (2.34-3.97) 3.30 (2.39-4.54) 3.90 (0.57-26.55)
Included in outcome
definition
n1 8 - -
F 2.11 (1.88-2.37)
R 2.73 (2.10-3.55)
Other n 13 4 0
F 4.00 (3.42-4.67) 6.93 (4.39-10.92)
R 4.03 (2.96-5.48) 5.70 (2.63-12.37)
Between levels PB < 0.001 NS NS
Number of cases 1-50 n 21 18 8
F 4.62 (3.42-6.24) 3.85 (2.81-5.28) 2.09 (1.31-3.34)
R 4.90 (3.34-7.18) 3.85 (2.81-5.28) 2.09 (1.31-3.34)
51-100 n 23 14 6
F 3.08 (2.64-3.60) 4.92 (3.84-6.30) 4.83 (3.06-7.61)
R 3.21 (2.48-4.16) 5.28 (3.88-7.03) 5.14 (2.53-10.45)
101-200 n 29 19 1
F 2.61 (2.35-2.89) 3.93 (3.41-4.52) 14.50 (4.63-45.41)
R 2.92 (2.39-3.57) 4.71 (3.37-6.57) 14.50 (4.63-45.41)
201+ n 47 62 7
F 3.02 (2.92-3.12) 2.74 (2.66-2.83) 2.48 (2.19-2.81)
R 3.66 (3.02-4.43) 3.06 (2.78-3.27) 6.62 (2.44-18.00)
Between levels PB NS < 0.05 NS
Analysis type Prevalence n 84 103 14
F 2.57 (2.48-2.65) 2.82 (2.74-2.91) 2.39 (2.10-2.73)
R 3.14 (2.78-3.56) 3.44 (3.14-3.77) 6.60 (2.74-15.92)
Onset n 36 10 8
F 6.58 (6.11-7.09) 2.75 (2.42-3.13) 3.61 (2.81-4.64)
R 4.40 (3.41-5.69) 3.00 (2.31-3.89) 3.12 (1.74-5.60)
Between levels PB < 0.001 NS NS
Smoking product Any n 46 57 5
F 3.09 (2.92-3.26) 2.84 (2.72-2.96) 2.05 (1.78-2.36)
R 3.67 (3.05-4.40) 3.54 (3.17-3.97) 3.84 (1.20-12.22)
Cigarettes (ignoring
other products)
n 6 65 21 6
F 2.67 (2.57-2.77) 2.79 (2.67-2.91) 4.37 (3.54-5.40)
R 3.06 (2.60-3.60) 3.27 (2.84-3.76) 5.11 (2.45-10.65)
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Page 34 of 61= 110; CB 1.63, 1.50-1.78, n = 105; emphysema 3.52,
2.51-4.94, n = 17), though all clearly positive, are smaller
than the corresponding estimates for current smoking.
Individual RRs are only occasionally below 1.0 and
never significantly so. Estimates are little affected by
preferring RRs for ever smoking cigarettes to those for
ever smoking any product, the random-effects estimates
changing to 2.37 (2.12-2.64) for COPD and unchanged
for CB and for emphysema. They are little changed by
preferring least-adjusted RRs, with the estimates now
2.37 (2.13-2.63) for COPD, 1.72 (1.55-1.92) for CB and
3.68 (2.70-5.00) for emphysema.
For the main meta-analysis, the studies contributing
the greatest to the total weight are ZIELI2/females for
COPD (11.9% of the total of 3,510), and LAVECC/sexes
combined for CB (13.1% of 2,493) and emphysema
(48.4% of 300).
For the characteristics considered in Table 10, the pat-
tern of variation is quite similar to that for current smok-
ing seen in Table 7. Thus, for COPD, RRs are, for both
current and ex smoking, higher in males, lower in Eur-
opean studies, lower in cross-sectional studies, higher
where the outcome is mortality, higher for cigarette only
smoking and higher for never any product as the unex-
posed base. For CB, RRs are higher for mortality for both
current and ex smoking, but the differences by continent
seen for current smoking are not evident for ex smoking.
The same is true for differences by age-adjustment (not
shown in Table 10). The small numbers of emphysema
RRs for ex smoking (17) preclude reliable study of varia-
tion by level of the characteristics of interest. Further
details of variations in RRs by level of the characteristics
for all three outcomes, overall and (for COPD and CB)
by outcome subtype are given in the Additional files.
Table 7 Main meta-analyses for current smoking of any product (or cigarettes, if any product not available)
a
(Continued)
Cigarettes only n 8 4 1
F 8.51 (7.55-9.59) 3.27 (2.55-4.20) 7.72 (2.39-24.94)
R 7.47 (4.63-12.05) 3.36 (2.24-5.05) 7.72 (2.39-24.94)
Between levels PB < 0.001 NS NS
Unexposed base
c Never any product n 58 69 7
F 4.07 (3.89-4.26) 2.89 (2.77-3.01) 2.41 (2.11-2.77)
R 4.27 (3.51-5.19) 3.56 (3.20-3.96) 8.93 (1.83-43.50)
Never cigarettes n 62 44 15
F 2.34 (2.25-2.44) 2.74 (2.63-2.87) 3.18 (2.56-3.96)
R 2.87 (2.48-3.31) 3.21 (2.77-3.72) 3.30 (2.39-4.56)
Between levels PB < 0.001 NS NS
RR adjusted for age Yes n 63 65 13
F 3.47 (3.30-3.65) 2.57 (2.48-2.67) 2.52 (2.23-2.85)
R 3.66 (3.07-4.36) 3.05 (2.74-3.39) 5.77 (2.77-12.02)
N o n 5 74 89
F 2.76 (2.66-2.87) 3.33 (3.17-3.51) 3.57 (2.49-5.14)
R 3.34 (2.76-4.04) 4.10 (3.57-4.71) 3.35 (1.90-5.91)
Between levels PB < 0.1 < 0.001 NS
RR adjusted for
factors other than
age or sex
Y e s n 2 72 96
F 2.77 (2.61-2.94) 2.77 (2.65-2.88) 1.87 (1.62-2.15)
R 3.17 (2.65-3.80) 2.97 (2.57-3.44) 2.62 (1.65-4.17)
N o n 9 38 41 6
F 3.09 (2.98-3.20) 2.87 (2.75-3.00) 5.27 (4.30-6.46)
R 3.66 (3.11-4.31) 3.68 (3.29-4.12) 5.57 (2.67-11.62)
Between levels PB NS NS < 0.05
a Within each study, results are selected in the following order or preference, within each sex, for: unexposed group-never any product, never cigarettes, other;
smoking product-any, cigarettes (ignoring other products), cigarettes only; overlapping studies-principal, subsidiary; and then for single sex results in preference
to combined sex results. Results adjusted for the most potential confounders are selected.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p ≥ 0.1), PB = probability value for between levels
(see methods) similarly expressed.
c Includes acceptable near-equivalent estimate (see methods) if estimate for strictly defined never smoker base not available (COPD: 3 for never cigarettes, CB: 2
for never any product and 4 for never cigarettes).
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Page 35 of 61E. Risk by amount smoked
Table 11 summarizes the results of meta-analyses using
RRs categorized by amount smoked. These are based
on those 33 studies for COPD, 44 for CB and 10 for
emphysema which provided data that could be used in
the meta-analyses. For all three outcomes, results are
shown for one of the sets of “key values” (see methods)
and for the comparison of the highest and lowest expo-
sures. For all three outcomes, a clear increase is seen
for RRs for categories containing 5, but not 20, cigar-
ettes/day, with the meta-analysis RR increasing mono-
tonically with increasing amount smoked. Random-
effects estimates for categories containing 45, but not
20 cigarettes/day, are 9.50 (7.38-12.22, n = 26) for
COPD, 7.37 (5.86-9.28, n = 35) for CB and 7.19 (2.74-
18.87, n = 6) for emphysema. The key value analyses
do not use results for all the dose-response data avail-
able, as a number of the studies use broad dose-
response categories (such as 1-20 or 20+ cigs/day)
w h i c hs p a nm o r et h a no n eo ft h ek e yv a l u e s .T h e
“highest vs. lowest” analyses in Table 11 include results
from all the dose response relationships which can be
meta-analysed, and emphasise the positive relationship,
with random-effects estimates of 2.32 (1.90-2.83, n =
44) for COPD, 2.42 (2.10-2.79, n = 62) for CB, and
2.73 (1.23-6.04) for emphysema. Fuller results are
given in the Additional files. These results, which also
include some meta-analyses by level of selected charac-
teristics, show that the increase with amount smoked
is also clearly evident using an alternative set of key
values (1, 10, 20, 30, 40, 999), though numbers of
available RRs are quite sparse for the higher values,
and using least-adjusted rather than most-adjusted
RRs. The additional files also include available results
for some other studies which present dose response
data in a form that cannot readily be included in the
meta-analyses (e.g. comparison of mean or median
consumption in cases and non-cases). These results do
Table 8 Meta-regression analyses for current smoking of any product (or cigarettes if any product not available)
a
COPD CB
Characteristic Level Estimate
b (SE
c)p
d Estimate
b (SE
c)p
d
Constant +1.011 (0.156) +1.335 (0.258)
Sex Male Base < 0.05 Base NS
Female -0.218 (0.045) -0.097 (0.043)
Combined -0.007 (0.045) +0.039 (0.082)
Continent N America Base < 0.001 Base < 0.001
Europe -0.347 (0.051) -0.353 (0.052)
Asia -0.499 (0.079) -0.493 (0.070)
Other -0.510 (0.081) -0.144 (0.086)
Disease definition Mortality Base < 0.001 Base < 0.01
Lung function (COPD) or symptoms (CB) -0.435 (0.071) -0.104 (0.232)
Other +0.049 (0.076) -0.406 (0.232)
How asthma taken into account Ignored Base < 0.001 Base < 0.05
Excluded -0.334 (0.051) +0.159 (0.076)
Included in outcome definition -0.721 (0.072) No data
Other -0.055 (0.103) +1.225 (0.237)
Smoking product Any Base < 0.05 Base NS
Cigarettes (ignoring other products) +0.255 (0.084) -0.023 (0.136)
Cigarettes only +0.505 (0.099) +0.410 (0.136)
Unexposed group Never any product Base < 0.01 Base NS
Never cigarettes -0.446 (0.077) -0.127 (0.130)
RR adjusted for age Yes Base NS Base < 0.01
No +0.076 (0.050) +0.219 (0.039)
RR adjusted for factor other than age or sex Yes Base NS Base NS
No +0.148 (0.057) -0.007 (0.072)
Midpoint age Per 10 years +0.012 (0.002) < 0.05 +0.003 (0.002) NS
a Based on the same data as for Table 7. See that table for further definition of RRs selected for analysis, and numbers of estimates of each characteristic level.
b Estimates are of log RR. For a particular entry, the predicted RR for a given estimate is calculated by adding the constant to the values for each level applicable
to the estimate (taking the value for the base level as zero) and taking the exponential of the result.
c SE = standard error.
d The p value is estimated from the drop in deviance from removing the characteristic from the model using an F-test. It is expressed as p < 0.001, p < 0.01, p <
0.05, p < 0.1 or NS (p ≥ 0.1).
Forey et al. BMC Pulmonary Medicine 2011, 11:36
http://www.biomedcentral.com/1471-2466/11/36
Page 36 of 61n o ta p p e a ri n c o n s i s t e n tw i t ht h o s es u m m a r i z e di n
Table 11.
F. Risk by age of starting to smoke
There is rather limited evidence available for age of
starting, with only 10 studies for COPD, three for CB
and one for emphysema providing data usable in meta-
analyses. Table 12 summarizes the meta-analysis results.
Random-effects RRs for earliest compared to latest start-
ing are significantly elevated for COPD (1.49, 1.26-1.76,
n = 14) and CB (2.08, 1.29-3.35, n = 6), but not for
emphysema (1.14, 0.70-1.88, n = 2). The increase in risk
with earlier starting seen for COPD is consistent with
the results of the key value analyses, with random-
effects estimates rising to 3.12 (2.07-4.70, n = 8) for
categories containing 14, but not 18 years.
G. Risk by pack-years
Table 13 summarizes the results for pack-years, based
on 24 studies for COPD, eight for CB and two for
emphysema. Key value analysis was not attempted for
emphysema, due to the limited data. For COPD and CB,
a clear dose-response is seen, with meta-analysis RRs
increased for categories containing 5, but not 20 pack-
years, and increasing monotonically with increasing
pack-years. Random-effects estimates for categories con-
taining 45, but not 20, pack-years are 3.69 (2.79-4.86, n
= 15) for COPD, and 7.04 (5.06-9.79, n = 36) for CB.
The “highest vs. lowest” analyses confirm the existence
of a dose-response relationship for all three outcomes,
with random-effects estimates of 2.80 (2.37-3.30, n = 31)
for COPD, 3.09 (2.33-4.10, n = 11) for CB, and 2.42
(1.25-4.70) for emphysema. Fuller results are given in
the Additional files. As for amount smoked, these
results show that the dose-related increase can be clearly
seen using alternative key values (1, 10, 20, 30, 999), and
using least-adjusted rather than most-adjusted RRs. The
additional file also summarizes results for quite a
number of other studies presenting dose response data
in a form that cannot readily be meta-analysed. Many of
these reported a significantly increased risk with increas-
ing pack-years.
H. Risk by duration of smoking
Evidence for duration of smoking that can be used in
meta-analyses is only available for three studies for
COPD, three for CB and two for emphysema. Table 14
summarizes the results of the meta-analyses, which for
CB and emphysema are based on heterogeneous data.
Random-effects RRs for longest compared to shortest
duration show no clear pattern for COPD (1.12, 0.63-
1.98, n = 3), CB (2.25, 0.68-7.42, n = 4), or emphysema
(7.67, 0.15-390.65, n = 2).
I. Risk by duration of quitting (vs. never smoking)
The number of studies providing usable data for duration
of quitting compared to never smoking is seven for
COPD, and seven for CB, but none for emphysema. As
shown in Table 15, there is some evidence of higher risks
in short-term quitters for COPD, with the shortest vs.
longest random-effects meta-analysis estimate 2.21 (1.24-
3.94, n = 10) and a tendency for estimates to be lower for
the longer-term quitters in the key value analysis, though
the trend is not monotonic. For CB, evidence of higher
r i s k si ns h o r t - t e r mq u i t t e r si sl e s sc o n v i n c i n g ,w i t ht h e
shortest vs. longest estimate of 1.25 (0.99-1.59, n = 11)
not significant, and RRs varying little by key value. The
results are limited by the variability of the categories used
by different studies to classify duration of quitting. This
makes it difficult to find a key scheme which includes
sufficient numbers of studies across the range. For
instance, for COPD, the key scheme shown in Table 15
includes only three RRs at the two shorter levels, whereas
an alternative set of key values (20, 12 and 3 years, shown
in the Additional files) incorporates only three RRs at the
two longer levels.
Table 9 Main meta-analyses for current or ever smoking of any product (or cigarettes, if not available)a
Preference Statistic
b COPD CB Emphysema
Ever smoking to current smoking n 138 121 33
F 2.47 (2.40-2.53) 2.42 (2.36-2.48) 3.32 (3.04-3.61)
R 3.00 (2.71-3.32) 2.70 (2.51-2.90) 4.83 (3.46-6.73)
H, PH 10.61, < 0.001 5.61, < 0.001 9.95, < 0.001
Current smoking to ever smoking n 139 121 33
F 2.87 (2.79-2.95) 2.82 (2.75-2.90) 3.44 (3.13-3.78)
R 3.46 (3.07-3.90) 3.27 (3.02-3.54) 5.05 (3.51-7.25)
H, PH 13.15, < 0.001 6.53, < 0.001 10.52, < 0.001
a Within each study, results are selected in the following order of preference, within each sex, for: smoking status-ever, current or current, ever according to
analysis; unexposed group-never any product, never cigarettes, other; smoking product-any, cigarettes (ignoring other products), cigarettes only; overlapping
studies-principal, subsidiary; and then for single sex results in preference to combined sex results. Results adjusted for the most potential confounders are
selected.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom.
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REF SEX  Weight  Relative Risk  Relative Risk
(%)  95% CI  95% CI 
  ALESSA b  0.09  2.42 (0.80, 7.26) 
  ANDER1 m  0.04  3.27 (0.64, 16.79) 
  ANDER1 f  0.07  1.51 (0.44, 5.21) 
  ANDER3 m  0.01  55.86 (2.53, 1231.22)
  ANDER3 f  0.01  5.00 (0.17, 146.64)
  BEDNAR b  0.27  1.17 (0.62, 2.23) 
  BEST m  0.14  12.50 (5.13, 30.44)
  CHEN2 m  0.16  3.20 (1.40, 7.31) 
  CHEN2 f  0.28  1.26 (0.67, 2.34) 
  CLEMEN m  0.08  1.50 (0.47, 4.76) 
  DEAN1 m  0.65  2.46 (1.63, 3.70) 
  DEAN1 f  0.48  2.02 (1.25, 3.26) 
  DEJONG b  0.01  28.35 (1.68, 479.53) 
  DEMARC b 1.58  1.36 (1.04, 1.76) 
  DICKIN b 0.03  20.19 (2.68, 152.38) 
  DOLL1 m  0.33  5.00 (2.81, 8.91) 
  DOLL2 f  0.02  5.00 (0.52, 48.07) 
  EKBERG m  5.90  1.46 (1.28, 1.67) 
  EKBERG f  1.47  1.27 (0.96, 1.67) 
  FERRI2 m  0.19  1.76 (0.82, 3.77) 
  FERRI2 f  0.22  1.07 (0.53, 2.16) 
  FORAST f  0.45  2.00 (1.22, 3.27) 
  FUKUCH b  0.92  2.99 (2.12, 4.22) 
  GODTFR b  0.99  1.92 (1.38, 2.68) 
  HAMMO2 m  1.01  10.20 (7.34, 14.17)
  HAMMO2 f  0.77  5.85 (4.02, 8.53) 
  HARDIE m  0.20  4.63 (2.20, 9.74) 
  HARDIE f  0.42  2.32 (1.39, 3.88) 
  HARIKK m  0.15  1.47 (0.63, 3.41) 
  HARIKK f  0.01  10.08 (0.53, 192.08) 
  HIGGI4 m  0.61  3.02 (1.98, 4.61) 
  HO m  0.38  1.99 (1.17, 3.40) 
  HO f  0.28  2.31 (1.23, 4.34) 
  HOZAWA b  11.07  1.87 (1.70, 2.07) 
  HUHTI1 m  0.12  2.98 (1.16, 7.62) 
  HUHTI1 f  0.10  4.30 (1.54, 12.00) 
  HUHTI3 m  0.08  5.06 (1.57, 16.35) 
  JACOBS m  0.22  1.00 (0.50, 2.07) 
  JOHANN b  0.45  4.88 (2.99, 7.97) 
  KACHEL b  0.08  1.78 (0.56, 5.67) 
  KAHN m  5.29  4.10 (3.60, 4.80) 
  KARAKA b  0.21  1.31 (0.64, 2.69) 
  KATANC b  0.36  1.99 (1.14, 3.45) 
  KIM m  0.38  2.25 (1.32, 3.84) 
  KIM f  0.04  1.74 (0.35, 8.65) 
  KOJIMA m  0.39  2.43 (1.43, 4.13) 
  KOJIMA f  0.01  0.73 (0.04, 12.14) 
  KRZYZA m  0.12  2.34 (0.91, 6.01) 
  KRZYZA f 0.13  1.05 (0.42, 2.65) 
  LAM2 m  0.85  3.02 (2.11, 4.32) 
  LAM3 m  0.16  2.12 (0.92, 4.90) 
  LEBOWI m  0.08  4.39 (1.41, 13.69) 
  LEBOWI f  0.26  1.30 (0.68, 2.47) 
  LEE m  0.03  3.61 (0.45, 28.74) 
  LEE f  0.02  1.14 (0.13, 9.70) 
  LINDBE b 0.33  1.71 (0.96, 3.05) 
  LINDST b  1.82  1.67 (1.31, 2.14) 
  LUNDB1 b  0.45  2.14 (1.31, 3.50) 
  MADOR m  0.01  13.36 (0.58, 308.02) 
  MANNI1 m  1.65  1.98 (1.53, 2.56) 
  MANNI1 f  1.50  2.08 (1.59, 2.73) 
  MANNI2 b  2.39  1.83 (1.48, 2.27) 
  MANNI3 b  0.46  1.62 (1.00, 2.64) 
  MARAN1 b  0.76  5.86 (4.02, 8.56) 
  MARAN2 b  0.26  4.36 (2.29, 8.29) 
  MARCUS m  0.21  2.37 (1.14, 4.91) 
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Figure 11 Forest plot of ex smoking of any product and COPD-part 1. Table 10 presents the results of a main meta-analysis for COPD
based on 110 relative risk (RR) and 95% confidence interval (CI) estimates for ex smoking of any product (or cigarettes if any product not
available). The individual study estimates are shown numerically and graphically on a logarithmic scale in Figures 11 and 12. The weights
(inverse-variance) are also shown numerically, expressed as a percentage of the overall weight. The studies are sorted in order of sex within
study reference (REF). In the graphical representation individual RRs are indicated by a solid square, with the area of the square proportional to
the weight. Arrows indicate where the CI extends outside the range allocated. Where the RR value falls outside the range, the size of the
plotting symbol indicates the weight but the position is not true to the scale.
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Page 38 of 61J. Risk by duration of quitting (vs. current smoking)
For duration of quitting compared to current smoking,
data are available from one less study than for duration
of quitting compared to never smoking for COPD, but
f r o mt h es a m es t u d i e sf o rC B .T h el o n g e s tv s .s h o r t e s t
analysis shown in Table 16 is the inverse of the shortest
vs. longest analysis in Table 15. The key value analyses
are based on a limited number of RRs but are consistent
with the association declining with longer-term quitting.
For categories including 12, but not 7, years quitting
random-effects meta-analysis RRs relative to current
smoking are 0.52 (0.37-0.71, n = 9) for COPD and 0.65
(0.41-1.04, n = 9) for CB.
Further analyses based on within-study differences
Some studies provide independent RRs for males and
females for the same definition of outcome and expo-
sure. Random-effects meta-analysis of the male/female
sex ratio for current and ever smoking for each outcome
confirm the impression already gained from the analyses
 
0.2  0.4  1  25  50 
REF SEX  Weight  Relative Risk  Relative Risk
(%)  95% CI  95% CI 
  MATHES b  0.30  2.40 (1.31, 4.39) 
  MENEZ2 b  0.75  1.27 (0.86, 1.85) 
  MENEZ3 b  0.68  0.97 (0.65, 1.45) 
  MENEZ4 b  0.36  2.12 (1.22, 3.69) 
  MENEZ5 b  0.67  1.68 (1.12, 2.51) 
  MENEZ6 b  0.59  2.88 (1.87, 4.43) 
  MONTNE b  1.40  2.17 (1.64, 2.87) 
  MUELLE m  0.04  2.53 (0.46, 13.76) 
  MUELLE f  0.01  1.51 (0.07, 32.39) 
  NIEPSU b  0.13  3.27 (1.31, 8.18) 
  NIHLEN b 0.40  3.26 (1.93, 5.50) 
  NILSSO m  0.19  1.80 (0.85, 3.83) 
  NILSSO f  0.10  1.56 (0.56, 4.34) 
  PETO m  0.01  19.06 (1.13, 320.69) 
  RENWIC b  0.16  2.51 (1.09, 5.78) 
  RICCIO b  1.81  2.14 (1.67, 2.73) 
  SARGEA b  6.93  1.35 (1.19, 1.53) 
  SHAHAB b  4.43  1.88 (1.61, 2.20) 
  SHIN m  0.20  1.77 (0.84, 3.72) 
  SILVA b  0.25  0.78 (0.40, 1.52) 
  SPEIZE m  0.01  11.09 (0.66, 186.62) 
  SPEIZE f  0.07  3.80 (1.10, 13.13) 
  STERLI m  0.50  6.77 (4.24, 10.82) 
  STERLI f  0.49  6.14 (3.82, 9.85) 
  STROM m  0.31  2.16 (1.19, 3.92) 
  TANG m  0.28  2.18 (1.16, 4.09) 
  THUN m  1.22  8.75 (6.48, 11.80) 
  THUN f  1.41  7.04 (5.33, 9.30) 
  TODD m  0.03  6.97 (0.92, 52.85) 
  TODD f  0.01  0.73 (0.04, 13.50) 
  TRUPIN b 1.14  2.90 (2.10, 3.90) 
  TSUSHI b  0.13  4.81 (1.93, 12.00) 
  TVERDA m  0.11  1.39 (0.52, 3.74) 
  VESTBO b  3.22  1.40 (1.16, 1.68) 
  VIEGI2 m  0.37  1.42 (0.82, 2.45) 
  VIEGI2 f  0.35  0.88 (0.50, 1.53) 
  VONHER m  1.13  1.97 (1.44, 2.69) 
  VONHER f  0.30  0.71 (0.39, 1.29) 
  WEISS m  0.04  2.93 (0.61, 14.17) 
  XIAO b  0.17  5.90 (2.64, 13.22) 
  YAMAGU b 0.98  1.96 (1.40, 2.73) 
  YUAN m  0.11  1.52 (0.55, 4.19) 
  ZIELI2 m  7.81  2.97 (2.63, 3.34) 
  ZIELI2 f  11.86  1.61 (1.46, 1.77) 
Total (95% CI)  100.00  2.35 (2.11, 2.63) 
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Figure 12 Forest plot of ex smoking of any product and COPD-part 2. This is a continuation of Figure 11, presenting the remaining
individual study data included in the main meta-analysis for COPD shown in Table 10. Also shown are the combined random-effects estimates.
These are represented by a diamond of standard height, with the width indicating the 95% CI.
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0.2  0.4  1  25  50 
REF SEX  Weight  Relative Risk  Relative Risk
(%)  95% CI 95% CI 
  ALDERS m  0.57  2.52 (1.50, 4.24) 
  ALDERS f  1.41  2.63 (1.89, 3.66) 
  ANDER1 m  0.11  2.60 (0.78, 8.68) 
  ANDER1 f  0.09  1.22 (0.32, 4.67) 
  BECK1 m  0.03  0.53 (0.05, 5.11) 
  BECK1 f  0.06  1.49 (0.30, 7.55) 
  BECK2 m  0.04  1.58 (0.22, 11.03) 
  BECK2 f  0.02  0.64 (0.03, 12.18) 
  BEST m  0.10  12.50 (3.56, 43.84) 
  BJORNS b  3.75  1.00 (0.80, 1.20) 
  BROWN m  0.34  1.40 (0.72, 2.72) 
  CERVER b  8.18  1.53 (1.33, 1.75) 
  COATES b  0.24  1.10 (0.49, 2.44) 
  COLLEG m  0.11  2.22 (0.69, 7.12) 
  COLLEG f  0.23  2.84 (1.25, 6.43) 
  DEANE m  0.06  1.24 (0.26, 5.95) 
  DEMARC b 1.14  1.03 (0.71, 1.48) 
  DONTA2 m  0.15  1.64 (0.60, 4.52) 
  DOPICO m  0.10  0.73 (0.21, 2.52) 
  EHRLIC m  0.27  0.80 (0.40, 1.80) 
  EHRLIC f 0.60  1.30 (0.80, 2.20) 
  ENRIGH m  0.51  1.89 (1.09, 3.28) 
  ENRIGH f  1.46  1.64 (1.19, 2.28) 
  FERRI1 m  0.16  0.84 (0.32, 2.23) 
  FERRI1 f  0.13  1.17 (0.39, 3.49) 
  FOXMAN m  0.64  1.35 (0.83, 2.22) 
  FOXMAN f  0.60  1.36 (0.82, 2.25) 
  GOLDBE m  1.96  1.29 (0.97, 1.70) 
  GOLDBE f  0.87  1.19 (0.78, 1.81) 
  HAENSZ m  0.64  1.72 (1.05, 2.80) 
  HAENSZ f  0.35  2.29 (1.18, 4.47) 
  HARDIE m  0.06  8.70 (1.78, 42.53) 
  HARDIE f  0.24  2.65 (1.19, 5.86) 
  HARRIS m  0.08  1.74 (0.43, 7.03) 
  HAWTHO m 1.42  1.97 (1.41, 2.74) 
  HAWTHO f  1.00  1.94 (1.31, 2.88) 
  HAYES b  0.65  1.53 (0.94, 2.48) 
  HIGGI2 m  0.03  1.69 (0.17, 17.03) 
  HIGGI2 f  0.02  1.14 (0.06, 21.52) 
  HIGGI3 m  0.01  1.56 (0.06, 43.93) 
  HIGGI3 f  0.01  25.80 (0.96, 691.65) 
  HIGGI6 m  0.18  0.50 (0.20, 1.25) 
  HIGGI6 f  0.23  1.36 (0.60, 3.11) 
  HO b  0.77  2.15 (1.38, 3.37) 
  HOLLA2 m  0.11  1.43 (0.44, 4.70) 
  HOLLNA m 0.21  2.02 (0.85, 4.81) 
  HOLLNA f  0.04  0.32 (0.04, 2.46) 
  HOUSE m  0.73  1.17 (0.74, 1.86) 
  HOUSE f  0.68  1.71 (1.06, 2.75) 
  HUCHON b 3.03  1.25 (1.00, 1.57) 
  HUHTI1 m  0.17  2.48 (0.96, 6.44) 
  HUHTI1 f  0.12  3.38 (1.11, 10.34) 
  HUHTI3 m  0.48  1.38 (0.78, 2.43) 
  JOUSI1 m  5.72  1.30 (1.11, 1.53) 
  JOUSI1 f  1.16  0.79 (0.55, 1.13) 
  KAHN m  1.37  3.30 (2.30, 4.50) 
  KATO m  3.24  1.59 (1.28, 1.98) 
  KATO f  2.48  2.28 (1.78, 2.93) 
  KOTAN1 b  1.10  1.64 (1.13, 2.39) 
  LAMBER m  0.50  2.04 (1.17, 3.56) 
  LAMBER f  0.40  1.92 (1.03, 3.57) 
  LANGE2 b  1.68  1.70 (1.20, 2.20) 
  LANGHA m  4.01  1.55 (1.27, 1.88) 
  LANGHA f  4.15  1.21 (1.00, 1.47) 
  LAVECC b  13.05  2.29 (2.06, 2.56) 
  LEBOWI b  0.36  1.00 (0.52, 1.94) 
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Figure 13 Forest plot of ex smoking of any product and CB-part 1. Table 10 presents the results of a main meta-analysis for CB based on
105 relative risk (RR) and 95% confidence interval (CI) estimates for ex smoking of any product (or cigarettes if any product not available). The
individual study estimates are shown numerically and graphically on a logarithmic scale in Figures 13 and 14. The weights (inverse-variance) are
also shown numerically, expressed as a percentage of the overall weight. The studies are sorted in order of sex within study reference (REF). In
the graphical representation individual RRs are indicated by a solid square, with the area of the square proportional to the weight. Arrows
indicate where the CI extends outside the range allocated. Where the RR value falls outside the range, the size of the plotting symbol indicates
the weight but the position is not true to the scale.
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for males, though again the difference is not always sta-
tistically significant. For ever smoking, the meta-analysis
RRs of the sex ratio are 1.28 (1.02-1.60) for COPD, 1.16
(0.97-1.38) for CB and 1.44 (0.72-2.87) for emphysema,
based on, respectively, 31, 35 and 6 RRs. For current
smoking the estimates are 1.25 (1.00-1.58, n = 29) for
COPD, 1.17 (0.96-1.42, n = 35) for CB, and 1.98 (0.75-
5.22, n = 5) for emphysema.
Some studies also provide separate non-independent
least-adjusted and most-adjusted RRs for the same defi-
nition of exposure. There is little evidence that adjust-
ment reduces the RR for ever or current smoking. For
ever smoking, using the same preferences as in the main
meta-analyses (Figures 1, 2, 3, 4 and 5), the most-
adjusted estimate is lower than the least-adjusted esti-
mate for 14 of the 30 (46.7%) pairs for COPD, for 18 of
the 41 (43.9%) pairs for CB, and for 2 of the 5 (40.0%)
pairs for emphysema. For current smoking the corre-
sponding numbers are 11/26 (42.3%) for COPD, 16/36
(44.4%) for CB and 2/3 (66.7%) for emphysema. In no
case do the percentages differ from 50% (at p < 0.05),
and in each case the random-effects meta-analysis esti-
mate based on the least-adjusted pair members is simi-
lar to the corresponding estimate based on the most-
adjusted pair members (data not shown).
 
  0.2  0.4  1  25  50 
REF SEX  Weight  Relative Risk Relative Risk
(%)  95% CI 95% CI
  LINDST b  5.70  1.11 (0.95, 1.32)
  LUNDB2 m  0.34  2.82 (1.44, 5.54)
  LUNDB2 f 0.24  1.59 (0.72, 3.52)
  MAGNUS m 0.41  2.82 (1.53, 5.20)
  MANFRE m  0.07  1.95 (0.46, 8.34)
  MANFRE f  0.14  0.92 (0.32, 2.58)
  MELLST m  0.38  1.64 (0.87, 3.09)
  MENEZ1 b 0.40  1.59 (0.85, 2.96)
  MEREN b  0.93  1.00 (0.62, 1.40)
  MILLER m  0.22  1.79 (0.78, 4.09)
  MILLER f 0.03  2.60 (0.26, 25.96)
  MILNE m 0.09  5.33 (1.44, 19.74)
  MILNE f
0.10 
3.88 (1.12, 13.41)
  MOLLER b
0.02 
96.60 (4.14, 2253.15) 
  MUELLE m 0.06  3.75 (0.74, 19.04)
  MUELLE f 0.03  2.67 (0.27, 26.82)
  NEJJAR b  1.32  1.54 (1.10, 2.18)
  OGILVI m  0.19  1.52 (0.62, 3.71)
  OGILVI f 0.21  0.98 (0.42, 2.30)
  PANDEY m 0.12  9.28 (3.03, 28.40)
  PANDEY f  0.42  3.33 (1.81, 6.12)
  PELKON m  0.91  1.18 (0.78, 1.78)
  REID m  0.48  2.64 (1.50, 4.64)
  REID f 0.37  2.39 (1.26, 4.55)
  SAWICK m  0.34  2.46 (1.26, 4.83)
  SAWICK f 0.26  2.14 (0.99, 4.62)
  SHIMUR b  0.02  2.00 (0.11, 35.81)
  SILVA b  0.26  0.85 (0.40, 1.85)
  SOBRAD b  0.57  5.92 (3.53, 9.93)
  STJERN b  0.06  1.46 (0.29, 7.26)
  TROISI f  4.02  1.16 (0.96, 1.42)
  VIEGI1 m  0.12  4.90 (1.55, 15.52)
  VIEGI1 f  0.03  1.32 (0.16, 10.83)
  WAGEN2 b 1.75  0.93 (0.69, 1.25)
  WILHEL m 0.03  3.30 (0.34, 32.42)
  WOODS b 3.65  1.48 (1.20, 1.81)
  WOOLF f 0.04  0.28 (0.04, 2.26)
  YAMAGU b 1.10  1.54 (1.06, 2.24)
  ZOIA b  0.17  0.80 (0.30, 2.00)
Total (95% CI)  100.00  1.63 (1.50, 1.78)
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Figure 14 Forest plot of ex smoking of any product and CB-part 2. This is a continuation of Figure 13, presenting the remaining individual
study data included in the main meta-analysis for CB shown in Table 10. Also shown are the combined random-effects estimates. These are
represented by a diamond of standard height, with the width indicating the 95% CI.
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some studies allow comparison of RRs of the risk of
current smoking vs. never smoking for cigarette smokers
ignoring other products with equivalent RRs for cigar-
ette only smokers. These estimates are non-independent.
For 7 of the 9 pairs of RRs for COPD, for all 6 of the
pairs for CB (p < 0.05) and for both the pairs for
emphysema the RR is lower for cigarette smokers ignor-
ing other products. However the RR ratio is never mark-
edly different from 1, ranging from 0.78 to 1.13 for
COPD, from 0.84 to 0.99 for CB, and from 0.86 to 0.96
for emphysema.
RRs for a dose-related index of smoking may be
adjusted for other such indices. However, this is only at
all common for age of starting to smoke, where adjust-
ment for amount smoked is carried out in five of the 10
studies providing data for COPD, and in one of the
three providing data for CB. It is not possible to assess
the effect of adjustment for amount smoked, as three of
the six relevant studies provide the adjusted RR and no
other RR, and the other three provide only adjusted and
totally unadjusted RRs.
For all three outcomes, Egger’s test [16] shows signifi-
cant evidence of publication bias for both ever smoking
(COPD p < 0.001, CB p < 0.05, emphysema p < 0.01)
and current smoking (COPD p < 0.05, CB p < 0.001,
emphysema p < 0.05). Figures 16 (COPD), 17 (CB) and
18 (emphysema) show funnel plots for ever smoking. All
the plots give an impression of there being more lower-
weight RRs above the mean and more higher-weight
RRs below the mean.
Discussion
Evidence of a relationship
The meta-analyses carried out demonstrate a clear rela-
tionship of smoking to all three outcomes considered-
COPD, CB and emphysema. This is evident for ever,
current and ex smoking, and for outcomes based on
mortality, lung function, symptom prevalence or other
methods. That this relationship is causal is supported by
the evidence of a dose-response, risk increasing with
amount smoked and pack-years for all three outcomes,
and (based on more limited data) decreasing with
increasing age of starting to smoke for COPD and CB,
and with increasing duration of quitting for COPD. It is
also supported by the similarity of results based on
most-adjusted and least-adjusted RRs, and by within-
study comparisons showing that additional confounder
adjustment little affected estimates for the same expo-
sure definition.
 
0.2  0.4  1  25  50 
REF SEX  Weight  Relative Risk  Relative Risk
(%)  95% CI  95% CI 
  BEST m  0.80  12.50 (3.53, 44.27) 
  DONTA2 m  0.27  0.55 (0.06, 4.79) 
  ENRIGH m  5.54  2.15 (1.33, 3.47) 
  ENRIGH f  5.76  4.33 (2.70, 6.94) 
  HARDIE m  0.70  11.67 (3.01, 45.15) 
  HARDIE f  1.80  1.86 (0.80, 4.31) 
  HO b  2.25  3.25 (1.53, 6.91) 
  HUHTI1 m  0.30  10.24 (1.30, 80.49) 
  HUHTI1 f  0.56  3.09 (0.68, 14.11) 
  KAHN m  29.11  5.90 (4.80, 7.30) 
  LAVECC b  48.38  2.69 (2.29, 3.17) 
  LEBOWI b  1.23  6.65 (2.40, 18.48) 
  MILLER m  0.14  6.96 (0.34, 142.68) 
  MILLER f 0.10  2.85 (0.08, 99.49) 
  OMORI m  0.88  4.51 (1.35, 15.04) 
  SILVA b  1.91  1.06 (0.47, 2.41) 
  WEISS m  0.27  2.78 (0.31, 24.73) 
Total (95% CI)  100.00  3.52 (2.51, 4.94) 
  10  5  2 
Figure 15 Forest plot of ex smoking of any product and emphysema. Table 10 presents the results of a main meta-analysis for emphysema
based on 17 relative risk (RR) and 95% confidence interval (CI) estimates for ex smoking of any product (or cigarettes if any product not
available). The individual study estimates are shown numerically and graphically on a logarithmic scale. The weights (inverse-variance) are also
shown numerically, expressed as a percentage of the overall weight. The studies are sorted in order of sex within study reference (REF). In the
graphical representation individual RRs are indicated by a solid square, with the area of the square proportional to the weight. Arrows indicate
where the CI extends outside the range allocated. Also shown are the combined random-effects estimates. These are represented by a diamond
of standard height, with the width indicating the 95% CI.
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Page 42 of 61Table 10 Main meta-analyses for ex smoking of any product (or cigarettes, if any product not available)
a
Factor Level Statistic
b COPD CB Emphysema
All All N 110 105 17
F 2.12 (2.05-2.19) 1.56 (1.50-1.62) 3.50 (3.13-3.92)
R 2.35 (2.11-2.63) 1.63 (1.50-1.78) 3.52 (2.51-4.94)
H, PH 7.43, < 0.001 3.14, < 0.001 3.87, < 0.001
Sex Male n 44 46 9
F 2.80 (2.64-2.97) 1.63 (1.52-1.76) 5.12 (4.26-6.15)
R 2.87 (2.35-3.50) 1.80 (1.57-2.06) 4.70 (2.66-8.30)
Female n 28 35 4
F 1.92 (1.78-2.06) 1.52 (1.40-1.65) 3.50 (2.36-5.19)
R 2.02 (1.53-1.68) 1.64 (1.40-1.93) 3.50 (2.36-5.19)
Combined n 38 24 4
F 1.83 (1.74-1.92) 1.54 (1.46-1.63) 2.68 (2.30-3.12)
R 2.07 (1.83-2.35) 1.44 (1.22-1.71) 2.68 (1.58-4.54)
Between levels PB < 0.001 NS < 0.05
Continent N America n 36 37 9
F 2.77 (2.61-2.93) 1.45 (1.32-1.60) 4.70 (3.97-5.57)
R 2.98 (2.35-3.78) 1.47 (1.25-1.73) 3.82 (2.30-6.34)
Europe n 50 55 6
F 1.81 (1.73-1.89) 1.57 (1.50-1.65) 2.71 (2.32-3.17)
R 1.99 (1.76-2.25) 1.71 (1.51-1.94) 3.00 (1.70-5.28)
Asia n 16 7 2
F 2.84 (2.91-3.25) 1.94 (1.69-2.23) 3.56 (1.88-6.75)
R 2.79 (2.23-3.48) 2.17 (1.63-2.88) 3.56 (1.88-6.75)
Other or multicountry n 8 6 0
F 1.52 (1.31-1.76) 1.34 (1.14-1.57)
R 1.58 (1.22-2.05) 1.33 (1.13-1.57)
Between levels PB < 0.001 NS < 0.05
Study type Case-control n 11 9 0
F 3.38 (2.78-4.10) 1.65 (1.38-1.98)
R 3.45 (2.26-5.28) 1.87 (1.18-2.96)
Prospective n 35 10 4
F 3.92 (3.60-4.26) 1.59 (1.40-1.81) 5.32 (4.36-6.49)
R 2.88 (2.23-3.73) 1.79 (1.24-2.60) 2.99 (0.91-9.84)
Cross-sectional n 64 86 13
F 1.85 (1.78-1.92) 1.55 (1.49-1.62) 2.87 (2.50-3.30)
R 1.99 (1.81-2.19) 1.60 (1.45-1.75) 3.16 (2.50-4.00)
Between levels PB < 0.001 NS < 0.01
Outcome
subtype
Mortality n 29 2 2
F 4.41 (4.04-4.80) 3.61 (2.61-4.99) 6.02 (4.90-7.40)
R 3.55 (2.75-4.57) 5.57 (1.56-19.92) 6.56 (3.93-10.94)
Lung function (COPD) or
symptoms (CB)
n5 1 7 6 -
F 1.86 (1.78-1.93) 1.39 (1.32-1.46)
R 1.92 (1.72-2.13) 1.50 (1.36-1.64)
Other n 30 27 15
F 1.87 (1.74-2.02) 1.90 (1.78-2.04) 2.78 (2.43-3.18)
R 2.18 (1.80-2.64) 1.84 (1.58-2.14) 2.95 (2.23-3.91)
Between levels PB < 0.001 < 0.001 < 0.001
Smoking
product
Any n 43 53 4
F 1.76 (1.65-1.88) 1.64 (1.55-1.74) 2.72 (2.31-3.19)
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a (Continued)
R 2.09 (1.78-2.45) 1.67 (1.45-1.93) 2.72 (2.31-3.19)
Cigarettes (ignoring other
products)
n5 9 4 9 1 2
F 2.07 (1.99-2.15) 1.46 (1.38-1.54) 4.42 (3.76-5.18)
R 2.19 (1.94-2.47) 1.53 (1.38-1.70) 3.33 (2.17-5.10)
Cigarettes only n 8 3 1
F 6.79 (5.87-7.86) 2.80 (2.13-3.67) 12.50 (3.53-44.27)
R 5.78 (3.81-8.77) 3.28 (1.84-5.84) 12.50 (3.53-44.27)
Between levels PB < 0.001 < 0.05 < 0.1
Unexposed
base
c
Never any product n 54 65 6
F 2.41 (2.28-2.54) 1.69 (1.60-1.79) 3.67 (3.23-4.16)
R 2.60 (2.12-3.17) 1.75 (1.53-2.01) 4.70 (2.58-8.53)
Never cigarettes n 56 40 11
F 1.96 (1.88-2.04) 1.44 (1.36-1.52) 2.93 (2.28-3.76)
R 2.15 (1.92-2.42) 1.50 (1.35-1.66) 2.99 (1.96-4.56)
Between levels PB < 0.05 < 0.05 NS
a Within each study, results are selected in the following order or preference, within each sex, for: unexposed group-never any product, never cigarettes, other;
smoking product-any, cigarettes (ignoring other products), cigarettes only; overlapping studies-principal, subsidiary; and then for single sex results in preference
to combined sex results. Results adjusted for the most potential confounders are selected.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p ≥ 0.1), PB = probability value for between levels
(see methods) similarly expressed.
c Includes acceptable near-equivalent estimate (see methods) if estimate for strictly defined never smoker base not available (COPD: 3 for never cigarettes, CB: 2
for never any product and 4 for never cigarettes).
Table 11 Meta-analyses for amount smoked
a
Amount smoked Statistic
b COPD CB Emphysema
Number of sets
c 42 57 11
About 5 cigs/day
d, g N4 0 5 3 9
F 2.58 (2.39-2.78) 2.04 (1.91-2.16) 2.21 (1.88-2.59)
R 2.89 (2.41-3.45) 2.32 (2.07-2.60) 4.24 (1.88-9.55)
H, PH 3.58, < 0.001 2.08, < 0.001 7.82, < 0.001
About 20 cigs/day
e, g N2 3 3 3 6
F 6.24 (5.79-6.73) 3.64 (3.33-3.98) 7.10 (4.83-10.44)
R 6.21 (4.72-8.17) 4.43 (3.68-5.32) 5.07 (2.04-12.61)
H, PH 7.83, < 0.001 3.32, < 0.001 3.56, < 0.01
About 45 cigs/day
f, g N2 6 3 5 6
F 9.83 (8.85-10.92) 6.00 (5.48-6.57) 12.39 (7.49-20.50)
R 9.50 (7.38-12.22) 7.37 (5.86-9.28) 7.19 (2.74-18.87)
H, PH 3.28, < 0.001 4.66, < 0.001 2.23, < 0.05
Highest v lowest N 44 62 11
F 2.22 (2.08-2.37) 1.99 (1.87-2.12) 1.41 (1.17-1.70)
R 2.32 (1.90-2.83) 2.42 (2.10-2.79) 2.73 (1.23-6.04)
H, PH 6.02, < 0.001 3.65, < 0.001 7.50, < 0.001
a Within each study, results are selected in the following order of preference, within each sex, for: smoking status-current, ever; unexposed group (where
relevant)-never any product, never cigarettes; smoking product-cigarettes (ignoring other products), cigarettes only, any product; overlapping studies-principal,
subsidiary; and then for single sex results in preference to combined sex results. Results adjusted for the most potential confounders are selected.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p ≥ 0.1).
c Number of sets of RRs available for the key value analysis, where base for comparison is never smoked.
d Category for which results are provided includes 5 cigs/day but does not include 20 cigs/day.
e Category for which results are provided includes 20 cigs/day but does not include 5 or 45 cigs/day.
f Category for which results are provided includes 45 cigs/day but does not include 20 cigs/day.
g Base for comparison is never smoked.
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The studies are remarkably consistent in reporting an
increased risk in ever smokers. Only two of the 271 RRs
for the three outcomes combined considered in Figures
1 ,2a n d3a r el e s st h a n1 . 0 .H o w e v e r ,s t u d i e sa l s ov a r y
markedly in the magnitude of the estimated RR, as illu-
strated by the high values of H seen in the meta-ana-
lyses of the major smoking indices, which often exceed
5 and sometimes exceed 10. (H values of 5 and 10 are
t h es a m ea sI
2 values [17] of 80% and 90%). This is
unsurprising given the many sources of variation
involved, including sex, location, timing, study design
and populations, definition of outcome and exposure,
type of product smoked, and extent of confounder
adjustment.
Using univariate and multivariate (meta-regression)
methods, we investigated variation in risk by a number
of characteristics of the study and the RR. For each
outcome no characteristic on its own explains a major
part of the variation, and substantial excess heteroge-
neity remains even after fitting multivariate models.
However, differences in the strength of the association
with smoking by level of some characteristics are
apparent, these differences being quite similar for each
outcome and each major smoking index. RRs tend to
be higher for North American studies, for males, and
for cigarette smoking than smoking of any product.
For COPD RRs are substantially higher for studies of
mortality or onset, especially those where the defini-
tion of COPD excludes asthma, and lower where the
definition is lung function based. Studies of mortality
are less common for CB or emphysema, but also give
relatively high estimates. Effects of some other charac-
teristics, such as study timing and study type, though
significant in some univariate analyses, are not signifi-
cant with the multivariate approach. As some charac-
teristics are correlated (e.g. mortality studies are often
prospective, US studies are more often prospective
than elsewhere, and studies using lung function criteria
are commonly cross-sectional) it is not straightforward
to identify underlying effects. However, we feel that
the main meta-regression models for ever smoking
(Table 6) and current smoking (Table 8) for COPD
and CB are useful in explaining some of the heteroge-
neity, their usefulness being confirmed by the fact that
adding in further characteristics did not significantly
improve prediction. Particularly for COPD, the meta-
regressions show there are many characteristics that
independently modify the risk estimates. Meta-regres-
sions were not tried for emphysema, where there were
Table 12 Meta-analyses for age started to smoke
a
Age started Statistic
b COPD CB Emphysema
Number of sets
c 10 2 2
About age 26 years
d, g N 6 Insufficient data Insufficient data
F 1.74 (1.29-2.34)
R 1.91 (1.25-1.91)
H, PH 1.48, NS
About age 18 years
e, g N 6 Insufficient data Insufficient data
F 1.96 (1.60-2.41)
R 2.11 (1.08-4.11)
H, PH 7.43, < 0.001
About age 14 years
f, g N 8 Insufficient data Insufficient data
F 3.34 (2.74-2.08)
R 3.12 (2.07-4.70)
H, PH 2.88, < 0.01
Earliest v latest N 14 6 2
F 1.41 (1.30-1.52) 1.99 (1.42-2.79) 1.14 (0.70-1.88)
R 1.49 (1.26-1.76) 2.08 (1.29-3.35) 1.14 (0.70-1.88)
H, PH 1.29, NS 1.54, NS 0.01, NS
a Within each study, results are selected in the following order of preference, within each sex, for: smoking status-current, ever; unexposed group (where
relevant)-never any product, never cigarettes; smoking product-cigarettes (ignoring other products), cigarettes only, any product; overlapping studies-principal,
subsidiary; and then for single sex results in preference to combined sex results. Results adjusted for the most potential confounders are selected.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p ≥ 0.1).
c Number of sets of RRs available for the key value analysis, where base for comparison is never smoked.
d Category for which results are provided includes 26 years but does not include 18 years.
e Category for which results are provided includes 18 years but does not include 14 or 26 years.
f Category for which results are provided includes 14 years but does not include 18 years.
g Base for comparison is never smoked
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tionship was weaker than for ever or current smoking.
Sources of variation are discussed further in the fol-
lowing paragraphs.
Sex
If possible, sex-specific results are included in the meta-
analyses, with combined sex results included only if not.
Though variation by sex was not significant in all the
main analyses, risk estimates generally tended to be
higher for males than females. This is supported by
additional analyses comparing RRs within-study for the
same outcome and exposure definition. The higher RRs
for males do not necessarily indicate any greater sus-
ceptibility, and seem more likely to reflect increased
smoking. We note that some publications (e.g. [18-20])
have suggested that women may have a greater suscept-
ibility than men to the effects of smoking on COPD or
lung function, but others (e.g. [21-23]) have suggested
the opposite. A detailed overall assessment of this aspect
is beyond the scope of this paper.
Age
In the meta-regressions a continuous variable was
included that indicated the midpoint of the age group to
which the RR applied. The fitted coefficient was always
positive, but significant (at p < 0.05) only for current
smoking for COPD. Note that for each study only RRs
for the whole age range were entered, though the avail-
ability of age-specific data was recorded. Proper assess-
ment of the relationship of age to the RRs for the
different outcomes would require entry and analysis of
these further data. For the present, the data can only be
regarded as indicating that RRs for studies in older
populations may be greater than those in younger
populations.
Location
The meta-regressions showed significant variation in
risk by continent, mainly due to higher RRs for North
American studies. Similar differences are seen in the
univariate analyses for emphysema, and also for ex
Table 13 Meta-analyses for pack-years
a
Pack-years Statistic
b COPD CB Emphysema
Number of
sets
c
28 11 3
About 5
d, g N 23 10 Insufficient
data
F 1.13 (1.06-
1.20)
2.11 (1.74-
2.55)
R 1.25 (1.09-
1.44)
1.74 (1.17-
2.58)
H, PH 2.06, < 0.01 2.85, < 0.01
About 20
e, g N 11 8 Insufficient
data
F 1.68 (1.58-
1.79)
4.54 (3.69-
5.58)
R 2.53 (1.87-
3.43)
4.54 (3.69-
5.58)
H, PH 4.44, < 0.001 0.63, NS
About 45
e, g N 15 8 Insufficient
data
F 3.14 (2.97-
3.32)
7.33 (5.98-
8.97)
R 3.69 (2.79-
4.86)
7.04 (5.06-
9.79)
H, PH 6.34, < 0.001 1.82, < 0.1
Highest v
lowest
N 3 11 13
F 2.82 (2.69-
2.97)
2.52 (2.25-
2.82)
1.86 (1.40-
2.47)
R 2.80 (2.37-
3.30)
3.09 (2.33-
4.10)
2.42 (1.25-
4.70)
H, PH 4.09, < 0.001 2.23, < 0.05 1.79, NS
a Within each study, results are selected in the following order of preference,
within each sex, for: smoking status-current, ever; unexposed group (where
relevant)-never any product, never cigarettes; smoking product-cigarettes
(ignoring other products), cigarettes only, any product; overlapping studies-
principal, subsidiary; and then for single sex results in preference to combined
sex results. Results adjusted for the most potential confounders are selected.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95%
CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity
chisquared per degree of freedom, PH = probability value for heterogeneity
expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p ≥ 0.1).
c Number of sets of RRs available for the key value analysis, where base for
comparison is never smoked.
d Category for which results are provided includes 5 pack-years but does not
include 20 pack-years.
e Category for which results are provided includes 20 pack-years but does not
include 5 or 45 pack-years.
f Category for which results are provided includes 45 pack-years but does not
include 20 pack-years.
g Base for comparison is never smoked.
Table 14 Meta-analyses for duration of smoking
a, b
Duration of
smoking
Statistic
c COPD CB Emphysema
Longest vs.
shortest
N3 4 2
F 1.12 (0.63-
1.98)
2.73 (1.52-
4.92)
7.82 (2.00-
30.58)
R 1.12 (0.63-
1.98)
2.25 (0.68-
7.42)
7.67 (0.15-
390.65)
H, PH 0.76, NS 3.60, < 0.05 8.31, < 0.01
a Within each study, results are selected in the following order of preference,
within each sex, for: smoking status-current, ever; never cigarettes; smoking
product-cigarettes (ignoring other products), cigarettes only, any product;
overlapping studies-principal, subsidiary; and then for single sex results in
preference to combined sex results. Results adjusted for the most potential
confounders are selected.
b The number of sets of RRs available for key value analysis, where base for
comparison is never smoked, is 3 for COPD, 4 for CB and 3 for emphysema,
and no key value analysis was carried out.
c n = number of estimates combined, F = fixed-effect meta-analysis RR (95%
CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity
chisquared per degree of freedom, PH = probability value for heterogeneity
expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p ≥ 0.1).
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explained, but it could relate to differences in diagnosis
not fully accounted for by the model, in amount
smoked, or in type of product smoked. However a vari-
able accounting for the predominant long-term use of
blended cigarettes in some countries (including the US),
and of flue-cured Virginia cigarettes in others (including
the UK and Canada), did not significantly predict risk.
Study timing
In the univariate analyses of ever and current smoking
RRs varied significantly by when the study was pub-
lished, but the pattern was erratic, with no trend. Study
timing did not, however, add predictive power to the
multivariate models. This suggests that differences
between the periods studied are correlated with differ-
ences in other study characteristics. The term COPD
has only been widely used in the last 25 years or so, and
definitions based on lung-function have been changing,
so there may well be differences by time in the nature
of outcomes we classified as COPD. There have also
been changes in the nature of the product smoked, with
reducing tar deliveries of cigarettes and declining use of
pipes and cigars[24].
Definition of the disease outcome
For all RRs meta-analysed, the outcome had to be CB
specifically, emphysema specifically or COPD generally.
Thus each RR applied only to one outcome. The term
COPD is quite recent, so data from some earlier studies
which might legitimately have been included may have
been excluded or entered against the wrong outcome.
Some early studies described their outcomes as CB. If
they supported their definitions by ICD codes incorpor-
a t i n ga l lt h ec o r ec o m p o n e n t so fC O P D ,w er e c l a s s i f i e d
the outcome as COPD. However, where ICD codes were
not given, we left the outcome as CB, though we suspect
Table 15 Meta-analyses for duration of quitting (vs.
never smoked)
a
Duration of quitting Statistic
b COPD CB
Number of sets
c 10 11
About 12 years
d, g n1 0 9
F 3.45 (2.96-4.01) 1.40 (1.21-2.62)
R 2.12 (1.06-4.26) 2.20 (1.33-3.65)
H, PH 12.74, < 0.001 8.04, < 0.001
About 7 years
e, g n3 5
F 8.15 (5.88-11.28) 1.83 (1.49-2.25)
R 4.94 (1.21-20.07) 2.36 (1.29-4.32)
H, PH 14.80, < 0.001 6.52, < 0.001
About 3 years
f, g n3 7
F 3.58 (2.44-5.25) 2.16 (1.82-2.57)
R 4.08 (0.80-20.77) 2.42 (1.73-3.38)
H, PH 16.66, < 0.001 2.79, < 0.05
Shortest v longest n 10 11
F 2.20 (1.76-2.76) 1.29 (1.06-1.56)
R 2.21 (1.24-3.94) 1.25 (0.99-1.59)
H, PH 4.88, < 0.001 1.29, NS
a Within each study, results are selected in the following order of preference,
within each sex, for: smoking status-current, ever; unexposed group (where
relevant)-never any product, never cigarettes; smoking product-cigarettes
(ignoring other products), cigarettes only, any product; overlapping studies-
principal, subsidiary; and then for single sex results in preference to combined
sex results. Results adjusted for the most potential confounders are selected.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95%
CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity
chisquared per degree of freedom, PH = probability value for heterogeneity
expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p ≥ 0.1).
c Number of sets of RRs available for the key value analysis, where base for
comparison is never smoked. No data available for emphysema.
d Category for which results are provided includes quit 12 years ago but does
not include quit 7 years ago.
e Category for which results are provided includes quit 7 years ago but does
not include quit 3 or 12 years ago.
f Category for which results are provided includes quit 3 years ago but does
not include quit 7 years ago.
g Base for comparison is never smoked.
Table 16 Meta-analyses for duration of quitting (vs.
current smoking)
a
Duration of quitting Statistic
b COPD CB
Number of sets
c 91 1
About 3 years
d, g n2 7
F 0.77 (0.51-1.15) 1.07 (0.91-1.25)
R 0.77 (0.51-1.15) 1.00 (0.70-1.43)
H, PH 0.28, NS 3.85, < 0.001
About 7 years
e, g n2 5
F 1.03 (0.62-1.70) 1.00 (0.84-1.19)
R 1.03 (0.62-1.70) 0.87 (0.47-1.61)
H, PH 0.53, NS 9.89, < 0.001
About 12 years
e, g n9 9
F 0.52 (0.43-0.63) 0.61 (0.53-0.69)
R 0.52 (0.37-0.71) 0.65 (0.41-1.04)
H, PH 1.93, < 0.1 9.11, < 0.001
Longest v shortest n 10 11
F 0.43 (0.34-0.53) 0.78 (0.64-0.95)
R 0.45 (0.24-0.84) 0.80 (0.63-1.02)
H, PH 5.78, < 0.001 1.28, NS
a Within each study, results are selected in the following order of preference,
within each sex, for: smoking product-cigarettes (ignoring other products),
cigarettes only, any product; overlapping studies-principal, subsidiary; and
then for single sex results in preference to combined sex results.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95%
CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity
chisquared per degree of freedom, PH = probability value for heterogeneity
expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p ≥ 0.1).
c Number of sets of RRs available for the key value analysis, where base for
comparison is current smoking. No data available for emphysema.
d Category for which results are provided includes quit 3 years ago but does
not include quit 7 years ago.
e Category for which results are provided includes quit 7 years ago but does
not include quit 3 or 12 years ago.
f Category for which results are provided includes quit 12 years ago but does
not include quit 7 years ago.
g Base for comparison is current smoking.
Forey et al. BMC Pulmonary Medicine 2011, 11:36
http://www.biomedcentral.com/1471-2466/11/36
Page 47 of 61that sometimes the outcome might better have been
COPD.
For COPD, the definitions allowed vary considerably,
and the cases may not represent a homogeneous set.
Thus population-based cross-sectional studies using
lung function criteria alone probably include cases with
less severe disease than studies in hospitals or using
mortality records. Most prospective studies of incidence
made no attempt to trace deaths, so may have omitted
more rapidly progressive cases. We have not studied
v a r i a t i o ni nr i s ki nt h o s ef e ws tudies presenting results
by severity of disease. Similar considerations apply to
CB and emphysema, though less strongly, partly because
there were fewer studies of mortality.
F o rC O P DR R sa r eh i g h e rw h e nt h ed e f i n i t i o nw a s
based on mortality than when based on lung function or
other criteria. Compared to RRs based on lung function,
the meta-regressions indicated that RRs based on mor-
tality are about 1.5 times higher for both ever and cur-
rent smoking. The tendency for RRs based on mortality
to be higher is also seen for CB and emphysema, but
based on fewer studies.
For COPD RRs also clearly vary by how asthma was
taken into account. For most studies, co-existing
asthma was ignored (i.e. diagnosis was made
independent of asthma, and both cases and non-cases
could include asthmatics). However there were some
(mainly mortality) studies where asthma is part of the
outcome definition (e.g. COPD = CB, emphysema or
asthma). Here, usually only the underlying cause of
death is considered, so the possibility of a CB or
emphysema case also being recorded as having asthma
does not arise. RRs are much lower for these studies.
For others, asthmatics had been totally excluded, and
RRs tend to be intermediate.
Study type
For COPD particularly, the univariate analyses show a
tendency for RRs to be higher for prospective studies
than for other designs. Study type did not contribute in
multivariate analyses, probably reflecting its strong cor-
relation with disease outcome definition, prospective
studies tending to present mortality results, but other
study types tending to use lung function, symptoms or
other criteria.
Aspects of smoking
For COPD the meta-regressions show significant varia-
tion by smoking product, with RRs highest for smokers
of cigarettes only, lowest for smokers of any product,
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Figure 16 Funnel plot for ever smoking and COPD. Funnel plot of the 129 relative risk estimates for ever smoking and COPD included in the
main meta-analysis in Table 5 against their weight (inverse-variance of log RR). The dotted vertical line indicates the fixed-effect meta-analysis
estimate.
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Page 48 of 61and intermediate for smokers of cigarettes (ignoring
other products). As the estimates for cigarette only smo-
kers depended largely on just two large studies
(HAMMO2, THUN), we further investigated the differ-
ence between smokers of cigarettes only and smokers of
cigarettes by within-study comparisons. This confirmed
the tendency for cigarette only smokers to have higher
risks. Though we have not considered data for smoking
of pipes and cigars only, the results are consistent with
a greater effect of smoking cigarettes than other pro-
ducts. Smokers of any product include some who smoke
no cigarettes at all, while smokers of cigarettes include
some who smoke cigarettes and pipes/cigars and who
are likely to smoke less cigarettes per day than smokers
of cigarettes only. For CB and emphysema there are few
RRs for cigarette only smokers, but these also suggest
higher risks for this group.
For COPD, the results show a higher RR where the
unexposed group is never any product than when it is
never cigarettes. This is consistent with the absolute risk
being higher where the unexposed group includes some
smokers (of pipes/cigars), than where it does not. How-
ever, this pattern is not seen for CB and emphysema.
We investigated the dose-response relationship by
meta-analyses for five exposure measures-amount
smoked, age of starting, pack-years, duration of
smoking, duration of quitting (both vs. never smokers
and vs. current smokers).
Meta-analysis of RRs expressed relative to never smo-
kers or relative to current smokers is hampered by the
different categories used by different studies to define
level of exposure, so we also analyzed RRs comparing
extreme levels of exposure within smokers, an approach
allowing all studies to be included (including those only
presenting analyses for smokers). For all three outcomes,
risk increases with amount smoked and pack-years. For
COPD and CB earlier starters have significantly higher
risks, and risk also tended to decrease with longer-term
quitting. Data are too few for emphysema to make infer-
ences for age of starting and duration of quitting. The
only measure showing no dose-relationship is duration
of smoking but data are very limited. Note that all the
outcomes are chronic diseases and disease presence may
affect smoking habits. Depending on when smoking
habits are recorded, this may bias downwards associa-
tions with these dose-related measures.
Derivation of RRs
About a third of RRs used in meta-analyses are available
from the source or can be derived directly from cross-
tables of exposure by outcome. Otherwise more com-
plex methods had to be used to derive the required RR.
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Figure 17 Funnel plot for ever smoking and CB. Funnel plot of the 114 relative risk estimates for ever smoking and CB included in the main
meta-analysis in Table 5 against their weight (inverse-variance of log RR). The dotted vertical line indicates the fixed-effect meta-analysis estimate.
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Page 49 of 61It was reassuring that whether or not the RR was
derived did not add predictive power to the main meta-
regression model, suggesting that use of derived RRs
caused no material bias.
Effect of studies with high RRs or large weight
The statistical analyses investigated the role of various
characteristics on the estimated risk of the three out-
comes in relation to smoking, but did not formally test
the effect of exclusion of specific studies with extreme
RRs or large weights. For ever and current smoking, we
have noted the highest RRs and those contributing most
to the total weight. For COPD and CB, where each ana-
lysis involves over 100 most-adjusted RRs, no single RR
contributes more than 12% of the total weight, and the
distribution of RRs and of standardized residuals from
the meta-regression models did not suggest any single
RR had an undue influence. For emphysema, the situa-
tion is different. There are fewer RRs, only 28 for ever
smoking and 22 for current smoking, and one study
(LAVECC) contributes substantially to the overall
weight (49% for ever, 62% for current) while having a
relatively low RR (2.05 for ever, 1.76 for current).
Furthermore, study AUERBA, which does not provide
a nR Rf o re v e rs m o k i n g ,h a sas t r i k i n g l yl a r g eR Ro f
489.54 for current smoking.
We therefore investigated the effect of exclusion of
these studies on the combined current smoking RR,
where the problem is most severe (Table 17). It can be
seen that exclusion of AUERBA substantially reduces
the random-effects estimate, while exclusion of
LAVECC substantially increases the fixed-effects esti-
mate. Both exclusions, particularly AUERBA, reduce the
heterogeneity substantially.
Why should the estimates vary so much? LAVECC
was a large national health survey in Italy, in which
437/22, 376 (2.0%) male and female current smokers
of any product and 595/44, 172 (1.3%) male and
female never smokers of any product reported they
had emphysema or respiratory insufficiency, with no
independent check on the diagnosis. AUERBA
involved an examination of whole-lung sections pre-
pared from lungs removed at autopsy, with 816/839
(97.3%) male current cigarette smokers and 20/176
(11.4%) male never smokers of any product diagnosed
as having minimal, slight, moderate, advanced or far
advanced emphysema. These percentages differ widely
between the two studies and reflect differences in
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Figure 18 Funnel plot for ever smoking and emphysema. Funnel plot of the 28 relative risk estimates for ever smoking and emphysema
included in the main meta-analysis in Table 5 against their weight (inverse-variance of log RR). The dotted vertical line indicates the fixed-effect
meta-analysis estimate.
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Page 50 of 61what is considered emphysema. Someone interviewed
in a survey would be unaware of lower grades of
emphysema. For AUERBA it is possible to derive RRs
f o rh i g h e rg r a d e so fe m p h y s e ma. For instance, restrict-
ing attention to advanced or far advanced emphysema
reduces the rate in the male smokers to 134/839
(16.0%), and in never smokers to zero, so still indicat-
ing an extremely high RR.
We also compared the results reported by AUERBA
with those reported in the other autopsy studies
(ANDER2, PRATT, RYDER and SUTINE), although
only results for ever smoking are available in those stu-
dies, PRATT being of males and the other studies of
both sexes combined. Among never smokers of any pro-
duct, rates of emphysema (ANDER2 30/51 = 58.8%,
PRATT 15/97 = 15.5%, RYDER 21/73 = 28.8%, SUTINE
28/73 = 38.4%) are all much higher than reported by
LAVECC and also higher than reported by AUERBA.
Among ever smokers of any product (cigarettes only for
ANDER2), rates of emphysema (ANDER2 = 89.5%,
PRATT = 42.0%, RYDER = 75.5%, SUTINE = 69.2%)
are again much higher than reported by LAVECC but
clearly lower than reported by AUERBA. While it is
clear that emphysema rates based on autopsy studies are
much higher than those based on surveys, (and also
than those based on mortality studies, data not shown),
t h ev e r yh i g hR Rs e e ni nA U E R B Ai sd u et oaf a r
greater discrimination between smokers and never smo-
kers than seen in other autopsy studies. These results
emphasise the problem of heterogeneity in deriving
combined estimates.
Representativeness
We excluded studies of populations with a co-existing
medical condition, with clearly atypical smoking habits
(e.g. cocaine users or residents of a homeless shelter),
or with clearly atypical risk (e.g. alpha-1 antitrypsin
deficiency). Thus most studies include subjects
broadly representative of the general population. Some
studies had eligibility criteria such as long-term resi-
dence, household residence (excluding residents of
institutions or military personnel) or telephone sub-
scribers, criteria that may have resulted in under-
representing subjects with lower SES or more mobile
lifestyles. A few studies involved patients attending
their physician or clinics, who may have been less
healthy than average. It seems unlikely that any of
these effects would have materially affected the rela-
tionship between smoking and COPD.
Studies of subjects with a high occupational risk for
respiratory disease were excluded. The classification of
high risk was based on our educated judgment, and not
formally tested. Low occupational risk studies included
in this report involved armed forces personnel, doctors,
nurses, teachers, civil servants, professional and busi-
nessmen, coffeehouse and shop workers, postal, tele-
phone, transport and clerical workers, and outdoor
workers, as well as persons working in specific factories,
research facilities, or unspecified industry.
Some studies included were originally designed along
clinical or experimental rather than epidemiological
lines, and subject selection was unclear. These studies
are generally small, and any non-representativeness
would little affect our results.
Other sources of bias
It is well known that researchers are more likely to wish
to publish, and editors more likely to accept for publica-
tion, studies finding a statistically significant association
between exposure and disease. The published literature
may therefore overstate any true association or produce
a false-positive relationship. There is some formal evi-
dence of publication bias, with Egger’s test suggesting
bias in a number of the meta-analyses (see Figures 10 to
12). While some small studies showing no association
may never have been published, large studies are likely
to publish, and it is these which contribute most to the
meta-analyses. We have not attempted to quantify bias,
as formal methods are all based on assumptions which
cannot be tested, but it seems doubtful whether publica-
tion bias is a serious issue.
Another possible source of bias is misclassification of
smoking status. Random misclassification would dilute the
association, as would any tendency for cases to deny or
understate their smoking more than for the general popu-
lation. Any tendency for current smokers to claim to be ex
smokers, as might happen in a study conducted in a clini-
cal setting or where patients have been advised to stop
Table 17 Investigating the effect of excluding a study with a very large weight, (LAVECC) and/or a study with a very
high RR (AUERBA) on the meta-analysis, estimate for current smoking for emphysema
Studies included Fixed-effects RR (95% CI) Random-effects RR (95% CI) H
a
All 22 studies 2.61 (2.33-2.93) 4.87 (2.83-8.41) 11.54
Exclude AUERBA 2.36 (2.10-2.65) 3.62 (2.50-5.24) 4.48
Exclude LAVECC 4.95 (4.10-5.97) 5.20 (2.85-9.49) 8.50
Exclude both 3.89 (3.21-4.71) 3.85 (2.71-5.47) 2.55
a H is the heterogeneity chisquared per degree of freedom.
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Page 51 of 61smoking, would tend to inflate the risk for ex smoking.
Not only may misclassification rates vary by aspects of the
study design and the way questions are asked, they may
also vary by sex, age or other demographic variables.
The meta-analyses were conducted by combining
direct estimates of the RR (from prospective studies)
with ORs (from case-control and cross-sectional studies
and occasionally from prospective studies). ORs some-
what overestimate relative risks where the disease is not
rare [25], but here the overestimation is of little practi-
cal importance. Based on unadjusted data from prospec-
tive studies, where one could calculate both the relative
risk and the OR, we estimate that the median bias from
using the OR would have been only 1.01 for COPD and
emphysema, and 1.04 for chronic bronchitis.
Limitations
This review has various limitations, many unavoidable.
Lack of access to individual subject data limits the ability
to carry out meta-analyses using similar exposure indices
and confounder adjustment throughout, but obtaining
such data was not feasible given many studies were con-
ducted years ago. Obtaining a reliable definition of out-
come and exposure is often hindered by incomplete
information in the source papers. This review is also to
some extent limited by restricting attention only to strati-
fication by sex, and not attempting to record RRs subdi-
vided by age or other characteristics. We also limited
attention to specific indices of smoking, for example not
entering data on pipe or cigar smoking, filter/plain smok-
ing, or tar level. However we have recorded the availabil-
ity of such extra information, and further work
incorporating such data may give more insights. The pro-
cedures conducted for this review were extremely time-
consuming and it was impractical to bring the literature
included fully up-to-date. However consideration of data
from 218 studies published between 1953 and 2006
should give a reliable enough picture.
Conclusions
After excluding studies conducted in children or adoles-
cents, or in populations at high respiratory disease risk
or with co-existing diseases, we identified, from papers
published between 1953 and 2006, 218 studies which
relate one or more of a defined set of smoking indices
to COPD, CB and emphysema. One hundred and thirty-
three of the studies provide relevant data for COPD,
101 for CB and 28 for emphysema.
One major conclusion is that for each outcome the RRs
for a given smoking index were markedly heterogeneous.
Another conclusion is that estimates are clearly ele-
vated for all three outcomes. Individual study RRs vir-
tually all exceed 1.0, and based on random-effects meta-
analyses of most-adjusted RRs, estimates are elevated for
ever smoking (COPD 2.89, CI 2.63-3.17, n = 129 RRs;
CB 2.69, 2.50-2.90, n = 114; emphysema 4.51, 3.38-6.02,
n = 28), current smoking (COPD 3.51, 3.08-3.99, n =
120; CB 3.41, 3.13-3.72, n = 113; emphysema 4.87, 2.83-
8.41, n = 22) and ex smoking (COPD 2.35, 2.11-2.63, n
= 110; CB 1.63, 1.50-1.78, n = 105); emphysema 3.52,
2.51-4.94, n = 17). The consistency and strength of the
relationships are consistent with a causal relationship. A
causal relationship is supported by the fact that esti-
mates are not materially affected by adjustment for con-
founding variables, and by the evidence of a dose-
response relationship, with risk increasing with amount
smoked and pack-years for all three outcomes and
(based on more limited data) risk decreasing with
increasing starting age for COPD and CB and with
increasing quitting duration for COPD.
Our review also provides evidence that various charac-
teristics of the study and RR affect risk estimates. For
COPD, RRs are higher for males, for studies conducted
in North America, for cigarette smoking rather than any
product smoking, where the unexposed base is never
smoking any product, and are markedly lower when
asthma is included in the COPD definition. Variations
by sex, continent, smoking product and unexposed
group are in the same direction for CB, but less clearly
demonstrated. For all outcomes RRs are higher when
based on mortality, and for COPD are markedly lower
when based on lung function.
This comprehensive review provides further insight
into the relationship of smoking to COPD, CB and
emphysema.
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